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This thesis offers insights from knowledge management theory to understand the flow 
of knowledge across the multiple actors involved in the execution of a clinical trial in 
Latin America. In the last 12 years, the participation of Latin America in the business of 
clinical trials has significantly increased, becoming a highly demanded region to 
implement sponsored clinical research, overtaking regions like Africa, India, Southeast 
Asia, and Middle Eastern countries. Also, over this period, sponsors have increased the 
outsourcing of in-house activities such as trial monitoring, pharmacovigilance and 
regulatory services to Contracted Research Organisations (CROs), shifting the ‘two 
organisations’ and bi-directional relationship between the sponsor and the research 
sites. This change in the clinical trials landscape has also taken place in Latin America, 
where in addition to the CRO, the figure of Site Management Organisations (SMOs) 
has emerged to manage multiple research sites over the course of the trial. Therefore, 
the internationalisation of clinical research, plus the outsourcing of strategic activities, 
have transformed the implementation of clinical trials in the region.  
On the other hand, the results of a clinical trial depend strongly on the analytical skills 
and cognitive capabilities employed by people working on the project. These 
characteristics make the clinical trial a Knowledge Intensive Project (KIP), where the 
main project outcomes depend to a large extent on the use of knowledge by the 
workers, and the transfer of knowledge data and information across the multiple 
organisations working in the clinical trial. Because knowledge is the primary 
production factor in a clinical trial, and in the context of Latin America, to my 
knowledge, there is reduced research about the production of clinical evidence and the 
role of each one of the actors over the execution, the main research question that this 
thesis answers is: How does knowledge flow across organisations and is employed by 
people in their firms to implement the clinical trials and obtain their respective results?  
To answer this research question, I proposed and evaluated a three-step model to study 
the flow of knowledge, data and information across multiple organisations being part 
of the clinical trial and the use of these to produce the knowledge products by the 
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sponsor and the research sites. This model has its roots in the literature of knowledge 
‘models, work and processes’, the concept of interdependence and the literature of 
knowledge transfer and acquisition in the outsourced project. The model consists of 
three steps to address, at the inter-organisational level, the transfer and acquisition of 
knowledge, data and information and the interdependency on results; and at the intra-
organisational level, the use of knowledge and storage. The presented model was 
evaluated and complemented based on the evidence collected through a multi-case 
study of three multi-organisational clinical trials to evaluate three new vaccine 
candidates in Colombia, Brazil and Mexico.  
The findings of this research indicated that the model was robust to study the flow of 
knowledge, data and information between the sponsor and the research sites, from the 
design of the protocol to the production of the clinical data. The results also indicate 
that the presence of intermediaries decreases the transfer of knowledge and 
information between the parts, and induces the selectivity of the research sites toward 
one of the sources of knowledge, the Sponsor, the CROs or SMO. The evidence shows 
that the acquisition of knowledge by physicians demands a knowledge-destruction 
capability to actively employ the acquired knowledge in the trial and the constant 
presence of loops to reinforce the knowledge acquisition. The empirical findings of 
knowledge and data acquisition by the research sites and the sponsor contributed to 
developing the concept of permeability, contributing to the literature of knowledge 
acquisition in outsourced projects. This research addresses, for the first time, the 
implementation of vaccine clinical trials in Latin America countries and the 
contribution of the local researcher to the project, especially with their knowledge 
about the communities intervened. But it also highlighted some of the aspects that 
affect the implementation of clinical trials, such as the labour conditions in academia, 
which induce turnover, and the lack of harmonisation among clinical trial regulation 
in the region. In conclusion, the model proposed allowed me to address simply the 
complexities that take place in the production of knowledge products in multi-




One of the aims of this research is to study Latin America because of the strong 
participation of the region in the business of clinical trials and the changing landscape 
of this kind of projects over the last years. Clinical trials used to have the participation 
of two organisations. Now the number of firms has increased, making the operation of 
these projects more complex. The participation of organizations such as CRO 
(Contracted Research Organisation) and Site Management Organisations (SMOs) are 
changing the implementation of the clinical trials. The change in the implementation 
motivated the proposal of this research in the first place.  
The main objective of this thesis is to study how across multiple firms working on 
clinical trials deliver results that each firm produced. Likewise, how these firms share 
and use those results with their partners, and how those results become products. In 
the context of this research, a clinical trial is defined as a knowledge-intensive project 
because the strong demand of analytical skills required to produce the results, and 
these results, in turn, are denominated productive enquiries. To my knowledge the 
research on this topic is limited, therefore the main research question that emerged is: 
How does knowledge flow across organisations and is employed by people in their firms 
to implement the clinical trials and obtain their respective results?   The theory employed 
to study this “knowledge flow” is from knowledge management theory because it allows 
to pay attention exclusively to the use and production of knowledge over the course of 
the entire project. Using this theory, I propose and evaluate a conceptual model to 
answer this research question. The model is divided into three main steps: knowledge 
acquisition, knowledge use and knowledge transfer/storage. The concepts of 
interdependence and the literature of knowledge transfer and acquisition in 
outsourced projects are also employed in the model proposed.  The presented model is 
evaluated and complemented based on the evidence collected through a multi-case 
study of three multi-organisational clinical trials to evaluate three new vaccine 
candidates in Colombia, Brazil and Mexico. 
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The results of this research provide evidence that indicates that the theoretical model 
proposed is strong enough to study the complexities on the flow of knowledge across 
multiple firms working in a clinical trial. This model covered from the beginning of the 
project design until its production of clinical data, more data is required to study the 
production of the final product. One of the main outcomes of this project was the 
identification of intermediaries transferring information and knowledge and how they 
affected this process. The presence of these actors led place to a reaction from the 
receptor that I denominated selectivity, a reaction that is associated with a concept 
developed in this thesis that is permeability. In those cases, in which more than two 
sources transferred information, the receptor becomes more or less open to one of the 
sources. In other words, the receptor was more or less permeable to receive and use 
one of the sources information. Another significant finding of this work is the process 
of re-learning by experienced physicians to produce clinical data. This process is named 
in the literature as knowledge-destruction capability which had to be actively employed 
by experienced physicians to de-learn old practices and learn how to produce clinical 
data in the context of clinical research. This process required a constant 
communication with external sources to verify the validity of the new knowledge 
acquired.  
In conclusion, this research addresses, for the first time, the implementation of vaccine 
clinical trials in Latin America countries and the contribution of the local researcher to 
the project, especially with their knowledge about the communities intervened. But it 
also highlighted some of the aspects that affect the implementation of clinical trials, 
such as the labour conditions in academia, which induce turnover, and the lack of 
harmonisation among clinical trial regulation in the region. In conclusion, the model 
proposed allowed me to address simply the complexities that take place in the 
production of knowledge products in multi-organisational clinical trials in Latin 
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Chapter 1: Introductory chapter 
1.1. Introduction 
The success of a multi-organisational knowledge-intensive project lies in the use of 
knowledge in action and its flow across organisations. The main objective of this thesis 
is to develop and evaluate a conceptual model to study two elements in the 
management of knowledge in multi-organisational projects. The first element is the 
study of the flow of knowledge across organisations working on multi-site clinical trials, 
and the second element is the study of the use of knowledge by people in the 
organisations to meet their productive enquiries related with the project. To achieve 
the objectives, the principal research question of this thesis is: How does knowledge 
flow across organisations and is employed by people in their firms to implement 
the clinical trial and obtain their respective results?  
To answer this research question, a conceptual model was proposed and evaluated 
through a multi-case study design of three multi-organisational clinical trials taking 
place in Colombia, Brazil and Argentina. The purpose of this introductory chapter is to 
present to the reader the context in which this thesis takes place; that is, the 
implementation of sponsored clinical trials in Latin America and its evolution through 
time.  
The first section of this chapter seeks to provide the context of this research and 
discusses the changes in the landscape of the clinical trials over the last 20 years. This 
discussion defines the clinical trials as multi-organisational projects, where each 
organisation has specific and clearly defined responsibilities in the context of the whole 
trial. This review gives place to the research questions addressed in this thesis. 
In the second section of this chapter, I provide an overview of the structure of this thesis 
that leads to the answer of this principal research question and the content of each one 
of the chapters. As a result of this chapter, I expect that the reader has an understanding 
of the basics of this project, its contributions and an overview of the thesis. 
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1.2. Clinical trials like multi-organisational projects 
A clinical trial is a medical experiment that has the main aim of elucidating how a new 
drug or biological product is going to behave in the human body and in a population. 
The implementation of a clinical trial has shifted over the course of history since the 
first formal clinical trial about scurvy on sailors was described by Lind (1753). At that 
time, clinical research was conducted by physicians individually, who planned and 
executed trials with their patients, and they wrote their results in diaries or reports. 
Nowadays, clinical trials to evaluate new compounds are multinational, coordinated 
mainly by pharmaceutical companies that have the economic means to sponsor the 
high cost associated with clinical research. 
The scientific basis of the modern clinical trials was created in the nineteenth and 
twentieth centuries. In the nineteenth century, researchers widely employed statistics 
and the “calculation of probabilities” and mathematical concepts in the design of 
clinical trials (Matthews 2006). The designing of protocols, the randomisation of 
participants, and the double blinding of the trials are elements introduced in the design 
of the clinical trials in the nineteenth century (Stolberg 2006). The knowledge created 
in these studies paved the way for the first randomised controlled trial carried out in 
1946 by the MRC in the United Kingdom to evaluate the use of streptomycin in 
pulmonary tuberculosis. This trial is a model to conduct clinical research because of its 
meticulousness in the design and implementation. 
The lack of harmonisation of requirements to implement trials and accept the results 
across countries pushed the harmonisation of procedures to conduct clinical research. 
The declaration of Helsinki, the Nuremberg code (Pocock 1980) and the Belmont 
Report, and the need to harmonise procedures among the USA, Japan and Europe were 
the foundations for the creation of the Good Clinical Practices (GCP). The GCP is “an 
international ethical and scientific quality standard for designing, conducting, 
recording and reporting trials that involve the participation of human subjects”(ICH 
Harmonised Tripartite Guideline 1996, 1). As the century evolved, the pharmaceutical 
industry increased the implementation of multi-national clinical trials in emerging 
regions of Eastern Europe, Latin America, Asia, the Middle East and Africa (Jeong et al. 
2017), where recruitment is faster and with a lower cost. With the globalisation of 
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clinical research, the GCP-ICH have been adopted by other countries around the world 
to approve the implementation of clinical trials in their territories. In this way, in the 
last century, all the knowledge and regulatory frameworks defined the bases for the 
execution of international clinical trials in this century.  
Over the second half of the twentieth century, the pharmaceutical industry led the 
implementation of clinical trials to evaluate new molecules where the participation of 
academic institutions decreased, taking a secondary role (Chopra 2003). Clinical trials 
account for approximately 42% of the research and development funding spent by the 
pharmaceutical industry in the development of new products (Thakur and Contractor 
2008). The time between pre-clinical and clinical phase to obtain a product licence 
ranges from 6.8 to 18 years (Cockburn 2007). Over the last 30 years, there has been a 
shift in the industry to speed up this time. Pharmaceutical companies are outsourcing 
traditional in-house activities to foreign affiliates and Contracted Research 
Organisations (CROs) (Azoulay 2004; Thakur and Contractor 2008; Jeong et al. 2017). 
These CROs provide outsourced services to the pharmaceutical, biotechnology and 
medical device industries, including drug discovery, preclinical research, clinical 
research, protocol design, pharmacovigilance, regulatory services, clinical trial 
management, commercialisation, data management analysis and reporting (Delancey 
Street Partners LLC 2016; Ukwu et al. 2011b). 
There are four primary drivers required to outsource the clinical trial project to foreign 
countries. Firstly, there is the need to include diverse ethnic backgrounds when 
studying drug performance (Yasuda, Zhang, and Huang 2008). Secondly, trials are 
becoming more multinational because there is a need to identify the influence of 
intrinsic (environmental differences, culture diet, medical treatment) and extrinsic 
factors (genetic, people’s weight, physiological differences) on the variations in the 
drug response (Bairu, Spector, and Chin 2013; Aban et al. 2008). Thirdly, there is a need 
to decrease cost; it has been reported that the outsourcing of clinical trials to Asia or 
Latin America represents savings of around 50% and 90% (Bairu, Spector, and Chin 
2013). Fourthly, the evaluation of biological products or medicines to treat or prevent 
endemic diseases must be conducted in the endemic areas, so trials are outsourced to 
CROs that have experience working in these locations. Some of these reasons to 
outsource clinical trials are shared with other industries that also outsource services, 
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like the motivation to reduce cost or because the location provides an advantage to 
introduce a product or service (Anderson Jr. and Parker 2013).  
The outsourcing of clinical trial projects has taken place since the mid-80s in the USA. 
However, in Latin America, the rate of this activity has increased only over the last 20 
years, and the operations outsourced are mainly the execution of the clinical trial and 
monitoring activities. For some scholars, this change has represented a risk in the loss 
of knowledge by the pharmaceutical firms putting in risk innovation (Lowman et al. 
2012). Therefore, the internationalisation of clinical research, plus the outsourcing of 
activities, have transformed the implementation of clinical research and made a clinical 
trial a multi-organisational project (Ukwu et al. 2011a) involving multiple organisations, 
in some cases in various locations. Then, a research activity that was originally 
conducted and led by individual researchers is now a multi-organisational activity, 
highly regulated and structured, with defined guidelines and procedures. Then, the 
study of clinical trial projects can contribute to understanding key issues in another 
outsourced project, which will be discussed below.  
1.2.1. Clinical research in Latin America and research questions 
In the last 12 years, the participation of Latin America in the business of clinical trials 
has significantly increased. The number of registered trials in the region augmented on 
average 22% between 2002 to 2006 (Thiers, Sinskey, and Berndt 2008). In the specific 
case of vaccines registered in the database ClinicalTrials.gov, of the 7,244 clinical trials 
to evaluate vaccines, 421 trials contain data from Latin America (Mexico, Central 
America and South America). This number is higher than the number of trials 
conducted to evaluate vaccines in Africa, India, Southeast Asia, and Middle Eastern 
countries (Clinicaltrials.gov 2017). This fact shows the relevance of the region in the 
clinical trial market to evaluate vaccines. 
In the context of clinical trials sponsored by the pharmaceutical industry in Latin 
America, the sponsor used to outsource the project execution directly to the principal 
researchers. In these trials, the sponsor, through their local branches, directly 
transferred the protocol to multiple research sites and trained them directly; providing 
all the relevant information to execute the project. Therefore, obtaining clinical 
evidence was the product of the coordinated work between two types of organisations, 
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the sponsor and the research sites, where the outcome of one team was the input to the 
other; creating a bidirectional knowledge and data flow. However, over the last 20 
years, the clinical trial industry has been revolutionised by the presence of a third actor 
– the Contract Research Organisation (CRO) (Arnum 2014; Getz 1997; Ukwu et al. 
2011a). CROs have significantly transformed how clinical trials are conducted not only 
in Latin America (Petryna 2006) but also throughout the world. In the context of Latin 
America, the presence of CROs, especially in the field of clinical trials, has completely 
changed the ‘two organisations’ and bi-directional relationship separating the 
interaction between the sites and the sponsor, where the CRO becomes the sponsor’s 
intermediary in the country (Smed and Getz 2013).  
More recently, organisations like SMOs (Site Management Organisations) have 
emerged as a kind of umbrella organisation to coordinate the research sites and the 
implementation of the protocol in multiple settings, mediating the relationship 
between sites, principal researchers and the CROs. These SMOs emerged in the USA 
around twenty years ago (Maloff 1999), and ten years ago, private SMOs appeared in 
Latin America, especially in Brazil and Colombia. Additionally, to overcome the lack of 
local research capabilities, temporary SMOs have also been configured to coordinate 
inexperienced research sites and train them, as some of the cases studied in this project 
indicate. In this sense, SMOs have become a relevant actor in the transfer of 
information and management of the trial. Therefore, the participation of multiple 
actors involved in the clinical trials makes the implementation of the project 
fragmented, where each firm contributes with their knowledge and skills.  
In a clinical trial, knowledge is the primary productive factor, and organisations 
participating in the project constantly exchange it. The management of knowledge, 
which is core in a trial, is usually left over by people researching the clinical trial, or 
scholars reduce it to the study of the management of documents like archives and 
emails. I consider that holding knowledge or having it in documents and protocol is 
not enough to be successful in the project. I recognise that what matters in the study 
of knowledge in a clinical trial is the understanding of the use of knowledge to execute 
the tasks, and how knowledge flows and is transformed into products over the project. 
Then, in this new multi-organisational context, where multiple types of actors are part 
of the implementation of a clinical trial, emerges the next question:  
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How does knowledge flow across organisations and is employed by 
people in their firms to implement the clinical trials and obtain their 
respective results? 
To answer this principal research question, it is necessary to identify the actors involved 
in the production of the clinical evidence and their results. In this research, the two 
principal organisations that will be studied to understand the flow of knowledge, data 
and information are the sponsors and the research sites. In this thesis, I consider the 
CRO and the SMOs as intermediary organisations, and their study is associated to this 
intermediary role because they do not produce the critical knowledge products that 
give place to the collection of the clinical evidence. Based on this distinction, in Chapter 
2, I address the origin of these three sub-questions and the three central sub-research 
questions in this thesis are:  
Sub-Q1: How did the sponsor acquire and use knowledge, data and 
information to design the clinical protocol?  
Sub-Q2: To what extent does the structure designed by the sponsor to 
transfer knowledge, the permeability of the research sites, and the 
previous experience of people working on the project influence the 
acquisition of knowledge in the research sites? 
Sub-Q3: How is knowledge employed in the clinical research sites to 
produce the clinical data and transfer it to the sponsor? 
The answers to these three sub-research questions provide the basis to understand how 
knowledge flows across organisations in the multi-organisational project and how 
knowledge is employed in two main activities of the project: the creation of the protocol 
and the obtaining of the clinical data. The answer to this question is not only relevant 
to understand a new dynamic in the implementation of clinical trials. The answer can 
help clinical researchers to learn from other researchers’ experience to implement 
clinical trials. To answer these research questions, I will use concepts from knowledge 
management literature, primarily from the literature of knowledge management of 
outsourcing projects and the literature of knowledge ‘models, work and processes’, as 
will be detailed below.  
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1.3. Chapters overview  
With the aim of addressing the objectives raised above and answering the research 
questions, this thesis has a theoretical chapter, a methodological chapter, four main 
chapters, and a conclusion chapter. Below, I present a summary of the content of each 
chapter.  
1.3.1. Chapter 2: Theoretical frameworks  
In this chapter, I present the sub-research questions and I address extensively the origin 
of these questions based on the gap present in the literature of clinical trials and 
previous research on knowledge management associated with clinical trials. The 
second section of this chapter addresses the definition of knowledge in the field of 
organisational studies and justifies the adoption of the knowledge definition proposed 
by Cook and Brown (1999). The third section of this chapter introduces the concept of 
Knowledge-Intensive Projects (KIP) and defines clinical trials as KIP. The fourth section 
presents previous research on the management of knowledge in multi-organisational 
activities and projects such as KIP and outsourced activities. In the fifth section, I 
propose a model to answer the research questions and study the flow of knowledge 
across organisations and its use to produce the productive enquiries. The model offered 
to explain the management of knowledge within or across organisations combines 
models and factors from different areas of studies. The model has its roots in the 
literature of knowledge ‘models, work and processes’ (K. Grant 2011, 121) and I 
complement it with the concept of interdependency proposed by Thompson (1967) and 
the concept of permeability that I develop. Also, two key factors are identified in the 
literature of project outsourcing: people’s previous knowledge and the structural 
dimension to transfer knowledge (sources, channels and network structure) were 
added to the model. The last section presents a summary of the chapter. 
1.3.2. Chapter 3: Methodological chapter  
In this third chapter, I present the research design, data collection and data analysis. In 
the first section, I introduce the research design of this project, where I discuss the 
process of selecting a qualitative multi-case study approach and the advantage of this 
design compared to others to achieve external and internal validity on the study. In this 
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section, I explain the systematic literature review implemented to select the three 
dengue vaccine cases and the countries (Colombia, Brazil and Mexico) included in this 
research. In the second section, I explain the use of interviews to collect data, the 
process of accessing to information sources, the experience implementing the fieldwork 
and the limitation raised over the data collection. In the third section, I introduce the 
procedure for analysing the collected data using a grounded theory ‘Framework’ 
approach (Jane and Liz 2011). This method allowed comparisons and associations 
between and within cases, being entirely suitable for the research design of this project, 
permitting a systematic treatment of all units of analysis. In the fourth section, I present 
the ethical consideration of this research, and in the fifth section, I provide a reflection 
on my experience doing this research. The last part gives a summary of the chapter.  
1.3.3. Chapter 4: Use of internal and external knowledge by the 
sponsor to design the clinical trial 
This chapter answers the first sub-research question of this thesis: How did the 
sponsor acquire and use knowledge, data and information to design the clinical 
protocol? The conceptual model proposed in the theoretical chapter was employed to 
answer this question. In this sense, I analyse two aspects associated with the use of 
knowledge to design the protocol. The first one is how research teams internally 
manage their knowledge and previous results to create the clinical trial. Secondly, I 
analyse the acquisition of knowledge from external sources, considering the sources 
and channels employed to acquire data and information and the permeability of people 
towards external knowledge and information. The chapter is divided into four sections. 
The first one is the introduction. The second section addresses the management of 
knowledge and information residing within the boundaries of the sponsor’s clinical 
team to design the protocol. This section is divided into four sub-sections, each one 
dedicated to the use of different types of knowledge and information.  1) The use of 
guidelines to design the protocol. 2) The use of previous clinical and pre-clinical results. 
3) The use of knowledge to create the protocol. 4) The influence of the commercial 
interest of the sponsor designing the protocol. The third section discusses the 
acquisition of external knowledge, information and data to design the protocol. This 
section is divided into two sub-sections. The first sub-section addresses the acquisition 
of demanded information and the structures employed; the second sub-section 
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discusses the permeability of the clinical teams to external knowledge and information 
not requested. The fourth section is the conclusion of this chapter. 
1.3.4. Chapter 5: Acquisition of knowledge and information by 
the research sites 
This chapter aims to answer the second research question of this thesis: To what 
extent does knowledge-base of people working on the project, the structure 
designed by the sponsor to transfer knowledge, and the permeability of the 
research sites influence the transfer/acquisition of knowledge in the research 
sites? To answer this question, I will discuss the interdependency between the sponsor 
and the research site, and how these three factors positively or negatively impacted the 
transfer/acquisition of knowledge and information between the organisations. This 
chapter is divided into four sections. The first section is the introduction. The second 
section discusses the influence of the structure defined by the sponsor on the transfer 
of information and its respective acquisition by the research sites. This section is 
divided into three sub-sections. The first sub-section discusses the benefits of direct 
communication between the sponsor and the research sites. The second and third sub-
sections are focused respectively on the influence of intermediary actors such as the 
CROs and the SMOs on the transfer and acquisition of knowledge and the permeability 
of the teams towards these intermediaries. The third section discusses the relevance of 
the previous experience of the research sites on the acquisition of knowledge. This 
section is divided into three sub-sections. The first sub-section explains the 
configuration of the clinical teams and its relevance to the knowledge acquisition. The 
second sub-section focuses on the acquisition of knowledge of experienced research 
sites, and the third sub-section discusses the acquisition of knowledge of new research 
sites. The last section of this chapter provides the conclusions.  
1.3.5. Chapter 6: Opening the black box of the research sites. 
Implementation of the protocol 
This empirical chapter answers the third research question of this thesis, which is: How 
is knowledge employed in the clinical research sites to solve the productive 
enquiries related to the production of clinical data and its transfer to the 
sponsor? In this chapter, continuing with the use of the model proposed, I discuss at 
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the intra-organisational level how the personnel at the research sites use the acquired 
knowledge from the sponsor and the knowledge that they already had to implement 
the project, produce the data and transfer it to the sponsor. Answering this question, I 
pay particular attention to the know-how that is employed in the activities and the 
contextual knowledge used by the staff to advance on the project. This chapter 
separately addresses the key productive enquiries associated with the production of 
clinical data in five sections. The first section is the introduction. The second section 
discusses the integration and use of knowledge in the research sites. I discuss separately 
the standardisation of procedures and the use of knowledge in practice. The third 
section discusses learning loops that take place over the trial. The fourth section focuses 
on the transfer of data and the storage of knowledge, where I discuss the barriers to 
storing knowledge in the organisations once the project concludes. The fifth section 
presents the chapter’s conclusions. 
1.3.6. Chapter 7: Discussion and conclusions.  
This chapter aims to bring together the evidence collected and presented through the 
empirical chapters, the model proposed in this research and the literature previously 
discussed. In this way, in this chapter, I expect to provide a solution to the central 
research question of this thesis, identifying how knowledge, information and data are 
transferred, acquired and employed within and across organisations over the course of 
a multi-organisational project. This last chapter is divided into two main sections. The 
first section discusses the main empirical findings associated with each main research 
question. This section has three sub-sections, one for each research question. The 
second section explains the theory addressing each one of the steps of the model 
proposed. This section is divided into four sub-sections. The first sub-section discusses 
the knowledge transfer and the role of intermediaries. The second sub-section 
discusses the acquisition of knowledge and the influence of the previous experience 
and the permeability on this process. The third sub-section focuses on the use of 
knowledge in the productive enquiries. The fourth sub-section introduces a reviewed 
model complemented based on the evidence obtained in this thesis and discusses the 
further areas of research.  
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In summary, this thesis makes several theoretical and empirical contributions to the 
current literature in the emerging field of knowledge management in outsourced 
projects. To the best of my knowledge, this research is the first one that addresses at 
the same time the study of knowledge management at the inter-organisational and 
intra-organisational level in multi-organisational projects, presenting a holistic view of 
the process, including the transformation of knowledge and people’s contributions. 
This study addresses the knowledge flow from the beginning of the project until later 
stages. Second, this study makes a significant contribution to the mentioned field by 
proposing and evaluating a conceptual model to study the knowledge flow and its use 
in multi-organisational projects employing models from the knowledge management 
literature to study intra-organisational dynamics.  
This research proposes a robust model, that integrates critical steps and critical factors 
that influence the flow of knowledge in the multi-organisational project. As a next step, 
this model can be employed to study other industries to be validated before it can be 
generalised to the universe of multi-organisational knowledge-intensive projects. 
Nonetheless, this work advances on the study of multi-organisational projects and 
provides the evidence to suggest that this model explains the flow of knowledge in the 
context of clinical trials managed by different kinds of firms like pharmaceutical 
companies, biotech companies, or public research organisations. Third, this thesis 
introduces the concept of permeability, which is defined, enriched and evaluated 
through the empirical data collected. In this way, the theoretical framework proposed 
in this project sheds light on how knowledge is managed at the inter and intra-
organisational level by the actors participating in outsourced knowledge-based 
projects.  
1.4. Summary 
In this introductory chapter, I have presented the context of this research and an 
overview of the content of the following chapters. In the first section, I introduced the 
evolution of clinical trials over the last two centuries, briefly regarding the actors that 
participate in the trials, the scientific bases developed in the UK to implement clinical 
research and the internationalisation of clinical research. I consider this section 
essential because it allows an understanding that the actual process of implementing 
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clinical research is the result of a dynamic process, which can also change in the future. 
Then, this research is a picture of a specific moment in the evolution of clinical 
research. Based on this panorama, I introduced the principal research question and 
outlined the sub-research questions. In the second section of this thesis, I presented an 
outline of this thesis and the contents of each one of the following chapters.   
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Chapter 2: Research questions and 
theoretical framework 
2.1. Introduction 
This chapter aims to introduce the research questions of this project and provide the 
theoretical and conceptual framework to answer these questions. In this first section, I 
elucidate the research gaps in the study of the management of knowledge in the context 
of clinical trials, specifically in Latin America. These gaps are the basis to propose the 
principal research question and sub-research questions of this research. The second 
section of this chapter presents the definition of knowledge in this thesis. In the third 
section, I define a clinical trial as a knowledge-intensive project (KIP). In the fourth 
section, I introduce the previous research on the management of knowledge in KIP and 
outsourced projects and the different fields that have contributed to this study. In the 
fifth section, I propose a model to explain the flow and use of knowledge, data and 
information across organisations. In this model, I consider the critical steps raised in 
the literature of knowledge ‘models, work and processes’ (K. Grant 2011, 121) and key 
factors identified in the literature of knowledge management in outsourced projects. 
At the end of this section, I present how I’m going to use this model to answer each one 
of the sub-research questions stated in this thesis.  
2.2. Knowledge gap and research questions 
Regarding the outsourcing of clinical trials in Latin America or other regions, some 
clinical researchers have discussed within the clinical community the lessons learned 
by researchers implementing clinical trials and their reflections and suggestions to 
improve clinical research in these regions. Some aspects covered by these scholars in 
the clinical trial field are:  
1. Challenges in implementing public-private collaborations to evaluate vaccines 
(Eskola and Kilpi 2011). 
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2. How the regulation in countries different to the USA and western Europe 
regulations influences the trial implementation (Aban et al. 2008; McNay et al. 
2002; Duley et al. 2008; Choi and Ko 2010; Bairu, Spector, and Chin 2013). 
3. The need to create research capabilities in rural areas to implement trials (Ukwu 
et al. 2011a). 
4. The challenges and benefits of implementing trials in these countries (Chin 
2012; Aban et al. 2008; Bairu, Spector, and Chin 2013).  
5. The cost efficiencies related to the access to patients, the presence of competent 
and enthusiastic researchers who can implement complicated studies (“The 
Top Reasons for Conducting a Clinical Trial in Latin America” 2014; Chin 2012; 
Ukwu et al. 2011a).  
6. How to improve data quality (U.S. Department of Health and Human Services 
Food and Drug Administration 2006; Friedman et al. 2015; Chan et al. 2013; 
Gassman et al. 1995; Knatterud et al. 1998; Meinert 2012).  
But the actual using of knowledge over the course of these projects has been less study, 
which is really surprising because, as I said before, in these projects people’s knowledge 
is the principal production factor and main product. 
In the context of clinical trials, scholars in the field of management and innovation have 
studied some aspects associated with the management of knowledge over the course of 
the project. These researches have focused on where there is a risk of the pharma 
company losing knowledge and control over the project (Lowman et al. 2012; Aban et 
al. 2008; Thakur and Contractor 2008); the way in which decisions are made to 
determine what activities to outsource (Azoulay 2004); the impact of the clinical trial 
on the knowledge of the contractor (Thakur and Contractor 2008); the transfer of 
lessons learned from the research sites to the sponsor (Smed and Getz 2013); the ethical 
aspects of the outsourcing (Fisher 2008; Kamat 2014) and the adverse effect that the 
CROs have over this transfer process (Smed and Getz 2013).   
Regarding knowledge production in outsourced clinical trials, Azoulay (2004) has been 
the first one to address this issue. His study took place when the pharmaceutical 
industry was shifting from using internal monitors to outsource this activity to CROs. 
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He discussed the role of monitors in the production of data and knowledge within the 
clinical trial. In his view, outsourced monitors (CROs) were oriented to produce data 
about the quality of data obtained by site researchers, whereas industry monitors 
(working for the pharma company) focused their work on identifying causal 
associations and developed new knowledge useful for the project. Nonetheless, besides 
this study, the participation of each one of the actors in the clinical trials, about how 
knowledge flow and how different organisations contribute with their knowledge, has 
been little researched, and much less in research sites located in Latin America. This 
understanding is especially relevant in the clinical trial industry, as what is prevalent in 
the industry is a combination of offshoring to foreign affiliates as well as outsourcing 
to domestic and international CROs and SMOs, and knowledge has to flow through 
these vendors.  
Mistakes, omissions or misunderstandings on the transmission of information can have 
a direct influence on the project’s execution, leading to errors in the data, the 
production of wrong information and, at the end, the obtaining of inaccurate evidence. 
All this can have critical consequences for people’s health if clinical trials’ results are 
incomplete and the product is introduced into the market (as one of the cases will 
illustrate, Chapter 4. Pg. 84). To my knowledge, besides Azoulay’s (2004) study there 
has not been any research published that analyses the flow of knowledge, information 
and data and its use across the different actors that are part of the clinical trial. In a 
world that is more globalised and where projects are outsourced and fragmented 
among different firms, there is a need to understand, in the context of multi-
organisational projects, the flow of knowledge across organisations and its actual use 
in the specific project, and not only how firms individually become more competitive 
as a result of a project. For this reason, the principal objective of this study is to 
investigate the flow of knowledge and its use across the actors that participate directly 
in the project, from its design to its implementation. In this sense, the principal 
research question that this project aims to answer is: 
How does knowledge flow across organisations and is employed by 




This research provides new evidence on how knowledge is transformed, created, 
implemented in practice, and multiplied in a fragmented landscape composed of the 
multiple actors that participate in the design and execution of clinical trials. This 
research question is relevant because, each day, more research projects in different 
fields are implemented in collaboration among various groups, where knowledge flows 
and knowledge products are interdependent.  
This panorama is not only present in medical fields; in different industries, the 
outsourcing of key activities has been the constant of this century, especially in the IT 
sector, where the influence of outsourcing activities over the project results have been 
actively debated (Tafti and Zarb 2006). Therefore, I consider that the present research 
can contribute considerably to the study of knowledge in multi-organisational projects 
and give light to the aspect to be considered in the planning and execution of these 
projects. Of course, each project and industry has its particularities. Nonetheless, 
lessons learned in each industry can be shared, so in this way, this project can be 
relevant for multi-organisational projects in other fields.  
2.2.1. Sub-research questions 
The answer to this research question demands to know what the main activities in a 
clinical trial are, and the actors responsible for these. In this way, it is possible to analyse 
the flow of knowledge among organisations and their products. The first activity in a 
clinical trial is the design of the research protocol. The sponsor is responsible for creating 
the protocol, and the national regulatory agency of each country has to approve it. The 
second activity is the transfer of the protocol to the research sites to obtain the clinical 
data and other documentation associated with the project. In this way, the third critical 
activity is the implementation of the project by the sites. Finally, the fourth activity is 
the transfer of clinical data to the sponsor and its analysis to obtain the clinical evidence 
about the medical product under evaluation. Therefore, in total we have four main 
activities associated with the use and transfer of knowledge and three concrete 
knowledge-products are created and transferred. Firstly, the protocol designed by the 
sponsor; secondly, the clinical data produced exclusively by the research sites, and 
finally, the project result obtained only by the sponsor. This chain will be the one 
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addressed over the course of this thesis studying the use of knowledge and the demand 
or transfer of required knowledge, data and information to achieve the goals. 
The sponsor is the organisation responsible for the clinical trial. The sponsor’s first 
responsibility is to design the project’s research protocol. The protocol is a formal 
document that describes the objectives and all the processes and activities to be 
undertaken systematically and accurately in every single clinical site through the trial 
(Chin 2012; Knatterud et al. 1998). The information in the protocol consists of the 
objective(s), the endpoint, the methodology, statistical considerations, the logistics of 
the study, product dosage, patients’ inclusion and exclusion criteria, randomisation 
procedures, among others (Chin 2012; Knatterud et al. 1998; ICH Harmonised Tripartite 
Guideline 1996). Scholars have extensively discussed the need for a multidisciplinary 
perspective to design the protocol (Chin 2012) and the need to address the design 
aspects, such as scientific and logistic issues, data management, implementation and 
data analysis (Ottevanger et al. 2003; Goodarzynejad and Babamahmoodi 2015; Pocock 
1980). Nonetheless, the study about the acquisition and use of previous knowledge to 
design the clinical protocol has been less explored in the literature. I consider it 
fundamental to understand, from the sponsor’s perspective, how the clinical protocol 
is created to better understand the flow of knowledge across organisations in a clinical 
trial. Therefore, the first sub-research question of this thesis is: How did the sponsor 
acquire and use knowledge, data and information to design the clinical protocol? 
Chapter 4 provides the answer to this question, where I discuss how information flows 
towards the sponsor to create the protocol and design the clinical trial.  
Once the sponsor creates the protocol, the next stage is to transfer this document to 
the organisations responsible for the project’s execution. Within the clinical trial 
community, researchers have discussed that data’s validity may be dependent on the 
level of training received by the personnel working in the clinical trial and their 
familiarity with the study protocol (Gassman et al. 1995). According to the literature, 
the sponsor provides training to the sites. This training has the purpose of ensuring 
that all proceedings follow the practices in the industry, especially the GCP and the 
project documentation (Ukwu et al. 2011a). Research conducted by Subramaniam and 
Dugar (2012) emphasises the value of knowledge transfer and mentoring. Training does 
not only take place at the beginning of the trial. The identification of variation in the 
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clinical data demands additional training or modification of procedures to solve these 
issues and minimise the probability of future occurrences of deviations (Knatterud et 
al. 1998; Minisman et al. 2012; Ukwu et al. 2011a). For this reason, studying the training 
and transfer of knowledge becomes relevant to analyse the flow of knowledge.  
The literature of knowledge management in outsourcing projects has discussed the 
transfer of knowledge from contractors to providers. Bustinza et al. (2010) argue that to 
create a shared knowledge, the transfer of knowledge from contractors to suppliers 
becomes a subject of high relevance in multi-organisational projects. In this way, 
people can be on the same wavelength to understand the personnel in the other 
organisation and they can also learn the required information to execute a task. In this 
literature, three key factors can be identified for influencing the transfer of knowledge 
and information in an outsourced project. The first one, the structure created by the 
sender to transfer knowledge, data and information to the receiver. The second one, 
the previous experience and knowledge that the receptors have. And the third one, the 
openness of the people to accept and use the knowledge received (below I discuss these 
three elements), which I call permeability in this thesis. In a changing context, with the 
presence of new actors like the CROs and SMOs, little has been researched about the 
influence of these intermediaries on the acquisition of knowledge or the influence of 
the hierarchy to transfer knowledge on the acquisition of knowledge by the research 
sites. And much less attention is paid to the permeability1 of these last ones towards 
external knowledge.  
Therefore, the second research question that emerges in this thesis is: To what extent 
does the structure designed by the sponsor to transfer knowledge, the 
permeability of the research sites, and the previous experience of people 
working on the project influence the acquisition of knowledge in the research 
sites? This question is addressed in Chapter 5, where I discuss the impact of these 
factors on the transfer of knowledge and its acquisition by the research sites. 
The implementation of the protocol by researchers and staff in the research sites is an 
aspect that has received less attention, despite its relevance to the project. Research 
                                                          
1 Concept developed in the theoretical framework that has its roots in the not-invented here syndrome.  
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sites produce the clinical evidence and transfer the results to the sponsor, who analyses 
the data. Scholars have argued that the staff behaviour over the clinical research can 
compromise the safety and integrity of the trial and the subjects (Ottevanger et al. 2003; 
van Dongen 2001; Ippoliti 2013; Barnes and Florencio 2002b; Barnes and Florencio 
2002a). In turn, this behaviour influences the procedures to recruit participants 
(Geldenhuys et al. 2012; Goodarzynejad and Babamahmoodi 2015). Some of the 
problems described regarding the trial implementation include protocol violations, 
consent violations, fabrication of data, falsification of data and financial conflict of 
interest (Habermann et al. 2010; Gardner, Lidz, and Hartwig 2005; George 2016). To 
address these issues, many papers have focused on discussing how to improve data 
quality in clinical trials in general (U.S. Department of Health and Human Services 
Food and Drug Administration 2006; Friedman et al. 2015; Chan et al. 2013; Gassman et 
al. 1995; Knatterud et al. 1998; Meinert 2012). The majority of these papers advocate for 
the implementation of cost-effective procedures that guarantee the validity of the 
primary results (Knatterud et al. 1998), where some strategies to keep data quality 
include auditing, planning, analysis, inspection and tests of techniques (Ottevanger et 
al. 2003).  
However, scholars have limited their study about research sites’ dynamics to the 
problems associated with data quality, arguing that personnel at the sites do not 
contribute with their knowledge to the project (Fisher 2008). Far too little attention 
has been paid to the contribution of the sites to the project and the use of knowledge 
by physicians and other site’s members to obtain the clinical evidence. Therefore, the 
research question that emerges regarding the implementation of the project and the 
transfer of data is: How is knowledge employed in the clinical research sites to 
solve the productive enquiries related to the production of clinical data and its 
transfer to the sponsor? Chapter 6 provides an answer to this research question, 
where I open the black box of the contributions of the research sites.  
Then, answering the three research questions stated above, I expect to solve the central 
research question of this thesis, providing light on the flow of knowledge across 
organisations participating in multi-organisational projects and the use of knowledge 
in the main activities associated with a clinical trial in Latin America Countries.  
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2.3. Knowledge definition  
Until this point, I have introduced the research question, and I have focused the 
discussion on the literature related to clinical trials. Nonetheless, I have not defined 
knowledge, which is fundamental to set the epistemological basis of this thesis.  
Defining knowledge is not a simple task because, in the field of knowledge 
management, where this thesis is placed, multiple perspectives and definitions of 
knowledge have emerged. For example, in some cases knowledge is seen as a condition 
to access information (McQueen 1998), other researchers see knowledge as an asset or 
a production factor to make the firm more competitive (Bollinger and Smith 2001; 
Bustinza, Molina, and Gutierrez-Gutierrez 2010; Samoilenko and Nahar 2011; Maier 
2004), other researchers define knowledge as an outcome of organisational learning 
(Alavi and Leidner 2001; Bukowitz and Williams 1999; M. H. Meyer and Zack 1996). 
Then, in organisational studies and knowledge management, a consensus about 
knowledge classifications does not exist, making it challenging to define knowledge. 
Philosophers and sociologists of science have addressed the question of knowledge for 
a long time, but an agreement has not been reached. 
Despite this situation, the management of knowledge has become a fundamental aspect 
studied in organisations (Kogut and Zander 1992; Nonaka and Takeuchi 1995; Tsoukas 
and Mylonopoulos 2004; Evans, Dalkir, and Bidian 2014), where two different 
perspectives (definitions) about knowledge prevail. Tsoukas (1996) named the first 
perspective as a taxonomic view of knowledge, where scholars classify knowledge 
according to its content. Based on these classifications, scholars recommend strategies, 
routines and techniques to generate, encode, share and transfer the different types of 
knowledge in the organisation (Richard Rex Nelson; Sidney G. Winter 1982; Nonaka 
1994; Newman and Conrad 1999; Maier 2004). This taxonomy perspective is rooted in 
the taxonomy proposed by Polanyi (1966), of tacit and explicit knowledge, which has 
been the base to introduce multiple knowledge dichotomies such as: 
1. General vs specific (Samoilenko and Nahar 2011) 
2. Local vs universal (Oluikpe, Sohail, and Odhiambo 2011) 
3. Codified vs uncodified (Oluikpe, Sohail, and Odhiambo 2011) 
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4. Procedural vs declarative (Wiig 1993) 
5. Individual or social knowledge (Spender 1996).  
Nevertheless, authors such as Tsoukas (1996) have criticised this dichotomic or 
discretional view about knowledge. For him, this division does not recognise that tacit 
and explicit knowledge are inseparable and knowledge cannot always be classified in 
categories without considering the interlinks among them. Also, tacit knowledge is a 
necessary component of all knowledge (Tsoukas 1996).  
The second view about knowledge, in an organisation, aims to articulate know-how 
and know-what. Know-how is the ability of people to put into action what is known 
(Seely Brown and Duguid 1998), and the know-what represents an understanding of 
the generative process that constitutes phenomena (Garud 1997). This vision of 
knowledge is rooted in the separation between learning and use. Under this vision, 
there has been a concern about how to join the study of these two activities to 
understand how, in an organisation, learned knowledge is employed, and how the 
learning context influences the use of knowledge in action (Brown, Collins, and Duguid 
1989). In this second view of knowledge, knowing what to do, by itself, does not enable 
the execution of the task, so developing the know-how in action is fundamental to 
implement any work.  
In this second view of knowledge, Cook and Brown (1999) suggested that within 
organisations there exist two epistemologies of knowledge: the ‘epistemology of 
possession’ and the ‘epistemology of practice’. The epistemology of possession sees 
knowledge as ‘something’ that people have in their heads, and they can acquire and 
transfer. The epistemology of practice is about the use in the execution of the task of 
what is known; this means “knowing as part of the action”. According to Cook and 
Brown (1999), these two epistemologies are complementary and co-exist, and they are 
NOT oppositional. People possess knowledge, and it is through action that they identify 
if this content and procedures are enough to implement the task. If knowledge 
possessed is not sufficient or adequate to know how to execute a task (epistemology of 
practice), new knowledge, know-what, and know-how has to be acquired 
(epistemology of possession) until the individual is capable of culminating the task. For 
these authors, possessed knowledge must be seen as a “tool at the service of knowing, 
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not as something that, once possessed, is all that is needed to enable action or practice” 
(Cook and Brown 1999). Under this perspective, individuals develop new knowledge in 
practice, and this new knowledge becomes a new know-what and know-how for future 
activities and can help to solve the new problems. For Cook and Brown (1999), the 
knowledge possessed by people only makes sense once people implement it in practice, 
in productive inquiries.2 In this way, the epistemology of possession and practice are 
interlinked continuously.  
It is important to clarify in this thesis that the ‘epistemology of practice’ is not the same 
as practice theory or communities of practice, which can be easily confused by the 
reader and can lead to misinterpretations of the rest of the document. Practice theory 
is a broad intellectual landscape that has “emphasis on explaining the emergent 
constitution of the socio-material world through the micro-dynamics of everyday life 
in organisations” (Feldman and Orlikowski 2001, 1250). Practice theory argues that 
“everyday actions are consequential in producing the structural contours of social life” 
(Feldman and Orlikowski 2001, 1241). In other words, practices produce an 
organisational reality, which is dynamic and accomplished in ongoing everyday actions. 
On the other hand, a community of practice is the building block of a social learning 
system. In these communities, people learn, display capabilities and are evaluated by 
peers, who determine if they are trusted as a partner of the community (Wenger 2000). 
In contrast, the epistemology of practice is oriented to see how what people know 
(possessed knowledge) is used in everyday life rather than understanding the origin of 
routines or explaining an organisational reality or how people learn within their 
communities. Of course, this does not mean that one study cannot address at the same 
time the study of the epistemology of practices and possession, and the study of a 
community or the emergence of routines in an organisation, but this is not the scope 
of this research.  
The focus of this thesis is to understand the flow of knowledge across organisations and 
its use to produce the knowledge products in each one of the organisations. This 
objective implies that this research considers knowledge as an object transferred, 
                                                          
2 A productive inquiry is a form of knowing that seeks an answer, solution or resolution to questions or 




externalised and acquired between organisations and it is possessed by people to 
implement the actions which correspond with the epistemology of possession. The fact 
that this research aims to study the production of knowledge production through the 
use of knowledge means this research should address how what is known (know-how 
and know-what) is used to implement the tasks. Then, in this thesis, the definition of 
knowledge provided by Cook and Brown (1999) is adopted and knowledge is seen as a 
group of concepts, procedures, norms and know-how that people have (epistemology 
or possession) and it is acquired, employed to solve a productive enquiry (epistemology 
of practice) and efficiently transferred in multi-site clinical trials.  
2.4. Clinical trials defined as a knowledge-intensive 
project 
The design, implementation and conclusion of a clinical trial depend to a large extent 
on the knowledge and use of this knowledge by the people working on it. Jensen and 
Sandstad (1998) considered that a clinical trial is a Knowledge Intensive Project (KIP). 
Later on, Azoulay in 2004 employed the term KIP to refer to the production of 
knowledge in a clinical trial. In a general sense, scholars have openly used the KIP term 
to refer to a project in which results depend strongly on the analytical skills and 
cognitive capabilities employed on the project rather than on the implementation of 
repetitive procedures (Jørgensen 2002) (which require, of course, the use of knowledge 
but not strong analytical skills). For example, the term KIP has been employed to 
classify projects outside the pharmaceutical sector like service projects (Larsen 2001; 
Skjølsvik et al. 2007; Brinkley et al. 2009; Roy and Sivakumar 2012), engineering projects 
(M. Jensen et al. 2007) and software development projects (M. Jensen et al. 2007; Patton 
2007; Reich, Gemino, and Sauer 2012; Jørgensen 2002; Chi and Chen 2009; Tiwana and 
Ramesh 2001). All these projects have the use of knowledge work to design and/or 
execute tasks in common (Fong 2003). Under this logic, in this thesis, clinical trials are 
considered KIPs where the design and execution of the project lies on the knowledge 
used by epidemiologists, statisticians, physicians, doctors, nurses, technicians, 
monitors and people located across multiple organisations; and the main knowledge 
product is the evidence of the behaviour of a molecule or biological product in the 
human body or a population which achieves materiality in documents. Other sub-
products are the protocols, medical reports,  
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The previous research about knowledge in KIP has focused mainly on intra-
organisational projects and on understanding how firms and teams create knowledge 
over the course of the project, and how this can be stored and used in future projects. 
As a starting point, scholars have used the knowledge creation model proposed by 
Nonaka (1994) to study knowledge creation in KIP. This model assumes that individuals 
create new knowledge for the organisation by interconverting tacit and explicit 
knowledge, where individuals externalise, socialise, internalise and combine 
knowledge to create a new one (Nonaka 1994). However, a significant limitation of this 
approach is that it does not consider that knowledge is the result of an analytical 
activity. Therefore, the studies about KIP projects have only focused on the 
interconversion of forms of knowledge (tacit and explicit) and have left behind the 
actual understanding of how knowledge is employed in a project to obtain a result.  
For example, Jensen and Sandstad (1998) developed a model to understand how 
pharmaceutical companies store their knowledge and information to operate with 
maximal effectiveness, so the generated knowledge stays in the organisational memory 
for further use. Nonetheless, this approximation has focused only on the externalisation 
of knowledge and its storage. In the context of project teams, Fong (2003) employed 
Nonaka and Takeuchi’s model (1995) as a basis for understanding how knowledge is 
created in multi-disciplinary teams working on infrastructure development projects. In 
this model, knowledge creation is based on the interaction among team members to 
overcome social and cognitive barriers, where different knowledge-bases and 
experiences are combined to create new knowledge. Although this model considers the 
differences in the knowledge among team members and highlights how the 
combination of knowledge from diverse disciplines can lead to new knowledge, it pays 
less attention to the process of ‘learning by doing’ or ‘creating knowledge by doing’, 
which I consider critical in the process of producing knowledge products in KIP. In this 
sense, the studies about KIP projects have only focused on the interconversion of tacit 
and explicit knowledge and have left behind the actual analytical process of how 
knowledge is employed or not in a project to obtain a result. 
In the case of multi-organisational projects, Yeh (2008) studied the creation of 
knowledge in outsourced KIP. He employed Nonaka’s creation model to propose a 
framework to evaluate the production of knowledge in the boundaries between buyer 
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and supplier. The author considers that the interaction of people located in different 
organisations gives place to new knowledge, where people in one firm obtain new 
knowledge by being aware of a topic or issue related to the other organisation. 
However, similar to the previous research, this one was oriented to understand the 
transformation and transfer of tacit and explicit knowledge to create this awareness in 
the organisation, rather than to study the production of new knowledge as a product 
derivative of the implementation of the project where multiple organisations work. 
This fact appears to be a limitation of the emerging literature of knowledge creation in 
KIP to explain how the organisation produces knowledge products through the project.  
Some reasons that explain this gap are that the literature about multi-organisational 
projects, KIP and the study of knowledge have oriented to understanding how firms 
can be more competitive and can use their knowledge as a competitive advantage to 
innovate. So, this focus has made scholars pay more attention to the processes of 
storing knowledge and using it in following projects rather than understanding the 
actual use of knowledge in the project. This gap is the one addressed in this thesis, and 
for this reason, I consider it necessary to present previous research on similar topics 
such as outsourcing.  
2.5. Previous research about the outsourcing of 
knowledge activities 
The literature on knowledge management has concentrated principally on generating 
an extensive range of theoretical frameworks and models to describe how the 
organisation as a whole should create, store, diffuse and use their knowledge to add 
value to the company (Dalkir 2005; Baskerville and Dulipovici 2006; Rubenstein-
Montano et al. 2001). These approaches have been developed to answer questions like 
how an organisation can create new knowledge from data? How can new products be 
generated employing the organisational knowledge? And how can the core knowledge 
of an organisation be preserved? All these questions have implied an intra-
organisational perspective.  
Over the last 15 years, the interest in studying outsourcing activities to better 
understand how firms manage knowledge over the course of outsourced services or 
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projects has increased in the field of knowledge management. In recent years, some 
researchers on organisational studies employing a knowledge-based perspective of the 
firm and using concepts of the knowledge management theory have studied how 
sponsors should design the project to control the outsourced operations (Roy and 
Sivakumar 2011); how to promote innovation on the project’s transition stages (Roy and 
Sivakumar 2012); how to mediate power in the outsourced relationship (Handley and 
Benton Jr 2012); and how to integrate global knowledge networks (Anderson Jr. and 
Parker 2013). Nonetheless, the literature has not addressed the entire flow of knowledge 
from the beginning to the end across organisations. 
The reason for this turn is that, today, companies in a wide range of diverse industries 
are outsourcing or offshoring knowledge-based services to external firms. Thanks to 
the growth of information technologies, the outsourcing of knowledge-based services 
is becoming multinational. Outsourcing is increasing rapidly, augmenting between 
2000 and 2015 in 43.4 billion US dollars in revenue (Statista 2015). Outsourcing includes 
a wide variety of activities, such as accounting (Risman, Aman, and Hamzah 2012), 
financial services (Blumenberg, Wagner, and Beimborn 2009; Currie, Michell, and 
Abanishe 2008), information technology (Dibbern et al. 2004), and research and 
development (Lowman et al. 2012).  
Within the broad universe that composes the activities outsourced, some authors have 
focused the scope of their research to the outsourced activities that require high 
analytical thinking, use of knowledge and specialised skills to be implemented. These 
activities have been named knowledge process outsourcing (KPO) (Edvardsson and 
Durst 2014), which shares characteristics with the KIPs. The study of the KPO has 
focused on three broad areas of research. The first area addresses the motivation to 
outsource core activities. The second area has concentrated on the factors that affect 
the outsourcing (Lowman et al. 2012; Henley 2006). The third area has been about the 
knowledge management around outsourcing. This last area of study is divided into two 
lines of research: the first line is about how organisations manage their knowledge 
while they offer their services (Bustinza, Molina, and Gutierrez-Gutierrez 2010; Yan 
2011; Zhao, Yim-Teo, and Yeo 2004; Mohannak 2013). The second line of research is the 
management of knowledge across organisations participating in outsourced projects 
(Samoilenko and Nahar 2011; M. Jensen et al. 2007) or in inter-organisational 
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relationships (S. Gupta and Polonsky 2014; Ngai, Jin, and Liang 2008; Matinheikki et al. 
2016). The discussion in the following paragraphs is about previous research on 
knowledge management in outsourced activities. 
Similarly to studies in Knowledge Intensive Projects (KIPs), previous research on 
outsourced activities has focused on understanding how outsourced firms create new 
knowledge and store it to make the firm competitive over the outsourcing (Yan 2011; 
Zhao, Yim-Teo, and Yeo 2004; Matinheikki et al. 2016) and the effect that the 
outsourcing has over the knowledge and competencies of the contractor (Lowman et 
al. 2012; Aban et al. 2008). For example, Zhao et al. (2004) argue that outsourced 
companies should pay attention to how to retain, utilise and create knowledge, to 
improve their corporate memory and core capabilities, and develop a culture to 
promote knowledge sharing across organisations. For these authors, in the 
organisation, knowledge should be created, identified, modified and then integrated 
into the company’s processes in a continuous cycle of knowledge transfer, which should 
benefit all parties involved in the activity. On the same line of ideas, Yan (2011) 
considers that the implementation of a knowledge management system (an integrative 
software) within the organisation can support the acquisition, sharing, transfer, 
creation and application of knowledge in outsourced activities. For this author, the 
system designed to manage knowledge (IT infrastructure) should have an extensive 
knowledge warehouse to enable the knowledge acquisition and its posterior sharing. 
Once people acquire knowledge, this one can be employed in the business operations 
to innovate. Then, once again, the focus of research has been on knowledge and 
information storage. 
The second line of inquiry within the management of the outsourced project has been 
the management of knowledge across organisations participating in outsourced 
projects or services. This line has received more attention than the previous one, where 
the transfer of knowledge and the identification of factors influencing the outsourcing 
have been the focus of the research. In this sense, multiple authors have argued the 
need to create a shared knowledge among the actors to enable the transfer (Samoilenko 
and Nahar 2011; A. K. Gupta and Govindarajan 2000), and the relevance of interpersonal 
relationships among people working on offshore knowledge-intensive projects have 
been pointed out (M. Jensen et al. 2007). During outsourcing activities, organisations 
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receive new knowledge transferred by the contractor. This new knowledge has to be 
integrated with their local knowledge and operationalised to create the product 
demanded by the contractor (Jackson and Klobas 2008). In this process, the outsourced 
organisation develops new organisational capabilities to manage all knowledge and 
information, the old one, the one received, and the new one, when the capabilities are 
oriented to learn, apply, merge, create, record and transfer the knowledge (Dalkir 
2005). In this sense, different models have been proposed to manage knowledge across 
organisations. Samoilenko and Nahar (2011) proposed one model focused on the 
transfer of knowledge through training, where organisations share specific and general 
knowledge3 about the business activity. Another model is the one proposed by Ngai et 
al. (2008) to manage knowledge across organisations participating in complex products 
and systems development projects. This model consists of three processes: Knowledge 
Acquisition, Knowledge Implementation and Knowledge Transfer. 
2.6. Proposed model to study the knowledge flow 
between organisations and its use within teams  
2.6.1. The model’s building blocks 
The creation of models to explain the management of knowledge within or across 
organisations has its roots in the literature of knowledge ‘models, work and processes’ 
(K. Grant 2011, 121); literature that has not been limited to studying outsourced 
activities. In this body of literature, different models have been proposed to study the 
flow, the storage and/or use of knowledge within the organisation, considering in some 
cases the interactions with other firms to acquire and transfer knowledge and 
information (Evans, Dalkir, and Bidian 2014). The principal objective of some of these 
models is to explain how firms manage their knowledge to create value for the 
organisation and to be more competitive and innovative (Maier 2004). I consider that 
three models of this literature proposed by Meyer and Zack (1996), McElroy (1999) and 
Ngai et al. (2008) are useful for studying the flow of knowledge, data and information 
                                                          
3 Zack defined general explicit knowledge as a broad knowledge that is independent of particular events, 
while specific knowledge or information refers to knowledge that is context-specific, where specific 
categories and descriptions should be provided (Zack 1999).  
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and its transformation within and across organisations to create new products and 
implement tasks (Table 1 provides a summary of the three models).  
Although each model has its complexities and each one addresses different processes 
in the organisations, these three models coincide mainly in three aspects:4 the 
acquisition of knowledge, the use of knowledge in practice, and the transfer of results 
to internal or external users (Table 1). These three steps are critical to understanding 
                                                          
4 The scope of this section is not to discuss each one of the models; nonetheless, a summary of the steps 
proposed in each model are provided at Table 1. 
Table 1. Comparison of three knowledge management models that have been 
employed to explain the management of knowledge at the intra-organisational level.  
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the flow of knowledge, data and information in a firm. In the first step, people in the 
firm acquire knowledge, information and/or data from internal or external sources to 
implement the activities to increase their ‘knowing’ (McElroy 1999; Ngai, Jin, and Liang 
2008). The other reason to acquire data and information is to analyse it and transform 
it into products, where people already know how to process this information and data 
(M. H. Meyer and Zack 1996). The acquisition of knowledge can have two directions. 
The first one is an in-out direction, where the firm searches for external knowledge and 
information because they need it. The second direction is the out-in direction, where 
the organisation is the receptor of knowledge transferred by an external agent.  
The second element that these three models share is the use of the knowledge by people 
(acquired or the one that people already have) to execute actions. Either to analyse data 
or information (M. H. Meyer and Zack 1996) or as a part of the productive activity that 
the person is undertaking (McElroy 1999; Ngai, Jin, and Liang 2008). At this stage, the 
knowledge, information and data acquired are employed to execute the activities, 
produce the knowledge products, refine the data (M. H. Meyer and Zack 1996) or give 
a solution to the problems (McElroy 1999). And finally, the third aspect that these 
models share is the storage of results or lessons learned within the firm and/or transfer 
(McElroy 1999) to external organisations (Ngai, Jin, and Liang 2008; M. H. Meyer and 
Zack 1996), connecting the firm with another organisation. I consider that the attention 
McElroy (1999) gives to the existence of loops among the steps, and the evaluation of 
results is highly relevant because in clinical trials external actors and those doing the 
work are regularly reviewing the data, protocols and documents. Then, in each 
organisation, different cycles to gain knowledge exist, and these will be identified in 
the thesis. 
It is important to notice that although these models have an intra-organisational focus, 
the actions of an organisation are implemented by the people working there. As these 
authors point out, people are the ones that learn, interact and produce knowledge. For 
these reasons, the attention on the models rests on people, their learning and actions, 
and then the results are scaled up at the organisational level to discuss how the 
organisation can enhance, store or get benefit from the knowledge produced and 
acquired by the people working in the firm. 
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The combination of these models to understand the flow of knowledge across 
organisations and the use of knowledge within the organisation in the execution of 
activities provide the conceptual framework to answer the research questions stated in 
this research. In this way, the basis of the model proposed in this thesis to answer the 
research question includes the steps shared among the three models compared before 
(see Table 1). The steps are the next ones: (1) The acquisition and search of knowledge, 
data and information from external and internal sources. (2) The use of knowledge 
(knowing) to solve the productive inquiry and evaluate results. (3) Results Storage 
and/or transfer of results to other organisations. These three steps are not linear. 
Firstly, there can be loops among steps as McEloyid (1999) indicated, especially 
between the acquisition of knowledge and its use. These loops are because the 
evaluation of the products can give as a result that the knowledge acquired was not 
enough or because people did not achieve their goals. Secondly, the acquisition of 
knowledge and its use in practice can take place simultaneously, so this must be 
considered as a variation of a linear model. Thirdly, it is necessary to keep in mind that 
once products are transferred, some activities do not finish; in some cases, intermediary 
information and data is sent as part of the project. Another element to consider is the 
number of organisations and the interdependency among them.  
2.6.2. Inter-organisational dynamics in the model 
As I have mentioned, a multi-site clinical trial is a project that takes place across 
multiple organisations, which can be in one or various countries. I consider it necessary 
to analyse the dynamics that take place at the intra-organisational level and inter-
organisational level to study the process of producing the clinical evidence in a clinical 
trial. 
Newell et al. (2008) addressed for the first time the study of the interdependencies 
among multiple organisations working on numerous projects (complex project 
ecologies) to develop and evaluate drugs and therapies. Nonetheless, their study did 
not address the interdependencies that take place in a single project where multiple 
organisations participate and the role of these interdependencies in the production of 
results, as it is the case of a single clinical trial. In the context of multi-organisational 
projects, Adenfelt (2010) pointed out in her research about multinational projects, that 
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knowledge is an input and output. The starting point for the project execution is the 
knowledge pre-existing in the companies, and the knowledge produced is an output 
shared over the course of the project. This argument coincides with the concept of 
interdependency proposed by Kumar. et al. (2009) to explain the relationship between 
activities executed in different departments or organisation in the same project. They 
based on the concept of interdependency initially coined by Thompson (1967), claimed 
that two actions are interdependent if the output of one operation in one 
department/firm is the input for another department, and there is a dependence on the 
results. Although the concept developed by Thompson (1967) was in administrative 
theory and organisational studies, this concept has been employed to conceptualise the 
dependency on results among organisations participating in a multi-organisational 
project and can complement the models discussed above. 
At the inter-organisational level, the model that I propose considers the existence of 
interdependency among firms and their activities where the output of one organisation 
is the input of the other one to operate (Figure 1). In a multi-organisational project, 
more than two organisations can participate, then multiple interdependencies can be 
present in a project. The inclusion of the concept of interdependency allows us to 
understand the connections among organisations participating in a multi-
organisational project, the dependency on results and the directionality on the transfer 
of products between firms. In this way, it is possible to follow, from the beginning of 
the project until its end, how organisations exchanged their results, and how the first 
knowledge, data and information was transformed through the network of actors into 
the evidence of the vaccine efficacy, efficiency, and safety. 
This interdependency among products demands the constant acquisition and transfer 
of knowledge products across firms. The knowledge management literature about 
outsourced activities has paid particular attention to the study of the acquisition and 
transfer of knowledge. The research has focused on identifying critical factors that 
influence these two activities. I have identified three key factors highly reported in the 
literature of knowledge management in multi-organisational projects and outsourced 
projects, which impact the acquisition of knowledge and the transfer of knowledge, 
data and information to another organisation. The three factors are the sender-received 
dimension (in this thesis, structural dimension) through which knowledge, data and 
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information are acquired and transferred among firms; the knowledge-base of the 
people; and the permeability of individuals towards external information and 
knowledge. I consider it fundamental to include these three factors in the proposed 
model to study the flow of knowledge, data and information because they act as 
modulators of the knowledge flow across organisations and within organisations in the 
multidisciplinary project, as will be discussed in Chapter 4. 
In the context of outsourced projects, the transfer of knowledge to create a shared 
knowledge among project workers is fundamental. Samoilenko and Nahar (2011) argued 
that the client is the one responsible for planning and conducting the training and 
transfer of specific and generic5 information about the tasks to be implemented for the 
project. In this way, the supplier can have a deeper understanding of the project, and 
they can know what the contractor expects. Blumenberg et al. (2009) indicated that in 
IT outsourced relationships, the transfer of explicit knowledge has two dimensions. The 
first one is a content dimension, which includes the documents and training that 
contain the concepts required to reach a shared knowledge about the task and the 
project. The second dimension is a structural dimension, which consists of the 
structures that delimit the interaction between people and the transfer of knowledge. 
This dimension determines that people need to know who to contact to access or 
transfer information and what the hierarchies in the communication structure are 
(Blumenberg, Wagner, and Beimborn 2009). For example, not everybody in the firm is 
allowed access to top managers or to contact personnel in another firm directly. There 
are outlined structures to scale up information defined by the communication channels 
and rules to transfer the knowledge.  
About this structural dimension, multiple authors have pointed out the importance of 
the sources and the transmission channels to acquire and transfer knowledge, data and 
information (Mandják et al. 2015; Alavi and Leidner 2001; A. K. Gupta and Govindarajan 
2000; Anderson Jr. and Parker 2013). These two aspects are elements of the structure-
dimension defined by Blumenberg et al. (2009). In the first place, the source can be 
located inside and outside the firm (Mohannak 2013). Sveiby (2001) proposed that there 
                                                          
5 Zack defined general explicit knowledge as a broad knowledge that is independent of particular events, 
while specific knowledge or information refers to knowledge that is context-specific, where specific 
categories and descriptions should be provided (Zack 1999). 
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are two primary sources in an organisation. The first one is the people who have the 
knowledge, and the second is the organisational structures (i.e. warehouse, databases), 
where information and data are collected. Similarly, channels are classified into 
personal (Mandják et al. 2015) or impersonal channels (Freiden et al. 1998; Sveiby 2001). 
Personal channels correspond to the interaction among people to acquire knowledge, 
where people socialise, externalise their knowledge and internalise new knowledge, 
and impersonal channels are databases, information repositories, e-training etc. Then, 
sources and channels can take the same shape; they can be personal or impersonal.  
In some cases, the source and channels can be the same. For example, individuals 
transferring verbal information are at the same time the channel and the source of 
knowledge (Mandják et al. 2015). Alternatively, in other cases, humans are channels to 
transfer explicit information, like ‘boundary spanners’; they are intermediary people, 
carriers, that enable access to knowledge, information and data dispersed across 
multiple organisations, networks, and systems (Ansett 2005; S. Gupta and Polonsky 
2014; Levina and Vaast 2014). They do not have the knowledge or information, but they 
search for it externally and transfer it to the organisation. So, the analysis of the 
structure employed to transfer and acquire knowledge must consider these differences.  
Authors adopting a cognitive perspective of knowledge have suggested that people’s 
knowledge-base (basic skills, shared language and knowledge of scientific or 
technological developments) conditions the potential to acquire and introduce 
knowledge or information in the firm (Li et al. 2014; Nooteboom et al. 2007; Cohen and 
Levinthal 1990). The relevance of previous knowledge lies in the fact that the diffusion 
of knowledge is neither direct or straightforward; it requires a learning effort to be 
acquired (Akbar 2003). Memory works in an associative way, where people create new 
knowledge by establishing linkages with pre-existing concepts (Cohen and Levinthal 
1990; Nonaka 1994). Different authors have discussed the relevance of overlapping or 
shared knowledge among people working together to exchange knowledge (Alavi and 
Leidner 2001; Tuomi 1999). Nooteboom (1992, 2000) inferred that people working in 
different environments interpret, understand and evaluate the word differently.  
These differences in previous knowledge give place to the notion of “cognitive distance 
between people” (Nooteboom et al. 2007, 1017). It has been argued that on the 
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acquisition of knowledge, a long cognitive distance decreases the understanding among 
people, having a detrimental effect on the acquisition of knowledge (Nooteboom et al. 
2007, 1017). Specific shared knowledge is needed for collaboration and knowledge 
acquisition. Therefore, if a sizeable cognitive distance exists between people, a learning 
effort is necessary to acquire knowledge and achieve a shared knowledge. In this order 
of ideas, in the context of multi-organisational projects, previous knowledge has 
relevance on the acquisition of knowledge and creation of shared knowledge.  
Most of the discussions about knowledge-base have taken place at the firm level, where 
a knowledge-based theory of the firm has been developed (Nickerson and Zenger 2004; 
Kaplan et al. 2001); this theory that has its roots in the resource-based view of the firm. 
The primary objective of this theory is to integrate the knowledge residing in the 
organisation through a series of changes in the organisational structures to manage it 
(R. M. Grant 1996). Nonetheless, in the specific case of the influence of knowledge on 
the acquisition of knowledge in a project, the scope is entirely different to the one 
addressed in the knowledge-based theory, in which is studied how to optimise the use 
of knowledge present in the organisation (Nickerson and Zenger 2004). In the study of 
knowledge acquisition among firms, the term ‘knowledge-base’ refers to the previous 
knowledge that a person has (or group of people in a firm has) and how this previous 
knowledge allows them to acquire new knowledge, as discussed above. Therefore, it is 
essential to differentiate between knowledge-based theory and the concept of 
knowledge-base introduced here. In this research, the focus is on how previous 
knowledge influences the acquisition of knowledge, which is the aspect related to the 
knowledge flow.  
The third factor to consider in the acquisition of knowledge, data and information is 
the permeability of people towards external information and knowledge. Gupta and 
Govindarajan (2000) indicated that people’s motivations to acquire and receive 
knowledge influence the acquisition of knowledge. For these authors, the “not-
invented-here” syndrome, proposed firstly by Katz and Allen (1982), prevents the flow 
of information to the organisation and becomes a barrier to acquiring knowledge. This 
syndrome takes place where recipients consider that the information and knowledge 
transferred to them indicate that the sender is more competent. This syndrome 
happens if receivers want to diminish the value and relevance of the transferred 
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knowledge. Some authors have suggested that this attitude towards external knowledge 
can be considered a psychological issue, as it is individual-based (Grosse Kathoefer and 
Leker 2012), which prevents the acquisition of relevant knowledge or information for a 
project and has a negative consequence in the organisation (Lichtenthaler and Ernst 
2006). In contrast to this syndrome, Menon and Pfeffer (2003) suggest that in some 
cases the use of transferred knowledge is preferred by some firms rather than using the 
knowledge generated internally, which they may consider being less valuable or 
relevant, then, peoples are more receptive to acquire and use external knowledge. 
Although both positions could have adverse consequences for teams and organisations, 
what is critical to this discussion is teams’ permeability to acquire and use the 
knowledge received, which can create a barrier to the knowledge flow. 
As I presented above, teams and their members might be selective toward external 
information being sometimes closed entirely to receive external information and 
knowledge, or at other times, they are entirely open to receiving and using external 
knowledge. I use the term ‘permeability’, making an analogy between the selectivity of 
personnel at the teams and the process employed by the cells to control the absorption 
of polar and big molecules to maintain the cellular composition (Cooper 2000). A cell 
is more or less permeable to external molecules opening or closing 
specific transmembrane proteins that control their entrance. Based on this analogy and 
the information presented, I suggest that in the teams there can be different degrees of 
permeability to the external information, which is mediated by people’s motivations to 
accept (or not) the knowledge and information coming from outside its boundaries. 
Then, I propose two categories of analysis to study the permeability: high permeability 
and limited permeability. Teams are highly permeable or non-selective toward 
information and knowledge if people do not present a high resistance to external 
information; this is the case if teams prefer external knowledge rather than internal 
knowledge or do not question the external one. On the other hand, people are less 
permeable if they doubt the validity of the external knowledge, as is the case in the 
“not-invented-here” syndrome, where these teams select only information or 
knowledge that they consider pertinent or valid, or avoid the use of external 
information. I will use these two levels of analysis to determine how receptive and 
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permeable people were respecting external information, and identify the reasons that 
lead to these positions to accept it or not. 
2.6.3. The proposed model and its use to answer the research 
questions  
In conclusion, Figure 1 summarises the proposed model to answer the research 
questions and study the flow of knowledge across organisations and its use to produce 
the productive enquiries. The model has its roots in the literature of knowledge ‘models, 
work and processes’ (K. Grant 2011, 121) (Table 1). And it was complemented with the 
concept of interdependency, and critical factors that seem to influence the acquisition 
and transfer of knowledge: people’s knowledge base, the structural dimension to 
transfer knowledge and the permeability of people towards external knowledge.  
 The research questions elaborated in this thesis were built on the premise that a 
clinical trial is a multi-organisational project, where the sponsor and clinical sites 
produce interdependent knowledge products. The first product is the clinical protocol 
designed by the sponsor; the second product is the clinical data (obtained by the 
research using their knowledge, the protocol and information transferred by the 
sponsor). The use of this model will allow me to compare among the cases studied the 
Figure 1. Conceptual model proposed to study the flow of knowledge across 
organisations and its use within the firm. Graphic made considering a hypothetical 




flow and use of knowledge in the project activities, identifying trends and the 
differences among cases and organisations of the same type (Sponsor vs Sponsor, Site 
vs Site) in each one of the steps.  
The first research question of this project is how does the sponsor integrate internal 
and external knowledge, data and information to design the clinical protocol? 
Using the proposed model to answer the research question, I will analyse, at the intra-
organisational level, how the sponsors accessed information, data and knowledge 
required and combined it with previous results to produce the protocol. In this analysis, 
I will discuss how previous knowledge, or the lack of it, influenced the acquisition of 
knowledge and how the permeability of the clinical team towards external knowledge 
defined what knowledge was used or not in the protocol design.  
The second research question of this thesis is to what extent does the knowledge-
base of people working on the project, the structure designed by the sponsor to 
transfer knowledge, and the permeability of the research sites influence the 
transfer/acquisition of knowledge in the research sites? This question is about the 
interdependency between the sponsor and how the identified factors affect the 
acquisition of knowledge by the research sites. The answer to this question includes the 
sponsor and the site perspective. Firstly, the answer includes how the structure created 
by the sponsor to transfer information to the sites enabled (or not) the knowledge 
acquisition by the research sites, and how the presence of intermediary organisations 
influences the transfer process. Secondly, in this chapter, how the previous experience 
that people had in the clinical sites influences the acquisition of new knowledge is 
analysed. For this, it will be of the knowledge-base of the people receiving the new 
knowledge and information. I will identify the experience and training of the personnel 
and its relation to the acquisition of new knowledge and the creation or reinforcement 
of the conceptual basis and practices to execute the project. The evaluation of this 
factor is relevant, especially for studying new organisations without experience 
conducting clinical research. In this way, from these organisations, it will be possible 
to learn how people use their previous training or professional background as a tool to 
acquire new knowledge and close the knowledge gaps before initiating the project. 
39 
 
Finally, the model proposed will be employed to answer the third research question of 
this thesis, that is: How is knowledge employed in the clinical research sites to 
produce the clinical data and transfer it to the sponsor? This question takes us to 
the intra-organisational dimension of the research site and addresses the use of the 
acquired knowledge from the sponsor and the knowledge that already resides in the 
clinical team to execute the clinical trial and produce and transfer the clinical data. The 
production of the clinical data demands multiple activities from the personnel. 
Therefore, to answer this question, what specific knowledge was employed in each one 
of these activities, the relevance of the previous knowledge to implement new 
procedures, and how people had to develop new know-how to solve the productive 
enquiries and produce the clinical data will all be discussed.  
I discussed above how previous research on KPO has focused on specific aspects of the 
outsourcing. Nonetheless, scholars have not researched the flow of knowledge across 
the actors engaged in the outsourced activities, and the use of the knowledge within 
each firm to execute their task in the project. This thesis contributes to the study of 
knowledge management in multi-organisational projects, answering the research 
question stated above, studying for the first time the flow of knowledge over the course 
of a project and its use within the organisation to meet the project goals. Answering 
these research questions, I contribute not only empirically to the study of the 
production of clinical evidence in multi-organisational clinical trials, but also 
theoretically, using the literature of knowledge management models in a novel way. 
Firstly, proposing a model to study the knowledge flow across organisations in the 
context of a project. Secondly, evaluating the model introduced above for the first time 
along a chain of activities that take place across different organisations dispersed 
geographically, where various forms of interdependencies exist.  
2.6.4. Considerations 
Some people could consider that the results of a clinical trial are the result of the co-
creation of knowledge involving all the different organisations along the activities value 
chain of this product. To say that knowledge is co-produced, it is imperative that 
multiple stakeholders engage and integrate multiple perspectives that shape the 
understanding, and processes of knowledge generation and use (Rycroft-Malone et al. 
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2016). This condition is not met in the implementation of a clinical trial, where each 
organisation has clear responsibilities, and the boundaries between firms on the 
knowledge production are defined, and only the sponsor takes the critical decisions of 
the project.  
A clinical trial is a project where the only organisation responsible for the project is the 
sponsor. Yes, personnel at the research sites use their knowledge to produce the data, 
which is vital in the project, and I will be discussing how they do it and what knowledge 
they use. Nonetheless, this is their responsibility as an outsourced organisation to 
supply a service; service that demands the use of knowledge, but in the final results 
these providers are not allowed to take part, and their perspective is not integrated to 
generate the final results (new knowledge). Suppliers have reduced interference on the 
project design and data analysis, as this thesis will evidence. Even though when 
principal researchers at the sites tried to contribute to the project design, their 
comments, in some cases, were not accepted easily, which clearly indicates the 
boundaries on responsibilities in the project and until which point they could or could 
not contribute to the project. There are few cases where the sponsor decides to 
challenge the model proposed in the industry and decides to involve the principal 
researchers of the sites in the project design and analysis (as one of the cases illustrates). 
Nonetheless, this is an isolated case that I cannot generalise to argue that the results of 
a clinical trial are the product of the co-creation or co-production of knowledge. Then, 
in a strict sense of the word and analysing a recent definition of knowledge co-
production, it is clear that the result of a clinical trial is not the result of a co-production 
of knowledge. The results among organisations are interdependent but not co-
produced, and for this reason, this thesis will focus on the flow of knowledge and 
knowledge products across actors to achieve specific goals and finally produce the 
clinical data. 
2.7. Summary 
In summary, in this chapter, I have presented the research questions of this project and 
the theoretical framework to provide an answer to them. In the first place, I showed 
how, over recent years in Latin America, the landscape of the clinical trial industry has 
changed because of the emergence of new actors like CROs and SMOs. These actors 
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are reshaping implementation of the protocols and the relationships between the two 
traditional organisations in a clinical trial, the sponsor and the research sites. In this 
changing landscape, this chapter presented the research that has been conducted to 
study the production of knowledge in clinical trials, and it elucidated the gap that exists 
to understand the flow of knowledge over the course of the project in this new multi-
organisational project landscape. Based on these gaps, I introduced the central research 
question of this thesis. Then, I introduced the three sub-research questions of this 
project, which have their origin on the interdependency of two knowledge products in 
the clinical trial, the research protocol and the clinical data. 
The fact that the principal object of study in this thesis is knowledge, in the second 
section I presented the definition of knowledge and the reasons why I adopted the 
epistemology of practice and possession proposed by Cook and Brown (1999). This 
approach of knowledge brings together the cognitive perspective employed in the 
literature of knowledge management, and the study of the use of knowledge in action.  
In the third section of this chapter, I defined clinical trials as Knowledge Intensive 
Projects and presented the previous research on this topic in relation to the production 
of knowledge. Because outsourcing seems to be a repetitive action in multi-
organisational projects, and in multi-organisational clinical trials it is a constant.  
In the fourth section, I introduced the previous research about the outsourcing of 
knowledge activities, and the main research areas that have emerged to study these 
activities to then place this research on the research of the management of knowledge 
in outsourced tasks. In this section, I did a literature review of previous studies of 
knowledge management in outsourced activities and the gaps in these research studies 
mainly on the creation of knowledge in this context. Based on these gaps, in the fifth 
section I introduced, from the literature of knowledge, ‘models, work and processes’ (K. 
Grant 2011, 121): key models that have been proposed to study the flow, the storage 
and/or use of knowledge within the organisation that I consider useful to explore the 
flow and use of knowledge in multi-organisational projects. Based on these models and 
a review of previous studies on the transfer and acquisition of knowledge in outsourced 
projects, I proposed a model to answer the main and sub-research questions of this 
thesis. The model has two levels, one inter-organisational level, and one intra-
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organisational level. The first level addresses the interdependency of knowledge 
products across the organisation, considering three factors that influence the transfer 
and acquisition of knowledge and knowledge products across project teams. The 
second level addresses the production of the knowledge products within the teams and 
how knowledge is employed to meet the project goals, making a particular emphasis 
on how acquired knowledge and previous knowledge is combined in action to produce 
the productive enquires. I consider that the proposed model with the identified factors 
is robust to study the production of knowledge products (clinical data, protocol, 
reports) and the flow of these products, and different data, knowledge and information 
among various organisations (sponsor, CROs, clinical sites) in multi-site clinical trials. 
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Chapter 3: Research Design, Data 
Collection and Analysis  
3.1. Introduction 
In this chapter, I outline the research design, the qualitative data collection methods 
employed, and the analytical framework. In this way, I explain why I chose a multi-case 
study perspective and the rationality behind my methodological decisions. This chapter 
has six sections. In the first section, I explain the research design of this project, and I 
discuss why I selected a multi-case study as the method employed in this research and 
the procedure to choose the cases, and I introduce each one of the three cases. In the 
second section of this chapter, I present the methods employed to collect the data. I 
mainly discuss why I conducted semi-structured interviews and how I did the fieldwork 
to cover the three cases in the three countries, pointing out the challenges and 
limitations that emerged over the fieldwork. The third section discusses the strategy 
employed to analyse the data collected using a framework approach and the challenges 
and decisions implemented to translate the data. The fourth part addresses the ethical 
considerations of this research. The fifth section is a reflection of my position as a 
researcher. The sixth section is the summary of this chapter. 
3.2. Research design  
3.2.1. Comparative case studies  
In the last chapter, I discussed how past research on multi-organisational projects have 
not addressed the use of knowledge within firms and how it flows across multiple 
organisations participating in multi-organisational projects at the same time. In those 
cases where research and theory are at early stages, researchers have argued that a case 
study research design is particularly suitable (Bennasat, Goldstein, and Mead 1987) to 
advance on the field of studies. This method helps to capture a rich array of contextual 
data, and it is possible to study the phenomenon from the perspectives of diverse 
participants using multiple levels of analysis. In this way, previously unknown topics 
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can be understood, addressing complex processes. As Bhattacherjee (2012) indicated, a 
case of study is a method “well-suited for studying complex organisational processes 
that involve multiple participants and interacting sequences of events” (underlined 
added), as is the case for this project. Therefore, a case study research allows the 
researcher to unravel a complex set of factors and relationships, making the research 
dynamic, asking interviewees more questions between the various stages of the 
research project (Verschuren 2003).  
Nonetheless, those taking a positivist approach have criticised the use of a single case 
of study because of the low generalisability of the observed associations to the 
population (Verschuren 2003; Mookherji and Lafond 2013; Gray 2009). The use of 
comparative case studies has been proposed to address this issue, where two or more 
cases are covered to analyse the studied phenomenon across cases and within cases, so 
results and knowledge obtained from causal questions (How and Why) can be more 
generalisable (Bennasat, Goldstein, and Mead 1987). For this reason, this thesis follows 
a comparative case study design, with in-depth analysis of three vaccine clinical trials 
(three cases) to conduct a comparative analysis across cases and conduct a detailed 
analysis of each case. In this way, the richness of the case study method was conserved, 
and additional comparative analyses were performed. For this reason, I considered that 
the comparative case study method was the most valuable methodology for exploring 
and understanding the dynamics in the flow and use of knowledge in multi-site 
projects, in this way, addressing the complexity and dynamism of this study.  
According to Bhattacherjee (2012), the quality of a research design can be assessed 
regarding four primary attributes: internal validity, external validity, construct validity, 
and statistical conclusion validity. A good design has equilibrium between internal and 
external validity. The internal validity or ‘causality’ evaluates the direct association 
between independent and dependent variables, aiming to restrict the influence of 
external factors associated with the research context. Therefore, researchers must 
control the effects of extraneous variables, although this is not always a hundred per 
cent possible. The second attribute, external validity, refers to the possibility of 
extending the results from one context to the population. This validity is obtained 
evaluating multiple samples to attain a better picture of the population. The research 
45 
 
design that I employed aimed to find equilibrium between these two attributes to have 
a robust project and data to answer the research question.  
The process to achieve internal and external validity is named ‘elimination technique’, 
which consists of decreasing extraneous variables by holding them constant across 
treatments (cases) (Bhattacherjee 2012, 38). The elimination technique to select the 
cases and achieve the equilibrium had two components. Firstly, to achieve external 
validity, I decided to adopt a comparative case study method between three clinical 
trials in different stages of development. Comparing among cases, I expect to find 
enough evidence that allows me to elucidate key points that positively or negatively 
influence the flow of knowledge and also allows me to understand, within firms, how 
pre-existing knowledge and the one received converge to implement the productive 
enquiries.  
Secondly, in this research project, to accomplish internal validity, I identified one 
disease for which there were more than one vaccine/medicine candidate under 
development, and sponsors implemented the clinical trials in Latin America. In this 
way, I guaranteed the embeddedness of the selected cases in the same context; 
specifically, under similar market pressures, the same initiative to boost the 
development of the product,6 and the same epidemiological conditions. The three cases 
selected are not exactly identical; variations exist among them, which is expected in 
social science and must be considered in the analysis and allows the achievement of 
external validity. However, if I had included clinical trials for cancer, diabetes, or other 
chronic disease, the comparisons and analysis would have been more complicated 
because of the intrinsic difference between trials to evaluate drugs and vaccines.7 This 
large variance among cases would have blurred the inference and comparison. Of 
course, part of my analysis consisted of identifying the interaction of the cases with 
their surrounding context, but with the proposed design, the objective was to select 
                                                          
6 This makes reference to the demand of evidence to prove the vaccine’s efficacy and the work led by the 
DVI (Dengue Vaccine Initiative) to harmonise the requirements to introduce the first vaccine candidate in 
endemic countries. So, in this sense, the three vaccines are under this same institutional dynamic.  
7 For example, vaccine trials demand more volunteers than drugs trials, recruitment strategies are different; 
to evaluate new drugs in Latin America, physicians enroll their patients, in a vaccine trial, subjects are not 
patients and are enrolled using massive diffusion strategies (Chapter 6).  
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cases in a similar context to make more evident the difference or similarity between 
cases. 
Regulations are different in the three countries selected (Brazil, Colombia and Mexico). 
Therefore, to address this issue and achieve internal and external validity, I chose the 
countries based on the number of cases evaluated in the country, and at least one case 
should have a presence in the three countries. Selecting a case with a presence in 
multiple countries, I could contrast if variations in the local regulations in any way 
influenced the execution of the same project in each country. Having more cases in the 
same country, I could compare and identify the influence of the local regulation on the 
implementation of different projects, allowing me to identify and control the effects of 
this extraneous variable. Therefore, with this design, I aimed to find an equilibrium 
between internal and external validity having a better resolution on my results. 
3.2.2. Selecting the cases 
The three cases chosen in this research correspond to the clinical evaluation of three 
dengue vaccines in Colombia, Brazil and Mexico. The process to select the three cases 
was divided into two steps. In the first step, I revised the literature about drugs and 
vaccines under research that summarised the pipeline of products under development 
to prevent and treat infectious disease. These documents include published reports by 
consortiums supporting the development of new vaccines like those supported by the 
Bill and Melinda Gates Foundation and the Drugs for Neglected Diseases (DNDi). One 
key document was ‘A report on the prevention and treatment of disease through 
vaccines’ (America’s Biopharmaceutical Research Companies 2013). The data collected 
indicated that 137 vaccines aiming to prevent infectious disease were under 
development. Thirteen infectious diseases had more than two vaccines under 
development (Table 2), and four global alliances existed to speed up the development 





Table 2. List of infectious diseases for which existed vaccine candidates under clinical 
evaluation in 2013. In the last column are the countries in the Americas, where the trials 
took place. 
The second step to select the cases of study focused on the thirteen diseases identified 
that had new products associated. This step consisted of consulting the database 
clinicaltrials.gov8 to determine the clinical trials that had/have been conducted for 
                                                          
8 Managed by the NIH of the USA, where sponsors around the world voluntarily provide information about 
the clinical trials that they are running.  
 
Disease Phase Candidates 
Countries where vaccines 
were evaluated in the 
Americas (Clinicaltrials.gov) 
Anthrax Phase II 5 The USA (4) 
CMV 
Phase I and 
III 
2 The USA (2) Canada (1) 
Dengue 
Phase I, II 
and III 
8 
The USA (8), Mexico (1), 
Panama (2), Honduras (1), 
Puerto Rico (3), Colombia (2), 
Peru (1), Brazil (2), Dominican 
Republic (1),  
H5N1 
Phase I, II 
and III 
17 The USA (17) 
Hepatitis B 
Phase I and 
III 
2 The USA (2) 
Hepatitis C 
Phase I and 
II 




Phase I and 
II 
3 The USA (3) 
HIV 
Phase I and 
II 
25 The USA (20), Argentina (1) 
Malaria  
Phase I, II 
and III 
4 The USA (3) 
Meningococcal 
Phase I, II 
and III 
6 
The USA (5), Mexico (1), Panama 
(2), Dominican Republic (1), 




Phase I and 
III 
3 The USA (3) 
Prevention of 
herpes zoster 
Phase III 2 
The USA (2), Brazil (1), Mexico 
(1), Canada (1) 
Tuberculosis 
Phase I and 
II 
4 The USA (3) 
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these products, and, more specifically, if those trials took place in Latin America. As it 
is possible to see in Table 2, the vaccines to prevent herpes zoster, meningococcal 
infectious and dengue fever were the only vaccines evaluated outside the USA and 
include at least two Latin America countries. The rest of the vaccines have been 
assessed mainly in the USA or Europe and Africa (information not provided in Table 
2). Of these three vaccines, I selected the dengue vaccine candidates as cases of study 
because at least two of the vaccine candidates were evaluated in the same country 
(Panamá, Puerto Rico, Colombia and Brazil) compared with the other three options, 
which allowed me to make comparisons between cases in the same country. 
Once I decided on the disease, I identified the cases included in the study. For this, I 
reviewed the information published in the Dengue Vaccine Initiative reports (DVI 
2013), which indicated the stage of development of each one of the vaccine candidates. 
Of the eight candidates under development, four were on pre-clinical evaluation in the 
USA. One vaccine was evaluated in the USA for the clinical trial phase I. KINGE was 
evaluating its vaccine in Phase III in the USA and Colombia and the NUSTAN vaccine 
was evaluated in phase II in Brazil. SAVA evaluated its vaccine in Phase III in five 
countries in Latin America (Colombia, Mexico, Brazil, Puerto Rico, Perú). Therefore, of 
these eight options, I decided to study the three vaccines that were in the latest stage 
of clinical evaluation (phase II and phase III), and trials included Latin America 
countries. One of the advantages of these three cases is that each one has a different 
level of complexity in the number of actors and kind of organisations that are part of 
the project. In the NUSTAN case, the sponsor and the research sites had a direct 
communication, and there were no intermediaries present. The figure of the CRO 
emerged in the KINGE case, mediating between the site and the sponsor. In the case of 
SAVA, a CRO and SMOs were outsourced, which represents one of the most complex 
structures to execute the project. However, this case represented an excellent 
opportunity to study the changing landscape to implement clinical trials in Latin 
America. Over the fieldwork, I identified differences between the cases that were not 
anticipated over the project design because this information was not available in the 
published papers and reports. Nonetheless, these differences were very important to 
understand how the structure to transfer information influenced the flow of knowledge 
from the sponsor to the site over the transition period before the transfer started.  
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Once I selected the cases, the next decision was to choose the countries to visit to 
collect the research data. This decision was made based on the number of research sites 
located in each country and the budget available to conduct the fieldwork. For this, I 
created a sub-database in Excel with all the information about the cases, including the 
name of the vaccine, the sponsor, the clinical phase, clinical trial code in the database, 
the studied population, the country and state department where the trials took place. 
Until 2014, to evaluate SAVA, KINGE and NUSTAN vaccines, sponsors had registered 
38 clinical trials in the database clinicaltrials.gov, and 30 trials had been conducted 
partially or entirely in Latin America. At that time, vaccines were evaluated in seven 
Latin American countries, six Asia-Pacific countries, the USA and Australia. More than 
90 academic, public or private research organisations had participated in the global 
trials, where 12 were in Latin America. With this data, I could identify the number of 
studies implemented in each country and how many research sites were part of the 
project, as is presented in Figure 2.  
Figure 2. The number of research sites per country outsourced in each one of the cases 
of this research. 
 
Using this information, I decided to do the fieldwork of this investigation in Colombia, 
Brazil and Mexico. I selected Brazil and Colombia because two of the three candidates 
were evaluated there. I chose Mexico rather than Puerto Rico because Mexico had more 
sites, it was cheaper, and it has significant relevance in the clinical trial industry. Mexico 
is the second market to conduct clinical trials in all Latin America after Brazil. In this 
selection process, I also considered the life cost in each one of these countries and the 
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possibility of affording the fieldwork, which included the trip among countries and 
within the country to visit the research site. The result of this systematic approach to 
identify the case studied and select the countries to conduct the fieldwork allowed me 
to make comparisons within and across cases in different countries. Either comparing 
the same case between three countries or different cases within the same country 
(horizontal and vertical analysis). 
3.3. Methods of data collection 
Multiple methods of data collection are employed in a multiple case study design, 
including interviews, observations, pre-recorded documents, secondary data, surveys 
etc. (Bhattacherjee 2012, 93; Edvardsson and Durst 2014). Arksey and Knight (1999) 
suggest that interviews allow in-depth exploration of the meaning and understandings 
that people have about their context. My thesis aims to study how people in the 
organisations acquire, use and transfer knowledge when they are participating in a 
multi-organisational project to achieve the project goals. Attaining this objective is 
complex because of the presence of multiple organisations and the need to establish a 
design that allows us to grasp the dynamic, and cognitive dimensions of this research. 
For this reason, qualitative research was considered more appropriate to address the 
complexity and dynamism of this study. For this project, primary data were collected 
using semi-structured interviews with open-ended style questions9 (Appendix 1.). Using 
these questions, I could capture what researchers, technicians, monitors and sponsors 
wanted to express in their own words while still following an ‘informal’ structured 
dialogue.  
As Arksey and Knight (1999, 32) suggest, interviews are potent tools that encourage 
people to express their tacit perceptions, feelings and understanding about their world. 
This method favoured face-to-face situations, enabling rapport between myself as a 
researcher and the project’s member in their settings (Blaikie 2010). Semi-structured 
interviews allowed me to get into people’s memories about the project and bring up 
elements of what was, for them, being part of the project design (sponsor) or execution 
(site’s personnel and monitors). With in-depth interviews, I could pinpoint those 
                                                          
9 The number of interviews and personnel interviewed is detailed below.  
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specific elements related to the acquisition and implementation of knowledge to make 
them aware, to some extent, about what they had gone through. The people 
interviewed could reflect on the implicit and ‘normal’ way of doing new things and 
make them explicit. The use of semi-structured interviews enabled the identification of 
similar answers to contrast them; this type of interview also gave the opportunity to 
find unforeseen information. 
However, like it has been pointed out by different authors, interviews can have some 
limitations. The context of the interview and their unconscious bias can influence 
interviewees (Diefenbach 2009; Boyce and Neale 2006). I recognise that these are some 
limitations that could have been present in the data collection. In the first place, people 
can be unreliable witnesses of their own past experiences and activities; they can 
portray themselves as leaders or that they had everything under control. For example, 
in a few cases, principal researchers interviewed were more interested in narrating their 
successful story implementing the clinical trial. Then, when I identified that 
information had a substantial content of pretence and egocentricity, I counter-
questioned about the failures reported in the papers or that were told by other 
researchers or I rephrased the question to create a balance in the information. In this 
way, I could get an authentic account of the data. The ability to detect these biases 
improved with experience. So, initial interviews could have less counter-questioning, 
and, therefore, their analysis required greater caution. Also, all interviews were 
contrasted with the answers of other interviewees (details below). 
Over the interview, in addition to the questioner, I had a map of the theoretical model 
that I had elaborated to study the knowledge flow (Figure 3). Over the course of the 
interview, using this map, I assured I had covered each one of the steps in the model. 
The fact that I was using a semi-structured interview format allowed me to go deeper 
into specific topics that emerged over the interview, in this way, getting a rich insight 
about the project. Model and concepts discussed in the theoretical framework were the 
base for these interviews, and they followed a chronological format. The interview 
began with questions regarding the personal and institutional antecedents before 
moving to operational issues like the acquisition of knowledge or the execution of the 
project, the practices to implement the activities and the interaction with other 
members of the project. Because I’m studying multi-organisational projects, for the 
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interviews, I developed a question schedule for each actor involved in the project, one 
for the sponsor and another one for the personnel in the research site, including 
questions about the topic and the concepts under research. Nonetheless, because the 
model proposed was similar for both organisations, aspects like the use of knowledge, 
access to information and transfer of data and knowledge were asked in both 
interviews. 
Figure 3. Map employed to follow the flow of the interviews. 
 
 
I conducted 65 interviews, of which 49 were directly related to the cases of study 
(Appendix 2.) Of these interviews, 11 were about the KINGE case, 32 about the SAVA 
case, and five about the NUSTAN case. Each interview lasted between 40 minutes and 
two hours. Interviews related to the cases included five members of the sponsors (3 
SAVA, 1 KINGE, 1 NUSTAN), three CRO monitors (2 SAVA, 1 KINGE), six project 
managers (3 SAVA, 2 KINGE, 1 NUSTAN), three SMOs directors working for SAVA, 
eight principal investigators (6 SAVA, 1 KINGE, 1 NUSTAN), eight sub-researchers (6 
SAVA, 1 KINGE, 1 NUSTAN), three social workers (SAVA), two quality managers (1 
KINGE, 1 NUSTAN), one laboratory technician (SAVA), two health promoters (SAVA). 
The other interviews included regulatory agencies, ethical committees and members of 
the wider clinical research industry in Colombia, Brazil and Mexico, like clinical trial 
associations, which allowed me to understand the context of the clinical trials in these 
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countries. Additionally, in Mexico and Brazil, I attended annual conventions of the 
national clinical trial associations, where I interacted with leaders of the clinical trial 
industry. This information was useful to understand the debates in the communities in 
each country, the local regulations and the system, and the separation between the 
different actors regarding their participation in the debate. However, these interviews 
were not employed in the analysis because the objective of this trial was the production 
of clinical results over the course of a project and it does not have an objective to study 
the industry or, exclusively, the regulation. Also, I took an introductory course on Good 
Clinical Practices at the University of Edinburgh so I could better understand the 
concepts employed in clinical research and, in a way, the learning process experienced 
by the personnel at the research sites.  
As I mentioned before, other methods like participatory observation and surveys could 
have been used to collect data about a case of studies. However, these two methods of 
data collection were not suitable for this research. Although an ethnographic work 
could have been appropriated to investigate the practices of the personnel in the 
research sites to implement the project and the use of knowledge, this method was not 
suitable for three reasons. The first one is that it was not possible to conduct an 
observation about the initial stages of the project because the recruitment of 
participants, vaccinations and active evaluation of participants had passed. Therefore, 
personnel had a lower peak of work. The fact that my fieldwork took place in these low 
peaks of work was positive for my research because personnel at the site had more free 
time to answer questions. Interviews were more in-depth and not rushed (KINGE and 
SAVA cases). The second reason is the difficulty to get access to the research sites to 
observe the project implementation if they are evaluating volunteers. All information 
in clinical research is confidential, and every person that has access to the volunteers 
or is present during the project execution must be approved by the local ethical 
committee, even though monitors that are part of the project are not allowed to have 
contact with the volunteers or be present during the medical consultation. Therefore, 
getting this access and approval by each one of the ethics committees of each case 
studied could have taken around one year, so interviews were more suitable for 
collecting data. Finally, the fact that I decided to implement a multi-case study with 
locations in multiple countries implied that I had to be strategic and flexible with the 
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use of time to travel and collect the data. An ethnographic method does not allow this 
flexibility because it is necessary to spend more time at each site creating links with the 
personnel, building a relationship and collecting data. 
As for surveys, this method is more related to quantitative studies. This research 
focuses on understanding a process of acquisition, use and transfer of knowledge; for 
this reason, I was more interested in the narratives of researchers about their learning 
process, the interaction with other actors, and the use of knowledge to design the 
project or implement it. So, in-depth semi-structured interviews allowed me to capture 
the sequences of the story, the interdependency among organisations and the flow of 
the research project. Surveys could have been useful if the studied cases had had a larger 
number of research sites. Nonetheless, this data had to be complemented with 
interviews to address the complexities and unique aspects of each case.  
3.3.1. Fieldwork and some limitations 
Scholars have argued that the selection of interviewees must be guided to a great extent 
on the personal involvement of the person in the phenomenon under investigation, the 
power and influence of the people within the organisation, and their ability and 
willingness to answer the research questions adequately and accurately (Bhattacherjee 
2012; Diefenbach 2009). Therefore, before initiating any data collection, the first step 
was to identify key people in each one of the cases of study to access to them. Once I 
determined the cases and the countries to conduct the fieldwork I created a database 
with the names and positions of the people working in each one of these clinical trials. 
To achieve this, I employed the information published in the database clinicaltrials.gov, 
in reports of the advancement of the vaccine development, published papers, press 
reports, university reports and information published on social networks (Facebook, 
LinkedIn). I divided the sources into two categories, sponsors and researchers. The first 
category included the people working for the pharmaceutical companies or 
biotechnology organisations. The second category included the directors of the 
research sites responsible for the project’s execution, through which I expected to get 
access to the site personnel like nurses, project managers and technicians. 
Unfortunately, in the SAVA case, there was a sub-register of the research site’s principal 
investigators, therefore, in the field, I asked people involved in the case for the 
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information about the missed researchers and requested their support to contact them. 
This sub-register is explained by the complex structure of the SAVA case, as is discussed 
in Chapter 6, where the work of the site’s principal researchers was under the umbrella 
of an SMO (Site Management Organisation). 
One of the central decisions that a researcher must take is defining the study sites, the 
timeframe for the research and the boundaries of the study population (Schensul 2012, 
81). I spent a short nine months between October 15th, 2014 and July 9th, 2015 conducting 
fieldwork. Over this period, I travelled to Colombia, Brazil and Mexico to conduct the 
interviews. Because I was familiar with one of the cases of study, KINGE in Colombia, I 
decided to initiate my fieldwork in this country and with this case. In Colombia, 
through a network of friends and family, the practicalities of setting my fieldwork were 
not difficult (finding somewhere to stay, transport etc.). However, in Brazil and Mexico, 
I also had to sort out these issues alone because it was my first time travelling to these 
countries. In Brazil, I spent most of the time in the city of Sao Paulo, and in Mexico in 
Mexico City. It was easy to arrange trips to assist at conferences and visit the research 
sites located in other cities by staying in these capital cities.  
To convene the interview with the sources identified, I sent an email to the person with 
a brief leaflet containing information about myself, the objective, the length of the 
meeting, the topics of discussion and why the interview was relevant for my research 
(Appendix 3. has one example). The leaflet also explained the data handling and privacy 
closure, where it reassured every participant that they could withdraw from the 
interview at any time. In a few cases, I was requested to send questions in advance to 
the interviewee, to allow them to consider their participation in the research. If the 
person agreed to the interview, a date, time and place were convened. I must say, my 
nationality allowed me to get access to most of the cases. In each one of the three cases, 
at least one of the team members was a Colombian, so these researchers expressed their 
support for my research, and they were open to giving me an interview (I didn’t know 
this in advance). 
At the beginning of the interview, I explained to the participant more about the project 
and the objectives. I elaborated an informed consent form (ICF) in Spanish and 
Portuguese, and before the interview, I shared this one to participants before initiating 
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the data collection, and the interview started only after the person signed the ICF 
(Appendix 4.). The ICF stated that he/she voluntarily participated in the research, no 
reward was offered, they accepted the recording of the interview, and I stated that all 
information provided was confidential, so their identity would not be revealed. After 
the interview, I collected notes about observations and comments. Only one 
interviewee did not allow the recording of the conversation, then over the interview, I 
took notes, and once this one concluded, I made a voice note outlining the notes and 
the information that I remembered. Over the clinical trial, I reviewed the recordings to 
do an initial analysis and grasp the technical language of the practitioners of clinical 
research. In this way, my questions become more precise, and I could get a better 
answer. Also, the fact that I was trained as a biologist allowed me to talk with some 
researchers and sponsors using ‘scientific’ language, then complete information about 
the research was obtained. Additionally, at the time that I was conducting my 
fieldwork, relevant papers were published with the results of the researched cases, so 
this information was analysed to improve the quality of my interviews and examine the 
data previously collected.  
Before travelling from Edinburgh to Medellín (Colombia), I coordinated an interview 
with the principal researcher of the KINGE research site and obtained authorisation to 
conduct interviews with the staff. He helped me to get access to the sponsor who was 
visiting the city. In this way, I started my fieldwork. Once I concluded the review of the 
first case, I continued my fieldwork in Colombia, getting data about the SAVA case in 
Bogotá. To my surprise, researchers contacted were directors of the SMOs and they did 
not execute the project. These SMOs coordinated the research sites, which were in rural 
areas across the country. To get access to these sites, I requested authorisation from 
the SMO’s director. However, travelling to some of these sites represented a risk to me 
because sites were in territories with the presence of army groups (at that time, before 
the peace process). For this reason, I did not get authorisation from these researchers 
to visit and interview the personnel there, and, I considered these locations highly risky 
to travel alone. Nonetheless, I got access to other research sites located in the Andean 
zone, where the SMO’s directors helped me to make a bridge with these researchers, so 
I travelled to these rural areas to research the implementation of the project in the field. 
Through SAVA’s sponsor in Colombia, I got access to her peers in Brazil and Mexico. 
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Additionally, she introduced me to the regional director of the project, with whom I 
had an online interview, but I did not get explicit authorisation to use the information 
collected in the research. So, I did not include this interview in the study.  
During my fieldwork in Colombia, I prepared the visit to Brazil, and I scheduled, 
through email, an interview with the principal researcher working on NUSTAN’s 
project. This contact was the hook to travel to Brazil and initiate a snowball strategy to 
get access to other workers, especially in the NUSTAN case, where I interviewed most 
of the personnel directly involved in the project’s execution. One element to point out 
was that I sent all my information in English because I assumed that researchers were 
familiar with this language. However, once I travelled to Brazil, I realised that not many 
people in the sites spoke English and they preferred to talk in Spanish or Portuguese. 
Although I’m not fluent in Portuguese, I took Portuguese classes in Edinburgh before 
my fieldwork, so this helped me to interact with people and paraphrase some 
expressions in this language. Then, in this country, interviews were conducted in 
English, Spanish and ‘Portuñol’ (a mix between Spanish and Portuguese).  
In Brazil, especially in SAVA´s case, the access to the research sites was limited. In the 
first place, the sub-register of information about the principal researchers was large, so 
it was not possible to contact them directly. In the second place, SAVA’s representative 
was highly reserved with his contacts and only provided me with information about 
one research site, working on a different project in Recife. SAVA’s representative made 
clear that this was a personal favour because this researcher was his friend. Otherwise, 
he was not allowed to give me access to the other researchers. Although I interviewed 
this person, I did not include this data because it is not directly related to one of the 
cases. This situation placed a barrier to accessing the other sites; for this reason, 
information about SAVA sites in Brazil was not included in the analysis, which modifies 
the design initially proposed to understand the influence of the country level on the 
trial implementation, so most of the comparisons were between Colombia and Mexico. 
Nonetheless, to counteract this gap, I participated in local conventions to better 
understand the research context in Brazil. The other limitation was that I spent one 
month and two weeks in Brazil and this period coincided with religious and national 
celebrations. Then, this is a point that I need to consider in my next fieldwork.  
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In Mexico, I spent two and a half months researching the SAVA case, and I accessed the 
research site through two steps. At the interview with the sponsor, he accepted me to 
introduce me to the SMO director of the project in Mexico, which in turn (second step) 
also approved my visits to the research sites that he was coordinating in the country. 
Also, before my trip, I contacted other researchers associated with the project, so I 
scheduled interviews with them in Mexico City. I was strongly advised by the sponsor, 
researchers and personal friends in Mexico to avoid some states of the republic because 
of the internal conflict between drug cartels. For this reason, I visited three of the five 
sites because the other two were in violent areas. Once I got access to these locations, 
I coordinated the interviews, and I travelled to the rural research site, and there I 
collected the data.  
One of the challenges was that people at intermediary levels felt that they did not have 
the right to talk about the research because the confidentiality that is involved in 
managing patients’ data. However, when they understood that I was interested in their 
learning and working experience, establishing a fluent conversation was easy. In 
contrast, senior researchers were open to giving an interview and were much more open 
to answering the questions and sharing their experience; they knew their position in 
the project and did not see in me or the interview a threat to their work.  
During data collection, I made reports on the progress of fieldwork. The reports were 
reflections about the pertinence of the concepts used in the interview schedule. For 
example, once I concluded the interviews about the KINGE case, I presented my first 
report. For this report, I transcribed the interviews using the software Express Scribe, 
and I analysed them using NVivo to verify the pertinence of the concepts and the 
model, and if the questioner was allowing me to collect the required information, this 
case worked as a pilot study. Based on this information I identified a third actor in the 
clinical trial that participated actively in the transfer of information, not only 
monitoring, the CRO, so I had to design a questionnaire that captured the role and 
participation of this organisation in this activity over the course of the clinical trial. 
Also, I identified that large part of the interview was oriented into the transfer process, 
so I had to adjust the interview to get more information about the use of knowledge. I 
discussed all this information with my supervisors via Skype.  
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The fact that I conducted most interviews in Spanish improved the quality of the 
interviews. Additionally, I collected secondary information like published papers and 
reports. Together, semi-structured interviews and documents allowed me to 
understand how, in each organisation, knowledge was employed to produce their 
project products and how these products were transferred across the firms. 
3.4. Data Analysis  
“Qualitative data analysis is essentially about detection, and the tasks of defining, 
categorising, theorising, explaining, exploring and mapping are fundamental to the 
analyst's role.” (Jane and Liz 2011, 5) 
Determining the unit of analysis is important because it shapes the data collection and, 
specifically, the data analysis (Bhattacherjee 2012; Gerring 2004). In the literature of 
clinical trials and knowledge management in the outsourced or multi-organisational 
project, the unit of analysis is usually the firm. This perspective does not allow us to 
study the relevance of individual decisions directly and the acquisition, use and transfer 
of knowledge by people over the course of the project, either designing it or executing 
it. Because my thesis aims to study how, in multi-organisational projects, knowledge 
flows and is used to achieve the project goals, in this thesis the unit of analysis is the 
knowledge, data and information used, acquired and transferred by people over the 
course of the project. Because these units are intangible, those that can provide an 
account for this unit of analysis are the people working on the project. They are those 
that learn and know what and how to do the activities to achieve the objectives and 
solve the “productive enquiries” (Cook and Brown 1999). 
To conduct the data analysis, I used a grounded theory ‘framework’ approach (Jane and 
Liz 2011). This method enables comparisons and associations between and within cases, 
being entirely suitable for the research design of this project, and it allows a systematic 
treatment of all units of analysis. According to Maggs-Rapport (2001), a framework 
approach ensures that qualitative studies are methodologically robust, and provides 
transparency about the analytical process employed. This framework considers five 
stages: familiarisation, identifying a thematic framework, indexing, charting, mapping 
and interpretation. Familiarisation with primary data took place through listening to 
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the records, transcribing them and reading the information once the transcription 
concluded. Also, I reviewed the local regulations and the published papers associated 
with each one of the cases. The next step was the identification of a thematic 
framework. This step was made using the model proposed in Chapter 2 in the 
conceptual model section. Data indexing was implemented using the software NVivo. 
In this case, I used the software as a reference manager, where I created a coding system 
based on the model designed to study the transformation of knowledge over the course 
of the trial and how the execution of the project progressed in each research site. 
Although I introduced the data in the software using the node tool that the programme 
has, I did not use the software analysis tools. To analyse my data, I codified each source 
in the nodes created according to the model proposed in the theoretical framework. It 
was easy to explore the data, compare it and identify trends using this software. Also, 
it was possible to conduct a data triangulation comparing responses between 
interviewees about the same topic. Notably, triangulation helped to contrast the 
narratives of the personnel involved in the same activities either because they shared 
functions executing a task in the same case (i.e. all the staff involved in training in the 
same case) or they had the same jobs in different cases (i.e. physicians’ narratives in all 
cases). This analysis allowed me to determine the consistency of my data and to point 
out in those cases where discrepancies existed among the sources. At the end of this 
document at Appendix 2 is a table with a list of the interviews transcribed directly 
linked to the cases studied and the codes for the interviews quoted in this thesis.   
Data were collected mostly in Spanish, which implied a translation process to produce 
the final document and quote the answers. Over the writing process, two problems 
emerged. The first one is that in Spanish there are grammatical and syntactical 
structures that do not exist in English, and the second one was that personnel employed 
local jargon to express ideas. To solve these issues, in the literature two approaches 
have been proposed. The first one is to translate the quotes into English once the rules 
of English structure are applied (Bassnett 2005, 32). However, this process can lead to 
the loss of information (Ervin and Bower 1952, 597; Rubin and Rubin 2012). The second 
approach consists of a literal translation, word by word, which can lead to the loss of 
meaning in English and the readability of the text. Therefore, to address this issue 
translating the information, I focused on achieving the same meaning of the expression, 
61 
 
doing a literal translation of the text. In those cases where syntactical issues emerged, 
I complemented the information within brackets, or footnotes, or in extreme cases, the 
quote was grammatically and syntactically corrected.  
Some authors have argued that the extrapolation of results using cases of study can 
take place through an “analytic generalisation”, connecting the data with the theory 
(Mookherji and Lafond 2013). Therefore, the contribution of my findings to the study 
of multi-organisational projects will be through the discussion and comparison of the 
findings with the debates present in the literature. Some of these debates are the need 
for creating a shared knowledge across project members in different organisations, or 
the relevance of trust on the acquisition of knowledge, which is one of the findings in 
this research. In this way, I can compare, discuss and provide new evidence to the 
theoretical and conceptual debates that are around the flow and use of knowledge in 
multi-site or outsourced projects. I must admit that because of my previous background 
as a laboratory researcher, I do not pretend that the conclusions obtained in this thesis 
are entirely extendible to the entire universe of clinical trials or multi-organisational 
projects. For me, the results of any research are only valid for the context studied. Any 
generalisation requires new studies to verify if the new hypotheses are valid there. In 
the specific case of this research, for me, the execution of each multi-organisational 
project is unique in time, and nothing guarantees that, in a new project, the same 
people and same organisations would be working together and the results are 
replicated. In the cases studied, specific circumstances took place to bring together the 
organisations working on the project, circumstances that are not replicable in time. 
Secondly, human behaviour is not predictable and it changes as people obtain 
experience, even in the same project. Once the project concludes, the person and the 
organisations are not the same; they have gained or lost knowledge and probably would 
be facing a new project differently. Therefore, all generalisations should be cautious.  
3.5. Ethical considerations  
Before the beginning of data collection, I conducted the University of Edinburgh’s 
ethical self-audit Level 1 ethical review. The review showed that research design 
discussed here did not pose any cultural, physical or psychological risks to participants, 
in particular with the focus of the scheduled interview on aspects such as personal 
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interactions. Based on this evaluation, I, Sara Valencia Cadavid, confirm that I have 
carried out the School of Ethics self-audit about my proposed research project: A model 
to study the flow and use of knowledge in Outsourced Knowledge Intensive Projects: A 
multi-case study of three vaccine clinical trials in Latin America. Countries researched: 
Colombia, Brazil and Mexico, and that no reasonable foreseeable ethical risks have been 
identified.  
To uphold the agreement between the participants and myself about data 
confidentiality, I took a series of steps over the fieldwork and afterwards. Over the 
fieldwork, some researchers and sponsors manifested that they wanted to be 
anonymous and they didn’t want other persons associated with the trial know about 
the interview. Therefore, interviewing other people, I had to be cautious not to mention 
the other person’s name or use explicit information that another source had provided, 
which could potentially expose that person. After each interview, I transferred the data 
on a password-protected computer, and I deleted files from the recorder, and for each 
file, I used a codification system, avoiding the use of personal names. Additionally, I 
created a table with the information of all records and I assigned a fictitious name and 
a code on the writing process.  
3.6. Reflexivity 
Through this project, I have been reflexive about my background and how it influenced 
my research. The study of the social world over the PhD was challenging because of my 
positivist views about the natural sciences before initiating my PhD. My undergrad is 
in biology, with an intense experience in laboratory work and statistics. My previous 
experience with the social world was related to voluntary activities, political activism 
and a consultancy project to conduct a diagnosis of the implementation of local policy 
in marginalised schools.  
My reflections about the study of the social world before the PhD was low and, in fact, 
because of my training, I tended to use numbers and quantitative evidence that 
supported the arguments and dynamics of the spheres in which I was involved. This 
positivist position presented an initial conflict for me when I decided to conduct 
exploratory research to understand the flow of knowledge among research teams (an 
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initial proposal that changed as the project matured). Previous research on this topic 
has been qualitative, and the evidence shows that this process is dynamic and depends 
on the social relationships among actors, the people and the context in which 
interactions take place. This fact made me realise that although the social world is a 
reality out there (critical realism (Bhaskar 2008)), its study is challenging because 
multiple variables reshape the reality and what explains the dynamics in one social 
group does not elucidate the fluctuations in other social groups. Also, events occur in 
the real domain at times when the researcher cannot always can be present, as is the 
case for this research. Therefore, in those cases where full observations are not possible, 
it is necessary to interpret the data collected to try to elucidate the reality. Then, the 
way to ‘know’ about the social world and the actions conducted by individuals or the 
people is through interpretative means, where the analysis of the acts is based on the 
understanding and interpretation of the meaning and purpose of the individuals 
studied and their actions (Bhattacherjee 2012). So, this new world about social research 
meant, for me, a turning point in the way in which I had conducted research, switching 
from quantitative research to qualitative research. Nonetheless, some of my previous 
experience contributed to the design of this research, as I can see now in this reflection.  
From my background as a biologist, especially in cellular biology, and my previous 
experience doing quantitative research and standardising protocols and pre-clinical 
tests, it was evident to me when I worked in a laboratory that the results obtained from 
one experiment could not be extrapolated to other contexts and accounted for the same 
conditions. Then, interpretations of results had to be carefully made to explain a 
phenomenon, and any generalisation of results to a new context always required the 
statements of a new hypothesis and the execution of a new experiment to validate the 
previous results in the new environment. This perspective about the interpretation of 
results directly influenced the decisions that I made in my research design selecting 
three cases of study; three vaccines to prevent the same disease, and my precautions to 
generalise findings.  
The fact that I was assuming a role as a social scientist when I was interviewing 
personnel at the research sites and from the pharmaceutical sector placed me in a new 
situation. Under this context, I was an outsider that wanted to know about their 
experience in clinical research. When I introduced myself as a student of science and 
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technology studies at the school of social and political science the responder assumed 
that I did not have a ‘scientific’ background, so he or she had to use simple and 
understandable language to explain the activities that they were conducting to me. 
However, as I employed technical language and I mentioned my background as a 
biologist, people changed their language and used more sophisticated jargon and the 
connection improved, so this fact improved the quality of the data gathered and its 
veracity. 
3.7. Summary 
In this chapter, I have summarised the critical steps that I undertook to design this 
project, collect the data and analyse it. In this chapter, I discussed the reasons why I 
selected a comparative case study rather than other approaches and how, using this 
method, I created strategies to achieve internal and external validity to produce data 
with high quality. In the reflective exercise that was writing this chapter, I presented 
the process and logic that I followed to select the three cases studied and the countries 
visited to collect data. In this chapter, I also discussed the data collection process, the 
selection of the method to collect data, the design of the tools to collect it and the 
implementation of the interviews in the field. Also, I presented the limitations that I 
faced over the data collection, like the sub-register of information, the language barrier 
in Brazil, the negligence of people to provide information about the project, and the 
presence of army groups or drug cartels in specific areas in Colombia and Mexico, which 
limited the access to those regions. Finally, in this chapter, I presented the process to 
analyse the data using a framework approach and the decisions made to present the 
data in English. Also, I discussed the ethical considerations associated with this project, 
managing the data and keeping sources confidential. Therefore, in this chapter, I 
summarised the main decisions, actions, and reflections that took place over the 
project’s design and execution to ensure that this project was of high quality from a 




Chapter 4: Use of internal and 
external knowledge by the sponsor to 
design the clinical trial 
4.1. Introduction 
A clinical trial is a project where multiple actors participate. In these multi-
organisational projects, each actor has its responsibility where the product of one 
organisation turns into the input of another project member. In the theoretical 
framework, the concept of interdependency was employed to define this dependence. 
In the pharmaceutical industry, the sponsor has the clinical responsibility for the 
project, being the one in charge of the design of the project and contracting actors such 
as the CROs or research sites. The outcome of the initial planning stage is the protocol. 
The protocol contains a description of the project’s objectives, the scientific basis of the 
project, the procedures to produce the clinical and biological data, and the logistics of 
the study (Ottevanger et al. 2003). Nonetheless, the sponsor does not execute this 
protocol. Research sites and the CROs implement their respective tasks following the 
protocol. Then, because the protocol is the main knowledge product produced by the 
sponsor at the beginning of the clinical trial, the research question that emerges is: how 
did the sponsor acquire and use knowledge, data and information to design the 
clinical protocol? 
The implementation of a task requires the use of knowledge, information and data 
residing within the boundaries of the team and the acquisition of external knowledge. 
In the organisations, people use knowledge to refine data (M. H. Meyer and Zack 1996) 
or give a solution to problems (McElroy 1999). The present chapter precisely addresses 
the use of the knowledge residing within the boundaries of the team, and the 
acquisition of knowledge, to design the protocol. For this, I divided this chapter into 
two sections. The first section discusses the relevance of the previous experience and 
previous results to produce the protocol. The second section addresses the acquisition 
of external knowledge to design the clinical protocol, discussing the direct 
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communication between source and receptor, the permeability of teams to external 
knowledge, data and information and the use of boundary spanners (Tushman 1977) to 
access external data. The last section presents the conclusions of this chapter, where I 
show how clinical teams transform their knowledge, data and information in the 
protocol.  
4.2. Management of knowledge and information 
residing within the boundaries of the clinical team 
to design the protocol  
The clinical protocol has the step-by-step of the project, and it has all the scientific 
basis of the project. However, the knowledge employed by clinical teams to create the 
protocol remains relatively understudied. Previous research on protocol creation has 
focused on the interaction of people writing the protocol and the physical writing 
protocol process (Eapen 2007; Gennari et al. 2004; Weng et al. 2004; Weng et al. 2007). 
Nonetheless, they have not addressed the conceptual and practical knowledge involved 
in the protocol creation and how it is used to create the protocol. Aspects that this 
section discusses. 
During my interviews with clinical trial coordinators at KINGE, NUSTAN, and SAVA I 
asked what knowledge, information, or data they employed to design the clinical trial 
protocol. Personnel at these firms included in their answers five elements that shaped 
and constituted the initial knowledge, data and information required by the clinical 
team to design the protocol (Table 3). They are; (1) the knowledge and experience of 
the clinical team; (2) the previous results of preclinical and clinical phases; (3) the 
guidelines designed by the WHO to evaluate the vaccine and implement laboratory 
tests to measure antibodies in humans (two different guidelines); (4) the sponsor’s 
commercial interest and operative and social information and (5) epidemiological data 
about the disease incidence and prevalence in the locations when the trial took place.  
Like Table 3 shows, only three of the five elements were available within the firm in all 
three cases and the other information and knowledge resided in external organisations 
(sources), therefore, the clinical teams had to find strategies to access these sources. 
These elements coincide with the conceptual knowledge described by Gennari et al. 
(2004) in an ethnographic study about the protocol writing process. Nonetheless, their 
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research focused on the management of multiple versions to write a single protocol, 
and not on the use of different knowledge and information sources to design the trial.  
In this section, I will address the relevance of the knowledge residing within SAVA and 
KINGE clinical teams (Element 1) and previous results (Element 2) to adapt the WHO 
guidelines (Element 3) to design the clinical protocol. In the NUSTAN case, I will 
discuss how the team accessed previous results and used related knowledge to design 
the protocol. 
Table 3. Initial knowledge, data and information employed by clinical teams to create 
the clinical protocol. 
Knowledge, data and 
information 
Location of the source 
SAVA KINGE NUSTAN 
Element 1. The knowledge and 




Element 2. The previous results of 




Element 3. The guidelines 
designed by the WHO to evaluate 
the vaccine and implement 
laboratory tests to measure 
antibodies in humans (two 
different guidelines).  
External External External 
Element 4. Sponsor’s commercial 
interest.  
Internal Internal Internal 
Element 5. Operative and social 
information and epidemiological 
data about the disease incidence 
and prevalence in the locations 
when the trial took place. 
External External External 
4.2.1. The experience of the clinical team as a base to create 
the protocol and the use of previous clinical and pre-
clinical results  
Previous studies have revealed that protocol creation is a cooperative scientific process 
within a group of interdisciplinary clinical trial experts (Weng et al. 2004). In the three 
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cases studied, the clinical teams responsible for the protocol design comprised of 
disease experts, clinical writers, statisticians and epidemiologists. These clinical teams 
were responsible for writing the protocol defining the study intervention, study design, 
participants’ eligibility criteria, response variable, sample size, patient management 
procedures, monitoring for safety and benefit, and data analysis approaches as 
indicated in papers published with trial results. Clinical team members reported how 
the professional background of each one of these experts contributed to the design of 
the project “because to write a protocol it needs a deep knowledge about the pathology, 
the statistics, and many other things” [PM-USP, NUSTA, April-01-2015]. Then, each one 
of these members contributed from its area of expertise to the protocol writing. This 
element supports the argument of Tseng (2004), which considered that specialist 
knowledge of members of multi-functional teams is necessary to address the 
complexities that emerge in the projects. 
In the case of NUSTAN new clinical teams had to be configured, in contrast, the 
stability of KINGE and SAVA’s clinical team members between project phases allowed 
that the practical knowledge and experience acquired on previous trials (Element 1 
Table 3) benefited the protocol writing. A review of papers published by SAVA 
evidences how the team members were constant (Sabchareon et al. 2012; L. Á. Villar et 
al. 2013; L. Villar et al. 2014a). In this case, ten team members participating in the Phase 
II trial contributed to the design of the Phase III trial. In the case of KINGE, also the 
accumulated experience and knowledge of the clinical team was fundamental to design 
their Phase II, where the firm designed all the protocol, as Dr Jaime Plata (KINGE 
Sponsor) pointed out in the interview: “the principal study (Phase I) was designed by the 
company, the same for study Phase II”. For him, writing a protocol seemed an easy task 
that is part of his regular academic work. However, in this case, between Phase I (2011) 
and Phase II (2012) KINGE merged with Singaporean biotech. As a result, new members 
arrived at the team contributing with their insights to the design of the clinical trial 
Phase II and its implementation, as Dr Plata explained in the interview. For example, 
the Singaporean company used to outsource the project to a CRO, then in the new 
Phase II the project was outsourced and the contacts and management were through 
the Singaporean members. Therefore, new people in the clinical teams were sources of 
new knowledge and new practices to implement the project. Nonetheless, the fact that 
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KINGE personnel continued participating in the other phase of the project allowed that 
the knowledge acquired in previous phases was conserved and used in the Phase II trial.  
Members of NUSTAN, KINGE and SAVA employed previous clinical and pre-clinical 
studies in the protocol design (Element 2, Table 3). In the SAVA case, a paper published 
in 2010 summarised the results of all pre-clinical and clinical trials implemented up to 
that date (Guy, Saville, and Lang 2010). This paper indicated how previous clinical and 
pre-clinical results were used to design the new clinical phases to test the vaccine’s 
security and its immune performance. This publication revealed how the team started 
their clinical evaluations with a single dose of the vaccine and the last trial was 
implemented using a three-dosage schedule to induce a satisfactory immune activity 
(seroconversion) in the volunteers. The fact that the vaccine did not show a high 
efficiency with a single dose required intermediary trials to determine the optimal 
combination of vaccine schedules, dosage and administration route to be used in Phase 
III. KINGE used the results of the Phase I to narrow the scope of Phase II. In Phase I, 
KINGE compared two dose levels and two different administration routes 
(subcutaneous (SC) or intradermal (ID)) to identify the best dosage-route combination 
to stimulate the immune system. The clinical team using these results designed a Phase 
II trial evaluating a subcutaneous administration route, the high dosage formulation 
and two dosage schemes (day 0 and 91). Then, based on previous results, teams 
modified the hypothesis and variables evaluated in the new trials.  
In the literature about project teams, the relevance of team stability for the project 
success (Savelsbergh, Poell, and van der Heijden 2015) has been discussed. Stable teams 
enable learning and intra-team coordination (Akgün and Lynn 2002) and also facilitate 
coordination of interdependent work (Edmondson, Dillon, and Roloff 2007). What the 
cases of KINGE and SAVA indicate is that personnel stability allows using the 
experience obtained from the previous project to the new trial. However, the arrival of 
new personnel also brings new approaches to design a project, such as the KINGE case 
indicates. The evidence presented for KINGE and SAVA supports the argument that 
knowledge is re-used between interrelated projects like clinical phases (Owen and 
Burstein 2006), where the access to the knowledge acquired previously is critical for its 
further use in related projects (Formentini and Romano 2011). Therefore, in the clinical 
trials, the knowledge accumulated over the course of previous phases becomes the basis 
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for designing the protocol, and the continuity of the personnel across phases 
(interdependent-projects) allows the inclusion of these experiences in the design of the 
new protocol. Consequently, organisations sponsoring clinical trials should create a 
mechanism to ensure the continuity of their personnel in the organisation, so the 
knowledge acquired as a result of the trial stays in the boundary of the firm and can be 
employed in future projects because this knowledge is the base for creating the new 
projects.  
Table 3 indicated how, in the case of NUSTAN, the knowledge and experience of the 
clinical team (Element 1) and the previous results of pre-clinical and clinical phases 
(Element 2) had a dual origin. In the case of NUSTAN, it was necessary to configure a 
new clinical team hiring new personnel and consult with external organisations on the 
results of previous clinical trials to design the protocol. The fact that NUSTAN did not 
participate in preceding clinical phases and the organisation did not have a clinical 
division to conduct clinical trials explains these differences. Therefore, NUSTAN had 
to create a new clinical team to design and execute Phase II to evaluate the vaccine 
differing to SAVA and KINGE cases.  
Below, I will address this specific case, and the lessons to learn from the NUSTAN 
experience for those cases where sponsoring organisations do not have previous 
experience conducting clinical trials to evaluate new products.10 This reflection is 
relevant in the context of Latin America because if many national pharmaceutical 
companies and research institutions such as NUSTAN are developing new products or 
acquiring licences for new ones11 to implement clinical trials, then NUSTAN’s 
experience can contribute to these cases.  
In 2009, the NIH decided to implement a non-exclusivity licence mechanism for its 
new vaccine. The NIH licensed the vaccine to five organisations, including NUSTAN in 
Brazil, to continue the vaccine development, especially the clinical Phases II and III, 
                                                          
10 I make emphasis on evaluating new products, because there is another branch on clinical trials that 
evaluates new formulations or combination of drugs which have a different mechanism to be evaluated 
than new drugs.  
11 Information that is the result of a parallel research that I conducted to identify models to develop new 




and create the infrastructure to produce the vaccine locally. Up to that date, the NIH 
had implemented all pre-clinical and multiple Phase I trials to identify the best vaccine 
formulation.12 NUSTAN implemented the clinical trial Phase II in 2013, and Phase III 
initiated in 2016. Nonetheless, between 2009 and 2013, NUSTAN had to create a series 
of capabilities to implement the trial, including the configuration of the Division of 
Clinical Trials and Pharmacovigilance at the institute to design and coordinate the 
project. To create the clinical division, the institute’s director hired personnel with 
experience conducting non-interventional clinical projects, as Dr Pablo Esmeralda 
explained:  
“The strategy employed by NUSTAN was to search for personnel that maybe did 
not have that experience in the industry, but in some way had previous experience 
doing clinical trials in one or other way. They said we are going to assume this 
challenge together. And this is how I ended up on this journey. Then, a small group 
of people was gathered to try to make that development.” [NUSTAN Chair, Apr-13-
2017, underline added] 
Although NUSTAN recruited people with previous experience, according to Dr Pablo 
Esmeralda (NUSTAN Clinical R&D Manager), the configuration of the clinical team was 
challenging because “it is quite difficult to find outside the USA and Japan people with 
the knowledge to make protocols and generate a clinical development plan”. Then, this 
quote illustrates how scarce and centralised the knowledge is to lead the development 
of a product clinically. This knowledge is within the boundaries of the pharmaceutical 
industry in countries like USA, Japan and some countries in Western Europe with a 
strong background in implementing industrial clinical trials, as was presented in the 
introduction of this chapter. However, in countries where there is not a robust 
pharmaceutical industry, the knowledge to be a sponsor, to lead clinical projects and 
to create the protocols is scarce. People that had worked in academia or as a consultant 
for the WHO or the PAHO are those that possess related knowledge, and are those at 
the end who lead clinical trials like the one conducted by NUSTAN. Therefore, in the 
context of Latin America, it is important to create strategies to strengthen the 
knowledge to design and implement clinical trials of new products, which differs from 
clinical trials of commercial products.  
                                                          
12 This process consisted of identifying in each virus which concentration was the best to induce the highest 
immune answer.  
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As I presented in Chapter 2, the acquisition of knowledge is neither direct nor 
straightforward. It demands a learning effort (Akbar 2003) that employs the conceptual 
knowledge possessed by individuals. However, when this knowledge is not available 
within the team or organisation, one option is to introduce knowledge hiring people, a 
second option is training employees, and another option is creating alliances and 
partnership with external organisations to access to resources that cannot be recreated 
internally (Powell, Koput, and Smith-doerr 1996). These activities were necessary to 
acquire knowledge for the NUSTAN clinical team. The fact that NUSTAN selected 
personnel with related knowledge defined the bases from where the clinical team could 
build its knowledge of how to be a sponsor, design a clinical trial project and implement 
the clinical trial. The process to create the team’s knowledge to be a sponsor is 
illustrated in the following quote:  
“So, we started to design a structure of what is being a clinical trial sponsor. So, 
inside that structure we began to think, how is a product developed? This 
knowledge is part of the core business of any pharmaceutical company. When do 
you have a product, how do you develop it? So, we started to study and work on 
that… The clinical development has been an internal exercise, regarding what the 
disease immunology is, what neutralising antibodies are, and based on that we 
started to question the mathematical models that were published and we began to 
create our understanding.” [NUSTAN Chair, Apr-13-2017] Quote 1 
This statement nicely captures different elements of the learning curve of the team. In 
the first place, it illustrates how learning took place within the boundaries of the team, 
and a series of questions guided this learning. Secondly from the expression “we started 
to study and work on that” it can be inferred that the team had to acquire information, 
analyse it, put it into practice, and discuss it to create their knowledge about how to 
design a protocol. This process coincides with what McElroy (1999) proposes in his 
model, where problems are evaluated and based on this analysis; if the knowledge 
possessed is not enough to solve the task, the acquisition of knowledge is triggered. All 
this process to generate new knowledge as a team was guided by a cycle of questions 
and answers that strengthened their knowledge as sponsor and, at the end, defined 
what acquired information and knowledge was useful and valid to create the clinical 
trial.  
In this case the clinical team had to consult external sources to recreate in the firm’s 
boundary knowledge obtained in previous clinical trials. The primary source of external 
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knowledge to learn how to design the protocol was Dr Anna Battilega (pseudonym). 
She was the person responsible at the Johns Hopkins Bloomberg School of Public 
Health for implementing clinical trials Phase I for NUSTAN’s vaccine. The NUSTAN 
team regularly contacted her to obtain advice on the protocol design and obtain 
information about the previous trials that they implemented. In this way, through a 
direct communication channel with an external source, the team accessed external 
information about previous trials and knowledge to design the clinical trial Phase II. As 
a result, the protocol developed by NUSTAN aimed to evaluate the same vaccine 
concentrations employed by the NIH (source, clinical trial protocols and NUSTAN 
Presentation) using two dosages administered subcutaneously to a population between 
18 and 59 years old.  
In summary, the NUSTAN case illustrates the process to develop new knowledge to 
design a protocol in a case where clinical teams do not have previous experience with 
the research product and designing clinical trials. In the first place, it is important to 
hire personnel with knowledge close to the work to be undertaken, then from this 
knowledge-base, it is possible to build the new knowledge. Second, in the case that the 
project to implement is interdependent with a previous project, the team should ensure 
a communication channel with personnel involved in earlier stages to get access to 
knowledge previously developed and use it in the new project. Thirdly, the creation of 
the new knowledge requires a learning effort, where discussion and reflections are part 
of the activities to learn and create the necessary knowledge.  
4.2.2. Use of guidelines to design the protocol 
Within the clinical trial community, since 1983, statistical guidelines to design clinical 
protocol (Altman et al. 1983) and address knowledge gaps such as the statistical 
knowledge of the clinical teams which is reported as missed in the clinical teams 
(Romano and Gambale 2013; Wyatt et al. 1994) have been proposed. More recently, 
researchers and the WHO have created guidelines to address the evaluation of products 
for specific disease, providing medical and statistical knowledge to protocol designers 
(Lorch, O’Kane, and Taubel 2014). In the cases studied, sponsors’ personnel indicated 
that they used published guidelines as starting points to design their respective 
protocol for the vaccines evaluated (Element 3, Table 3). The guidelines employed were 
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the ones created by the WHO. The Department of Immunization, Vaccines, and 
Biologicals at the WHO developed two guidelines with the objective of resolving 
technical doubts about the design of the clinical protocol for the vaccine candidates. 
The public for these guidelines were national health authorities – who evaluate the 
protocol – and research scientists – who design the protocol to assess the vaccine. The 
first guideline was the 2007 WHO guideline “for plaque reduction neutralisation testing 
(PRNT) of human antibodies to the virus”13. And the second one is to design the 
clinical evaluation of vaccine candidates in endemic areas (Phase I- IV) (Initiative for 
Vaccine Research WHO 2008).  
The first guideline was employed by the three clinical teams on the design of their trials, 
as is stated in their published papers14 and Dr Pablo Esmeralda (NUSTAN Clinical R&D 
Manager) said, “there exists a kind of standard protocol developed by the WHO that 
everybody has to follow, … it is a protocol well established because the answer is simple, 
there are so many things to answer”. Ana Diamante (SAVA-Col) reinforced this 
statement by saying that “the WHO and the PAHO15 have guidelines to design clinical 
trials for infectious diseases, so you have to rely on these (guidelines)”. Also, the SAVA 
coordinator in Mexico explained this: “There is a lot of literature, and the protocol is 
made based on the previous protocol of disease burden to define which efficacy it [the 
vaccine] should have.” [SAVA Sponsor Mex, May-07-2015] Personnel at the clinical 
teams expressed how they employed clinical trial templates and these guidelines based 
on their aims. The next quote provides a clear example:  
“There is a statistical objective to prove that the vaccine is safe. [The design] 
depends on the type of population that you want for the study, the ages, the area 
background [epidemiological information] per country, all this affects the design.” 
[PI- R-IDVI, KINGE, Oct-15-2014] 
Like the quote indicates, the team had to consider multiple variables in the design, 
considering the population, the research product and the disease epidemiology. The 
process to adopt the guidelines to the research product and context required an 
                                                          
13 This biological measure correlates best with protection from subsequent virus infection. The objective of 
this document was to harmonise the measure of levels of Flavivirus-neutralising antibody titers in the 
serum of vaccinated, or infection-immune individuals. 
14 See paper (Guy, Saville, and Lang 2010). 
15 Pan-American health organisation.  
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analytical process and the use of information collected in previous trials. If the team 
did not have information to proceed with the design, they had to access to external 
sources to acquire knowledge or information to continue the process (the next section 
will detail this acquisition process).  
Nonetheless, not all sponsors developing vaccine candidates accepted these guidelines. 
The NUSTAN team strongly criticised the WHO guideline for plaque reduction 
neutralisation testing (PRNT) as the following quote illustrates: 
“The WHO have some guidelines of how should be [executed] the PRNT, but when 
you start to see in detail those guidelines, many holes were never closed like: how 
should the PRNT be implemented? For example, PRNT against what? Against the 
wild virus or the vaccine virus? Should there be a reference virus? How is made an 
inter-laboratory validation? What is the PRNT that I should use, PRNT 50, PRNT 
90? How should be done the specificity test? Is it worth? Nothing of that is resolved 
[in the guideline]. The guideline exists, and all papers [trials conducted by other 
sponsors] refer to that guideline, but in practice, many technical details about how 
to do it never were resolved, so each producer is doing it, in the way they consider 
[appropriate].” [NUSTAN Chair, Apr-13-2017] 
According to the NUSTAN Chair, the guideline had technical holes that any actor 
involved in the vaccine context addressed. In his view, the content of this guideline was 
designed to favour the evaluation and introduction of the first vaccine candidate 
available, which was the SAVA’s vaccine. Then, there was a conflict of interests. 
According to him, in the guideline the WHO did not include technical aspects needed 
for the evaluation of other vaccine candidates. The fact that the other vaccine 
candidates used different biological models16 could have affected the way to evaluate 
the PRNT. As a result, they decide to use the PRNT protocol developed by the NIH and 
some of the WHO recommendations. The NIH had implemented previous clinical 
phases, then, adopting NIH protocols, NUSTAN could make inter-laboratory validation 
to compare results among trials. Therefore, this analytical process gave place not only 
to the protocol. This analysis leads to criticisms of the scientific bases of the guidelines 
and to the adoption of alternatives to close the gap.  
As NUSTAN case illustrates, and the quote on page 72 shows, as the clinical team get 
confidence in their knowledge, they can criticise or call into question other teams’ 
                                                          
16 They were not using yellow fever virus; instead, they used recombined versions of virus trips.  
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approaches and the published literature, as it was in the case of the use of guidelines to 
design the protocol, which is part of the learning process of a new team. In this case, 
the team defined what was in the guidelines that answered the scientific criteria of their 
project design. So as this case shows, once a certain level of dominance of a topic has 
been achieved, it is possible to engage in the discussions taking place in the academic 
community. Then, this case provides evidence of how clinical teams continually 
evaluate the information acquired to design the project and the protocol, as McElroy 
(1999) suggests, on the creation of knowledge products, and this evaluation includes 
the raising of critiques to the knowledge accepted in a community. Therefore, the use 
of guidelines is not a straightforward process to create the protocol; it is an activity that 
demands reflection, criticism and comparisons of the guidelines with the knowledge of 
the clinical team. 
4.2.3. The influence of the commercial interest of the sponsor 
on the project design 
The commercial interest of each sponsor determined the design of the clinical trial and 
the protocol regarding the population included, the sample size and if the clinical trial 
would be multinational or in a single country (Element 4, Table 3). KINGE and 
NUSTAN Phase II had similar objectives; to evaluate the vaccine immunogenicity in 
healthy subjects.17 In both projects, the number of volunteers to enrol was similar: 
KINGE enrolled a total of 360 participants and NUSTAN 300 participants. However, 
KINGE and NUSTAN had different commercial interests. KINGE was interested in 
introducing its vaccine in Latin America and Asia-pacific countries,18 and NUSTAN only 
in Brazil. This difference meant that KINGE implemented a multi-national clinical trial 
in four countries compared with NUSTAN, which only included Brazil. Because of this, 
KINGE had to collect epidemiological information from each one of the countries, even 
if they had just one site there. A multi-national project involved having a monitoring 
team in each country, then this influenced the selection of the CRO. In the case of 
KINGE, this multi-national design implied an additional effort because they had to be 
                                                          
17All objectives were to evaluate the safety, tolerability and immunogenicity of the vaccine, the incidence 
of vaccine virus replication, and the immune response induced by the vaccine in populations with previous 
exposure to the virus. 
18 In some countries, the registration and licensing of clinical products (vaccines, medical molecules) is 
favoured if part of the data of the clinical trials was obtained in that country, with the local population.  
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sure that the protocol fulfilled the regulations of each country included. In contrast, 
NUSTAN only had to implement its trials in Brazil because they “are doing this project 
for the Brazilian population”, as NUSTAN’s Chair said. Because Sao Paulo was in the 
middle of an epidemiological peak, they decided to implement the trial in two research 
sites located at the University of Sao Paulo. Therefore, the planning process, the 
acquisition of epidemiological data, and the monitoring was more straightforward than 
in KINGE. Then, the interest of implementing a multi-national trial demands extra 
efforts on the project planning, including initial data collection. 
Another example of the implications of the commercial interest of the sponsor on the 
project design is evident in the SAVA case. In this case, initially, the clinical team did 
not consider implementing the trial in Brazil because the company did not have “a sort 
of department of clinical trials in Brazil” [SAVA Sponsor Brz, April-10-2015]. However, 
in Brazil, the virus is highly endemic, and Brazil is the biggest market of all Latin 
America for a potential vaccine. Also, for the sponsor, implementing a clinical trial in 
Brazil enables the obtaining of the registry to commercialise the product. Using these 
arguments, personnel in Brazil working in one of the pharmaceutical holding firms 
proposed to include Brazil in the trial, as Wallace Coutinho, coordinator of the project, 
said: 
“The country is the most important in terms of the market in Latin America; we are 
the 7th or 6th today in the pharmaceutical market… in the end, we were invited as a 
country to participate because sort of pressure from the market, so it doesn’t make 
sense if Brazil doesn’t take part of the trial because we will offer a massive market 
in the future at the end.” [SAVA Sponsor Brz, April-10-2015] 
So, SAVA included Brazil in the project because of this market pressure, and to 
coordinate the project, SAVA created an alliance with the pharma division of the group 
to outsource the project to the clinical unit of the pharma division to coordinate the 
trial locally. This team had to learn how to implement a vaccine trial based on their 
pharma experiences. Nonetheless, this learning was reported as challenging because 
endpoints evaluated in a pharma trial differ to the endpoints adopted in vaccine trials. 
In a pharma trial, endpoints include reaching a certain number of deaths or monitoring 
surrogate variables associated with health improvements. In a vaccine trial, the number 
of diseases reported defines the trial endpoint. Therefore, operative teams in Brazil had 
to develop new knowledge about how to implement a vaccine trial, as SAVA’s clinical 
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trial coordinator in Brazil indicated. In conclusion, the market interest of the sponsor 
to sell its vaccine directly influenced the design of the clinical trial regarding the 
number of volunteers to be recruited and the countries included.  
4.3. Acquisition of external knowledge, information and 
data  
The knowledge of the clinical team and the accumulated data and information 
produced in the clinical trials are fundamental blocks to design a clinical trial. 
Nonetheless, in the three cases studied, the clinical team had to acquire external 
knowledge, information and data to design a clinical protocol (Element 5, Table 3). The 
way of accessing this information, knowledge and data varied between cases. In the 
case of SAVA, it was necessary to use boundary spanners. In contrast, in the cases of 
NUSTAN and KINGE, researchers had direct contact with the source. Also, over the 
designing phase, the clinical team received suggestions on designing the project from 
external sources, like the national regulatory agencies and clinical researchers which, 
in some cases, were accepted but not in others. In this section, I continue tracking down 
the knowledge flow to design the protocol. I will specifically discuss the acquisition of 
external knowledge and information by the clinical teams, paying particular attention 
to the channels employed to access to these sources (direct communication or the use 
of intermediaries) and the permeability of the clinical team towards external 
information that was and was not directly requested by the team.   
4.3.1. Accessing and introducing knowledge, information and 
data required by the team 
Table 3 indicated how clinical teams required epidemiological information to design 
the trials, and they had to know logistical aspects about the countries and locations 
selected to anticipate any adverse situation and adapt the protocol to the local 
requirements. SAVA and KINGE clinical teams were in the USA, and the trials were in 
Latin America countries. Because of this separation, clinical teams did not know the 
practicalities to implement the protocol in these countries. Therefore, clinical teams 
acquired this information from local sources, creating inter-branch communication 
channels or inter-organisational channels. In the case of SAVA, the company had 
branches in Mexico, Colombia and Brazil, so the clinical team consulted the 
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information required to the local branches – inter-branches channel – as the next quote 
indicates: 
“We [branch] have an input… because we are going to do the studies in Mexico, we 
see if Mexican regulatory times does not impact the project, the project has to 
consider vaccination campaigns, that we don’t have any problem with the sites. 
Then, our input is relevant.” [SAVA Sponsor Mex, May-07-2015] 
In the KINGE case, the principal researcher had direct contact with the research group 
because they have a long story of scientific cooperation, then a direct communication 
channel between the two organisations allowed them to consult information directly 
(inter-organisational channel). One example of this communication is the next quote:  
“We had a meeting face to face (with the site personnel) … I had to understand the 
regional dynamics, because many times, I believed that something that I do in the 
United States they (R-IDTV Colombia) do it in the same way. Nonetheless, they tell 
us, no, here that cannot be made, or that is not correct you must change it. So, I 
had to make changes based on that.” [Sponsor- KINGE, Oct-25-2014] 
For the inter-branch and inter-organisational channel, both quotes show how a direct 
communication between the research sites and the source allowed to clinical team 
members to obtain rich insights into the local context. Insights obtained from local 
branches and sites allowed them to define the inclusion of research locations to the 
project. For example, Dr Jaime Plata [KINGE owner] has been interested in working in 
Apartadó-Colombia because this municipality presents a high disease incidence, which 
is ideal for running an efficacy clinical trial in less time. However, the region lacks 
adequate transport connections to send the biological samples from the site to the USA 
in less than 24 hours, so for this reason, the location was not selected. In KINGE and 
SAVA cases, sponsor personnel manifested the need to know in advance in which places 
it would be possible to implement the project, especially for security conditions: “you 
know that in our environment, it is not easy to work because of the insecurity” 
[Sponsor- KINGE, Oct-25-2014]. Unfortunately, in Mexico and Colombia, the drug 
traffic and internal conflict limited the implementation of the trial in highly endemic 
areas. For example, in Mexico “there were areas where the incidence was high, there 
was the population, but not the security conditions” [PI 1-Site2, SMO-3, SAVA-Mex, 
May-15-2015]. The exclusion of endemic areas in a clinical trial has consequences on the 
project results because without this information it is not possible to infer the vaccine’s 
efficacy in specific epidemiological scenarios where different combinations of the virus 
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circulate. Nonetheless, the security of people working on the project is essential, and 
despite the relevance of data, they cannot be exposed to these risks.  
The evidence for KINGE and SAVA’s cases indicate that the teams were receptive and 
used the insight gained from the local branches (SAVA) and local researchers (KINGE) 
to adapt the protocol to the local contingencies modifying procedures or coordinating 
the implementation of the clinical trial. Also based on this evidence, it is possible to say 
that in these two cases, the clinical team was permeable to this information because 
the headquarters demanded the information and they needed to understand the local 
conditions to determine the feasibility of the trial in the country, which is vital to 
coordinate the implementation of the project in multiple countries. So, the direct 
demand for information from the clinical team makes them highly permeable towards 
external sources. 
Only NUSTAN requested from external sources knowledge or information directly 
associated with the scientific content of the clinical trial, and they were open to 
receiving knowledge from sources that they considered valid. In this case, NUSTAN’s 
clinical team established collaborations with the principal researcher, Dr João Eduardo 
Espinela, considered an expert in the field of immunology in Brazil, to design the 
protocol and find alternatives to the methods employed to evaluate the immunology of 
the vaccine, as the following statements capture: 
 “The first draft was made by colleagues at NUSTAN, so they sent me the draft, and 
I was able to contribute to the study design and how the protocol was written.” [PI-
USP, NUSTAN, Apr-01-2015] 
“On the study Phase, II João is helping us a lot. Now that the theory of neutralising 
antibodies is in check [he is] helping us to find something on cellular immunology 
that can turn out to be another type of protection marker.” [NUSTAN Chair, Apr-
13-2017] 
These quotes indicate NUSTAN’s intention to receive comments from the principal 
investigator and co-create new knowledge to solve a knowledge gap present in the 
scientific community. These quotes also demonstrate the high permeability of the team 
to the external knowledge when they requested it and consider that the contra part has 
a valid knowledge that is trustful and useful for the project.  
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The fact that the NUSTAN team was new and they had to acquire more scientific 
knowledge than the other two cases to design the project can be one factor that explains 
why NUSTAN shared the protocol with local researchers. However, I consider that 
behind the openness of NUSTAN researchers to co-create the protocol with other 
researchers, is the fact that NUSTAN wanted to propose an alternative model for the 
way in which clinical trials are designed and conducted in the pharmaceutical industry. 
According to the NUSTAN Chair in the industry, clinical trials are poorly exposed to 
the scientific debate. In their case, they wanted to discuss, with researchers and the 
community, the protocol to make it more inclusive and scientifically robust.  
There are cases in which the sources in the country do not have the information or data 
required by the clinical team to design or adapt the protocol. Therefore, local teams 
had to design strategies to access data and information. For example, SAVA required 
epidemiological data of the countries included in the project to understand the disease 
distribution in each country over the last five years before the study. Clinical teams 
needed this data to calculate trial power and vaccine efficacy, as stated in SAVAs’ Phase 
III paper: 
“In these calculations, we assumed a dropout rate of 20% and a disease incidence 
of 0.64%. The assumed incidence was based on mean [disease name] incidence 
rates in the 4 or 5 years before enrolment, according to passive surveillance data 
provided by the municipalities in which the trial was conducted.” (L. Villar et al. 
2014a) 
To obtain this data and define the number of people to enrol per site, local branches 
acquired the role of boundary spanners, facilitating the transfer of data between the 
clinical team and the ministry of health, as SAVA’s project manager in Colombia 
indicated: 
“When you are designing a clinical trial you have local experts, we are those 
managing the trials locally, and WE help to search information… Those that design 
the studies are very centralised, and they don’t have all information, so the first 
thing that they have to do is to contact local people in those places… You need to 
surround yourself with public affairs teams; they will make all negotiations with the 
public entities19; they will help you to get all data from the government that you 
need for the study.” [SAVA-Sponsor Col, Mar-24-2015, underline added] 
                                                          
19 At the national level, health ministries have surveillance systems for some diseases to identify the 
incidence, the locations, the serotypes circulating, the age of infected people, etc. 
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Therefore, as it is possible to infer from the quote, the public affairs in endemic 
countries were responsible for searching and accessing the data and information on 
external sources to then introduce it in the organisation and transfer it across teams. 
In this case, the public affairs team refined these databases to select only the 
information and data requested by the clinical teams, because the “countries do not 
provide the databases as you need it” [SAVA-Sponsor Col, Mar-24-2015]. After this 
process, branches sent the data to the clinical team. The clinical team using this data 
calculated the trial power20 for the entire trial and each country (Colombia, Honduras, 
Mexico, Brazil and Puerto Rico). Also, with this data, they identified possible locations 
to implement the protocol and made the respective analysis to define the sample size. 
So, teams employed this information in the project design. Nonetheless, it is relevant 
to consider that the final selection of sites depended not only on the data analysis. The 
availability of technical capabilities in each country to implement the trial and create 
alliances with public and private SMOs (Site Management Organisations) were factors 
that defined the sites, the number of locations and the number of volunteers in each 
site, as was presented above. 
Knowledge management scholars have argued that organisations need to take care of 
their ability to manage challenges across boundaries (Levina and Vaast 2014). Boundary 
spanners emerge as a solution to these challenges. These are individuals who enable 
the sharing of knowledge by linking groups separated by location, hierarchy or function 
(Ansett 2005; S. Gupta and Polonsky 2014; Levina and Vaast 2014; Alavi and Leidner 
2001). Levina and Vaast (2014) propose the presence of two boundary spanners, 
nominated boundary spanners and boundary spanners-in-practice. The first ones are 
officially designated with specific responsibilities, whereas the second ones become 
spanners as a result of their actions and not necessarily because someone designated 
them with such a role. The SAVA case illustrates how headquarters nominate local 
branches as boundary spanners responsible to search for data. Moreover, these 
boundary spanners must use their knowledge about the requirements of the clinical 
teams to refine the data based on these needs and transfer it to the clinical teams. Then, 
in the SAVA case, boundary spanners are not only mobile actors who carry data, but 
                                                          
20 The trial power is the participants’ sample size calculated to minimise random errors; this depends on 
the desired age group and defined end-point. A study needs sufficient power to conclude about the effect 
of a treatment (Wang and Bakhai 2006, 9). 
83 
 
they are also active actors who interact with the data, processing them before being 
sent. The clinical teams employed in the protocol design the data and information 
accessed by these boundary spanners. Therefore, it is possible to say that a team is 
permeable to these external data and information in those cases that the organisation 
nominates its boundary spanners and assigns specific responsibilities directly related 
to knowledge acquisition. 
4.3.2. Selective permeability to external knowledge and 
information not requested by teams  
Up to this point, I have discussed how clinical teams accessed to external information 
that they demanded to design the protocol and the use of their previous experience and 
results to design the protocol. However, clinical teams also receive information and 
knowledge not directly requested, that they might have or might have not considered 
in the design. Therefore, here I will discuss how teams manage this unexpected 
knowledge and how the permeability of the clinical team mediated the use, or not, of 
this external knowledge. 
Initial drafts of the protocol in rare cases are shared with researchers to get feedback. 
In the clinical trial industry, the traditional practice is that the clinical team shares 
consolidated versions of the protocol with researchers only when the team is 
configuring the research network, as the next quote evidences: 
“The company always decides what study it wants to do and then searches for a 
principal researcher and says this is what we need to do, it is the company decision. 
Of course, over this process, there is some communication with the principal 
researcher to make small modifications, but the principal study is designed by the 
company.” [Sponsor- KINGE, Oct-25-2014] 
Then, as this quote suggests, the clinical team does not expect substantial comments 
on the project design from researchers. The section 4.3.1 presented how the sponsor is 
interested in discussing only information associated with the local regulation on 
procedures to implement the project. But the discussions that take place among the 
two parts are not associated with the core methodological design of the project, 
excepting the NUSTAN case. So, the clinical team does not have a clear intention to 
receive external comments because these are not expected or demanded. However, in 
the SAVA case, one atypical situation took place. One of the local researchers, Dr Rubi, 
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considered that the protocol had some designing problems and, therefore, he suggested 
amendments, as he explained: 
“I did corrections to the protocol that were not introduced because the laboratory 
didn’t want… [immunological explanation about his suggestions] …So, what they 
accepted to modify was that they would take a blood sample on the first five days 
to review if the person was positive [to the virus]. That would help us to know if the 
antigen was there and define if it is a new [infectious] case.” [PI 1-Site2, SMO-3, 
SAVA-Mex, May-15-2015]  
Although the researcher signposted that changes were accepted, the published protocol 
does NOT include the collection of a blood sample at day five for all participants, so his 
suggestion was partially accepted. To propose these changes, the local researcher had 
to convince the regional director of R&D about the veracity of his argument, as the next 
quote evidences: 
“With Ernesto Reyes (SAVA regional director of R&D), I had the conversation about the 
antibodies… he asked me, where is that published? And I sent 200 papers, and they said, 
you are right, but this is the protocol, and we cannot modify it.” [PI 1-Site2, SMO-3, 
SAVA-Mex, May-15-2015] 
SAVA’s regional director in this specific case acted as a boundary spanner-in-practice 
(Levina and Vaast 2014). He was not delegated to transfer information from researchers 
to the clinical team. In fact, no contributions from researchers were expected. However, 
this situation made it so that SAVA regional director assumed this role and regulated 
the flow of information between clinical researchers and the sponsor. The emergence 
of this boundary spanner-in-practice became a barrier across parts and knowledge 
provided by these researchers had to pass through filters before it reached the clinical 
team.  
Published results about the vaccine indicates a problem with the introduction of the 
vaccine in Asia countries. Results indicate that the suggestion made by the Mexican 
researcher could have contributed to identifying, on time, the limitations of the 
vaccine, protecting people that had not had contact with the virus if a blood sample 
would have been collected after the first vaccination. Moreover, because the 
pharmaceutical company did not collect blood samples to all subjects over the course 
of the trial, the data collected is being re-analysed, and blood samples collected over 
the trial have been re-evaluated but not all data is available. Then this case shows how 
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academics can contribute to the project design. However, in the pharmaceutical 
industry, the fragmentation within the organisations and the emergence of boundary 
spanners-in-practice decreases the flow of knowledge between clinical teams and 
researchers. Therefore, clinical teams do not receive all the contributions of researchers 
for the trial design.  
This situation shows how the sponsor did not expect a contribution from principal 
researchers, so they were not prepared to receive these comments. This point leads me 
to suggest that protocols could be shared with researchers in early stages, so their 
contribution can be analysed and considered with enough time. I do not pretend to 
suggest that principal researchers are always right and all their comments should be 
included immediately in the protocol. However, I consider it relevant to create a direct 
communication with the researcher and listen to their scientific suggestions, which can 
benefit the project.  
In a clinical trial, the sponsor must obtain approval from each local regulatory agency 
to implement the trial locally. As part of these evaluations, local agencies have the right 
to provide comments and suggest modifications to the protocol. Nonetheless, clinical 
teams not always are open to receiving these comments and implementing them. I 
presented above how the NUSTAN clinical team was open to receive comments from 
researchers consulted to design the protocol. However, the NUSTAN clinical team was 
less permeable towards the recommendations made by ANVISA (Brazilian regulatory 
agency). The agency delayed the approval of the protocol and required additional 
information once NUSTAN submitted the protocol. After some deliberation between 
ANVISA and NUSTAN the agency requested the next information: “the validation of 
the PRNT Test, essential for the primary outcome of Phase II study, which has, for its 
aim, to evaluate the immunogenicity of each one of the 4 serotypes” (Porto 2015), and 
“the presentation of Phase I results obtained in the United States” (Ministério do 
Planejamento 2015). According to Dr Esmeralda, the agency was expecting that 
NUSTAN implemented the same PRNT validation approaches employed by SAVA in 
Brazil21 and this was questioned for NUSTAN, as Dr Esmeralda pointed out:  
                                                          
21 ANVISA, as a regulatory agency, evaluated SAVA and NUSTAN protocols and SAVA’s protocol was 
evaluated first.  
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“SAVA standardisation process for the vaccine is supported on premises that make 
sense in certain productive areas, but, (they) do not have sense in clinical areas. 
This generates confusions because they [SAVA] published that information (paper 
published by SAVA in 2013 about the PRNT), and that information ends up being a 
referent for the agency, but those things are questionable… There was that gap in 
the PRNT guidelines, and particularly when you reflect on this, I did not expect that 
ANVISA would assume that role. I think that ANVISA was not prepared in this 
sense to address those gaps in knowledge. Maybe a higher agency could have 
addressed better those gaps in the knowledge than a lower agency… It was collective 
learning for them and us; we found a middle point, and we got a dialogue between 
the parts.” [NUSTAN Chair, Apr-13-2017] 
This quote expresses the frustration and discomfort of Dr Esmeralda with the agency 
for having used as a parameter the premises employed by SAVA to evaluate NUSTAN’s 
approximation to implement the PRNT test. But most importantly, this quote shows 
how NUSTAN call into question the agency’s knowledge and capacity to take decisions 
in situations when guidelines and standards have knowledge gaps. This quote 
evidences how the clinical team considered that ANVISA did not possess the 
knowledge to evaluate a protocol without any previous reference; the argument that 
was reinforced over the interview, as the next quote clearly indicates:  
“Our regulatory agencies in Latin America receive multinational project approval 
from one of the major agencies of the world, the FDA or EMA. The Latin American 
country is just another country where the study is being done. Therefore, deciding 
on a project is easier because you [agency] already have the reference for the 
evaluation of an agency with greater experience… In our case, ANVISA was the lead 
agency, and this creates an unusual situation for them, they have to take a decision 
about something that they did not have a reference for, and that created doubts, 
enquiries, and in some cases, generates impasse. ” [NUSTAN Chair, Apr-13-2017] 
Then, this lack of trust in the agency made it that NUSTAN did not readily accept the 
suggestions and requirements made by this agency. Despite this lack of trust, NUSTAN 
had to present results about their test validation with some modifications, which 
indicates that they had to address some of the agency requirements and follow their 
suggestions. For this reason, the team was semipermeable to external comments 
because they had to negotiate and assess ANVISA comments. The low permeability in 
NUSTAN’s case, to external scientific knowledge, reflects elements of not-invented 
here syndrome (Katz and Allen 1982) because the clinical team considers that the 
external organisations do not have the capabilities and knowledge to provide accurate 
suggestions. For this reason, the knowledge received is not considered valid and the 
permeability of the team to include this knowledge in the protocol design is low. 
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Therefore, trust in the capacities of the source is an important element that mediates 
the permeability of clinical teams. 
KINGE, located in the USA, received comments from the FDA to design its trials. 
KINGE’s interaction with the FDA was quite different compared with NUSTAN’s 
interaction with ANVISA. In the US, all sponsors considering the clinical development 
of any new molecule or biological product must register the new product as an 
“Investigational New Drug” (IND).22 The product developer holds a pre-IND meeting 
with the FDA to review the information, and during this process, the FDA provides 
opinions and suggestions to improve the clinical plan. The next quote presents KINGE’s 
experience about this meeting: 
“First, we prepared a document called pre-IND that states – this is what I’m thinking 
to do. They give you feedback, and they say, I think that you are on the right track, 
or maybe you must reflect about this or that. After that, we have time to prepare 
the IND. [Sponsor- KINGE, Oct-25-2014] 
The narrative of the sponsor about the process indicates that they did not question the 
knowledge of the agency on the process and used the comments provided by the agency 
to improve the IND, showing permeability towards this source, which is contrary to 
NUSTAN’s attitude of distrust of ANVISA criteria. Moreover, the sponsor considered 
that the agency had the right and authority to provide comments and they wanted the 
FDA validation of the trial. For this reason, the sponsor was open to adopting the 
agency comments. The expression “one always seeks approval from the FDA because 
many regulatory institutions worldwide follow the comments of the FDA” [Sponsor- 
KINGE, Oct-25-2014] shows that the power of the FDA over the sponsor is not only 
linked to their power to approve the protocol in the USA. The FDA power goes beyond 
the USA because agencies in other countries base their decisions on the comments 
provided by the FDA. Multinational companies know this fact, and they use the FDA 
power to their advantage to obtain approvals in the other countries; for this reason, 
they are also open to the FDA comments.  
                                                          
22 In the USA, any biological drug to be evaluated clinically in the country has to obtain the IND status; 
thus, this investigational new product can be used in humans and can be transported beyond the state 
borders for the clinical trials. The molecule dossier presented to the FDA has to contain information about 
animal pharmacology and toxicology studies, manufacturing information, and clinical protocols and 
investigator information (FDA 2000). 
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Then, as the NUSTAN and KINGE examples reveal, the regulatory agencies can have an 
active role in the design of a clinical trial. Their authority to allow the implementation 
of the trial gives them the right to question and request changes or additional evidence 
to implement the trial. However, their knowledge is not always considered valid or 
trustworthy by the clinical team and can be questioned, as the NUSTAN case 
exemplifies. So, both cases indicate that the permeability of the teams to external 
knowledge depends on how trustful and legitimate the clinical team considers the 
knowledge of the source to be.  
Figure 4. The permeability of the clinical team mediated firstly by the need for 
information, secondly by the presence of boundary spanners, and thirdly by the trust 
of the source.  
 
In summary, in this section, I have presented how the clinical team’s permeability 
towards external information depended on three factors illustrated in Figure 4. The first 
factor is the demand for knowledge. Clinical teams were highly permeable to external 
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information, knowledge and data if there existed a need or demand for this data and 
information within the clinical team. This was the case of KINGE, SAVA and NUSTAN, 
who directly consulted the source, such as local researchers and the local branches 
(Figure 4-1.a) and they were open to their comments. Also, if teams demanded the 
information and used boundary spanners to access it, they were also open. This was the 
case of SAVA, who accessed databases of the health ministry through the headquarters 
(Figure 4-1.b).  
The second factor that influenced the permeability of the team towards external 
knowledge and information was the trust that the clinical team had on the source. This 
factor played a crucial role in those moments where the clinical team did not demand 
knowledge (Figure 4- 2). Examples of this are the different openness of KINGE and 
NUSTAN towards the comments of their respective regulatory agencies. KINGE was 
open towards contributions provided by the FDA because they trusted the agency 
criteria; in contrast, NUSTAN was reluctant to accept the recommendations provided 
by ANVISA. 
Finally, the third factor that influenced the permeability of the teams towards external 
information and knowledge was the presence of intermediary actors, who filtered the 
information and knowledge flow between the source and the clinical team. This was 
the case of the SAVA regional director of R&D, who regulated the communication 
between local researchers and the clinical teams, and also the case of the public affairs 
offices at the local branches (Figure 4- 1.b, 3). In the SAVA case, boundary spanners 
helped to get access to external knowledge, but also external actors acting as 
intermediaries between the team and researchers filtered unsolicited information from 
the research team, revealing the dual role of boundary spanners on the access and 
transfer of information as filters or information seekers. 
4.4. Conclusions 
This chapter aimed to answer the research question how did the sponsor acquire and 
use knowledge, data and information to design the clinical protocol? To answer 
this question, in the first section, this chapter addressed the intra-organisational 
dimension of the clinical teams to use knowledge, data and information to design the 
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protocol. In the second section, this chapter presented the acquisition of data and 
information to create the clinical protocol, discussing the team’s permeability towards 
external sources. This chapter illustrates that the protocol design is not linear, and 
although clinical teams first employ their previous experiences, results and guidelines 
to design the protocol, the emergence of questions, and gaps in knowledge, data and 
information, trigger learning loops and the acquisition of knowledge data and 
information. In the end, the combination and use of their knowledge give place to the 
creation of the protocol. Figure 5 summarises the flow of knowledge to design the 
protocol, including the acquisition of internal and external sources of knowledge, 
information and data. Over the design of the protocol, not only medical, 
epidemiological, and regulatory knowledge and information is acquired and used to 
design the protocol. Knowledge and information about logistics in the endemic areas 
and the security conditions are needed to create the clinical trial, and the access and 
use of this knowledge and information reshape the protocol, especially the sample 
population defined for each site (Elements Table 3). 





The results indicate that individual knowledge of the clinical team members was crucial 
for designing the protocol and the project (Figure 5-1). Almost all teams planning these 
projects had previous experiences doing this work, and they know how to do it using 
their professional and academic experience. Nonetheless, there are differences between 
sponsors according to their level of experience. The continuity of the clinical team 
members that worked on the previous project allowed a flow of knowledge from one 
phase to the other one. In this way, in interdependent projects, the knowledge acquired 
on the last clinical phases is preserved and used to create a new project. In contrast, in 
newly constituted clinical teams, the previous related knowledge provided a base on 
which to build new knowledge associated with the design of an interventional study, as 
the NUSTAN case illustrated, but the new clinical team had to make a learning effort 
to design a protocol and an entire project. For this, the new clinical team established a 
direct communication channel with personnel that worked on the previous trials.  
As it was perceived by the people interviewed, it seems that designing the protocol was 
a simple process once they had all the information and data required. The evidence 
presented indicates that within the boundaries of the sponsor there existed the 
conceptual knowledge (medical, epidemiological) to design the protocol. The sponsor 
employed the information and data gathered from previous clinical and pre-clinical 
trials to create the new protocol, which is necessary for interdependent projects like 
the clinical trial phases (Figure 5-2). However, when the sponsor had cognitive gaps or 
required information, the team consulted external sources to acquire knowledge and 
information (Summary of the knowledge flow to design the clinical protocol by the 
sponsor. Figure 5-3). The experienced clinical team requested very precise data or 
information; in contrast, inexperienced teams searched for knowledge sources to teach 
them how to design the trial. In this chapter the concept of permeability was 
operationalised and evidence was presented regarding its relevance on the knowledge 
flow to create knowledge products.  
The permeability of an organisation to external information depended on the demand 
of the team for it; unsolicited information and knowledge were less absorbed compared 
with data and information directly requested by the clinical team. As the data indicated, 
the openness to using this knowledge was mediated by the trust placed on the source. 
The cases of KINGE and NUSTAN provide a clear example of this openness. In the 
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NUSTAN case, the clinical team did not trust the knowledge of the agency to evaluate 
the project, and therefore, they were reluctant to address their comments in the first 
instance. On the contrary, KINGE trusted the comments provided by the FDA and 
consequently, the clinical team was open to adopting the FDA suggestions in their 
work.  
The direction of knowledge acquisition is crucial because it determines the flow of 
knowledge and information, it modulates the interaction between the actors, and it 
influences the permeability of people towards external knowledge. In the case of SAVA, 
it was possible to differentiate between two types of boundary: nominated boundary 
spanners and boundary spanners-in-practice. Nominated spanners had the clear 
responsibility of searching, refining and transferring data residing in the health 
ministries and also, in contrast, boundary spanners-in-practice, who emerged because 
their role in connecting the clinical team and the local researchers became information 
regulators, filtering the knowledge and information suggested by principal 
investigators to the clinical team. In this case, boundary spanners controlled the flow 
of information between researchers and the clinical team, so information transferred 




Chapter 5: Transition stage. Transfer 
and acquisition of knowledge and 
information from the sponsor to the 
research sites 
5.1. Introduction 
In the last chapter, I discussed how the sponsor created the protocol using the 
information accessed from external sources and the knowledge accumulated by the 
clinical team. In this way, the clinical team transformed initial knowledge, data and 
information in a knowledge product. In this chapter, I will discuss the process to 
transfer the information and knowledge from the sponsor to the research sites, and the 
acquisition of this knowledge by the local researchers. In the model proposed, this 
chapter addresses the interdependency between the sponsor and the research sites, 
where the protocol and associated information is transferred to research sites to 
continue with their work and produce the clinical data. In the theoretical chapter, I 
discussed how the correct understanding and acquisition of relevant information to 
execute the task by the outsourced organisations is fundamental to the project’s 
success. If the sponsor is capable of creating a shared knowledge about the project 
among all actors, the chances of project success are higher (Bustinza, Molina, and 
Gutierrez-Gutierrez 2010; Enberg 2012).  
From the literature of knowledge management, three key factors were identified that 
influence the acquisition and transfer of knowledge to outsourced research groups or 
firms: (1) the sources and the channels of information, knowledge and data; (2) the 
permeability of individuals towards an external information and knowledge; and (3) the 
knowledge-base of the actors participating in the transfer/acquisition process. The 
identification of these three factors led me to the second research question of the 
project: To what extent does the structure designed by the sponsor to transfer 
knowledge, the permeability of the research sites, and the previous experience of 
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people working on the project influence the acquisition of knowledge in the 
research sites? Therefore, in this chapter, I discuss in more detail how these three 
factors positively or negatively influenced the transfer and acquisition of knowledge 
and information by the research sites. Using the data of the three cases of study I 
address, at the inter-organisational level, the flow of knowledge among organisations 
in interdependent activities. 
My data indicate that for each of the cases, these three factors have a distinct influence 
on the acquisition of new knowledge into the sites. The first section of this chapter 
discusses how the structural dimension of the transfer of information influenced the 
acquisition of knowledge within the research sites. Three elements mainly defined the 
structure of the network: the direct communication between the site and the sponsor, 
the outsourcing of the project to a CRO, and the outsourcing of the creation and 
management of research sites to SMOs. In the first place, the evidence indicates that, 
if the sponsor did not outsource the project to a CRO or there existed a direct 
communication channel between the site and the sponsor, sites received all the 
information required to implement the project. In contrast, in a structure where 
multiple intermediaries are present, the acquisition of knowledge and information by 
the site is slow because information is transferred incompletely and breaks in the 
communication among parts exist. Additionally, this section addresses the 
permeability of the staff towards external information. The data reveal that the sites’ 
personnel were open to information transferred from experienced researchers or 
monitors that they trusted. In contrast, the staff were less receptive to the information 
transferred by monitors with limited experience in clinical research. The presence of 
multiple sources transferring information to the sites created confusion in the research 
group, so the evidence indicates that a low number channels employed to transfer 
information has positive benefits on its acquisition by the sites and the sites are more 
open to receiving the new information.  
The second section discusses how the knowledge-base of the personnel working at the 
research site mediates the acquisition of information about the project and the key 
concepts of clinical research. In the first place, this section presents how specifically 
the regulation in Colombia determined the professionals that can work on the project, 
defining the professional knowledge that must compose a site. Secondly, this section 
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discusses the influence of previous experience (knowledge-base) on the acquisition of 
knowledge and the cognitive distance between the knowledge to be acquired and the 
knowledge residing on the site. As it will be discussed, experienced staff on clinical 
research had the practical and conceptual knowledge to understand the protocol; 
knowing the procedures to implement it and they knew what information to expect. 
So, these personnel had a knowledge-base from which they easily built their 
understanding of the project, the research product and the procedure. Thus, their 
cognitive distance regarding the knowledge required to execute the project was short. 
As it was expected, personnel that did not have experience working on clinical trials 
had to develop new knowledge about clinical research before being part of the project. 
However, the process to create this knowledge varied according to the research sites 
and previous experience as practitioners. In academic research groups, new staff were 
trained by their colleagues on the regulations and procedures to follow the GCPs, so 
the environment enabled them to learn the practical and conceptual knowledge to 
implement the trial. Whereas personnel working on new research sites were trained 
theoretically by the SMOs on the core concepts of clinical research, but all practical 
knowledge was without examples, so the lack of a learning environment decreased the 
speed to learn new knowledge. Despite the context of the research site, people with 
vast experiences as physicians, but without research experience, encounter more 
challenges in learning the practicalities of clinical research than people without any 
previous practical experience, which partially contradicts the argument that a previous 
knowledge base enables the acquisition of knowledge. What this evidence reveals is 
that previous conceptual knowledge enables the acquisition of conceptual knowledge, 
but some practical knowledge related partially to the activity to be undertaken can be 
an obstacle to learning new practical knowledge.  
5.2. Structure to transfer information and its influence 
in the acquisition of knowledge by the research 
sites 
In a clinical trial, the sponsor requires that all staff working on the project at the 
outsourced organisations understand the protocol and the task to be implemented. The 
validity of the data produced by the site depends to a large extent on the training of the 
personnel and their knowledge about the study protocol (Gassman et al. 1995). 
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Research conducted by Subramaniam and Dugar (2012) emphasises the value of 
knowledge transfer and mentoring in the trials. Nonetheless, the acquisition of 
knowledge is not straightforward for the sites, as this section presents, where the 
channels and sources employed by the sponsor to transfer the information played a 
significant role in this process.  
In the literature of knowledge management in outsourced projects, Blumenberg et al. 
(2009) indicated that the transfer of knowledge from one organisation to another has 
two dimensions: a ‘content dimension’ and a ‘structural dimension’. The content 
dimension refers to the composition of the training and the documents transferred that 
have the concepts to understand the project. The channels, sources employed, and 
hierarchies to transfer the information, defined the structure to transfer knowledge 
among organisations and the hierarchies in the communication procedures, such as 
knowing whom to contact. In the three cases studied, the content dimension was 
similar, with some specific differences between cases regarding the proper procedures 
to implement. In all the cases, sites received information about the protocol, the 
vaccine, the management of the informed concern, the molecule brochure, manuals, 
the Standard Operative Procedures (SOPs) and Good Clinical Practices. In the 
particular case of SAVA, sites received training to manage communication media and 
how the principal researcher should proceed if he was called to provide a disclaimer in 
any legal case associated with a participant.  
However, the structural dimension differed considerably across the three cases. 
Channels, sources and the protocols of communication from the sponsor to the sites 
were different, as is shown in Figure 6. In the NUSTAN case, the interaction between 
the site and the sponsor was direct. However, in the SAVA and NUSTAN cases, two 
factors influenced the structure to transfer information and knowledge from the 
sponsor to the sites. The first one was the outsourcing of the project to a CRO; the 
second one was the outsourcing of the management of research sites to SMOs. Each 
one of these structures had a significant impact on people’s acquisition of knowledge 




Figure 6. Structural dimension for the transfer of information for each one of the cases 




5.2.1. Direct communication between the sponsor and the 
research site 
The outsourcing of the management of the project to a CRO is the first factor that 
determined the structure for the transmission of information (Figure 6). However, of 
the three cases, the NUSTAN case was the only one that did not outsource the project 
to a CRO. This decision benefitted the transfer of information and training of the 
personnel about the protocol, as I will explain. In the NUSTAN case, the 
communication between the sponsor and the sites was direct. The sponsor trained the 
staff at the research site on the protocol and procedures, as one of the sub-researchers 
and NUSTAN Chair said: 
Quote 1: “We had the protocol specific training, some of them were provided by 
the sponsor.” [Sub-Res-USP, NUSTA, Apr-14-2015].  
Quote 2: “We teach the team about the research product, what the product means, 
what the clinical development plan means […], how clinical research works, more 
from the conceptual standpoint than the formal one, the management of the 
archive of the monitoring system.” [NUSTAN Chair, Apr-13-2017].  
Also, in NUSTAN’s facilities, all sites’ data managers were trained to use the software. 
All this training was face-to-face, which allowed a direct communication, and all the 
questions that emerged were resolved in situ and on time. NUSTAN decided not to 
outsource the trial monitoring to a CRO, and they created an internal monitoring team 
to evaluate the site performance and provide feedback. Regarding this specific activity, 
the sponsor had a clear vision about the monitor’s role in transferring knowledge:  
“Monitoring activities are oriented on building the site, on explaining why 
[something occurs]. This [monitoring] is not a witch hunt; this is about teaching 
what it means clinical research and why the procedures are done in a certain way… 
Monitors are not rewarded for finding many mistakes; on the contrary, if they find 
many mistakes it is because they [monitors] are not doing well their job… All 
training provided has to be focused on explaining to the centre why they are doing 
that; it is not ‘this is not what you have to do’.” [NUSTAN Chair, Apr-13-2017] 
Over the course of the project, the monitor provided training to the site personnel, as 
the quote indicates. This training focused on explaining the scientific basis of the 
protocol. In this sense, the research sites learned about the logic behind and scientific 
rationality of the task stated in the protocol. This approach differs to the other cases 
where monitors provided training on the process and reviewed operative information. 
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For the NUSTAN Chair, personnel at the research sites needed training on specific 
aspects related to the trial and data management, and they did not need training on 
how to manage patients, as is clear in the next quote:  
“I think that we do not teach them how to manage the subjects. On the contrary, 
they teach us. We do not have that pretention; we are not clinicians there in the 
front line, they are, they know much better than us. This is for sure.” [NUSTAN 
Chair, Apr-13-2017] 
Then, the NUSTAN clinical team had confidence in the knowledge of the sites related 
to the management and care of participants. Thus, there is a real trust in the site 
capabilities by the sponsor to implement the protocol. Therefore, the NUSTAN case 
shows the interest of the sponsor on transferring a substantial knowledge about all 
aspects of the project establishing direct communication with the sites. 
In the cases of SAVA and KINGE, although the sponsor delegated some of the training 
to the CROs and SMOS, in both cases, an investigation meeting took place before 
initiating the project. At this meeting, the sponsor directly interacted with the principal 
researcher of the project and staff to explain the project and the protocol. However, not 
all information was transferred in this meeting (Following sections 5.2.3). In the case of 
KINGE, in this meeting, the site’s personnel were trained in the conservation of the 
vaccine’s cold chain,23 informed consent, the vaccine and the protocol. Additionally, 
the sponsor outsourced the training on GCP to an organisation that provided online 
courses, which is a common practice in the industry24 and also was employed in the 
SAVA case.  
Similarly, in the SAVA case, at the beginning of the project in Colombia and Mexico, 
the local branch, the CRO and the SMO coordinated meetings with the sites to provide 
training.  
 “All the principal investigators are invited to this meeting, one sub-researcher and 
the trial coordinator (per site). There they are taught everything, they are trained 
                                                          
23 “The purpose of the vaccine’s ‘cold chain’ is to maintain product quality from the time of manufacture 
until the point of administration by ensuring that vaccines are stored and transported within WHO-
recommended temperature ranges.” (WHO 2015) 
24 The pharmaceutical companies have been working on creating a unique GCP training for the industry 
under the frame of the Transcelerate biopharma initiative, so a site does not have to do a different course 
for each sponsor, saving time because sites will not need to complete duplicate training.  
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in the molecule, in the protocol, in the operational guides, in the diaries, in 
everything that is going to be used in the study, they are trained there (meeting). 
And then, there is an opening visit; it is close to when we are going to start the study 
when the first patient is going to be included. In the research site, the rest of the 
staff is trained in everything related to the protocol.” [SAVA-Sponsor Col, Mar-24-
2015] 
“The initial training was on the protocol, and on the selection of the volunteers etc. 
The second part was about the process to take the (medical) notes, how to fill out 
the files, and how to be careful with the deviations. The last training was about 
details where we learn how to adhere the subjects, what it is and what I can use and 
what I cannot use to avoid misunderstanding.” [PI-Site3, SMO-3, SAVA-Mex, Jul-
08-2015] 
For the opening visit, in both countries, the CRO, the local branch and the SMO 
travelled to each one of the research sites as the two quotes suggest. The content of the 
training covered the protocol, the vaccine’s cold chain, the informed consent, the 
molecule brochure, the management of the database, sample handling, file 
management and participant follow-up, and management of protocol deviations. In 
these meetings a face-to-face interaction between the parts took place, and it created 
an initial understanding of the project by the research site personnel, as the second 
quote points out.  
One can conclude that these investigation meetings are common practices across the 
pharmaceutical industry, which allow the transfer of knowledge and information from 
the sources (sponsor) to the research sites. These meetings set the basis for the research 
sites to implement the protocol-interdependent task, following the instructions and 
guidance provided by the sponsor, the CROs and the SMOs (if they are present); in this 
way a shared knowledge about the project is created. A number of researchers have 
reported the relevance of initial encounters between contractor and supplier in 
transnational and outsourced projects to enable knowledge creation and sharing 
(Adenfelt and Lagerström 2006; Bhalla and Terjesen 2013; Samoilenko and Nahar 2011). 
It has been argued that face-to-face meetings enable the co-creation of a shared 
meaning and understanding of the project between the distributed actors, which is 
more challenging, employing information technology (K. Kumar, van Fenema, and von 
Glinow 2009). The fact that the sponsor did not delegate the transfer of this content to 
a CRO indicates the relevance of this knowledge for the project, and how, despite the 
presence of other communication channels, in vaccine clinical trials, the specific 
101 
 
knowledge about the project is received by the research that sites receive from the lead 
organisation. Therefore, in a multi-organisational project, bringing together the project 
members in the investigation meeting is essential for the execution of interdependent 
task because it allows direct communication among the parts and these personal 
channels (Mandják et al. 2015) allow the transfer and acquisition of procedural and 
conceptual knowledge.  
5.2.2. Influence of the outsourcing of the clinical trial 
management to CROs 
In the SAVA and the KINGE cases, the sponsors in the headquarters decided to 
outsource the management of the clinical trial to CROs, which included outsourcing 
part of the project training. This decision determined the communication structure and 
hierarchy to transfer information from the sponsor to the sites, and it had consequences 
on the acquisition of knowledge by the research sites. The reason to outsource the 
project varied between the two cases. In the case of KINGE, the firm did not have 
branches in Colombia and in any of the countries where they implemented the trial. 
Therefore, they decided to outsource the coordination of the trial to the CRO-1, which 
acted as the sponsor’s legal representative in Colombia and the other countries. As Dr 
Jaime Plata (KINGE sponsor) stated: “The CRO was in charge of everything, of 
everything at a particular cost.” The CRO was responsible for the entire coordination 
of the trial, including: 
“Local trial insurance, the importation and conservation of the cold chain of the 
clinical product (vaccine), the exportation of biological samples, data management, 
monitoring of research sites,25 verification of audits to the sites, verification of 
national and international standards fulfilment, training to the sites, and 
submission of the protocol to the national regulatory agency.” [Monitor-CRO, 
KINGE-Col Nov-27-2014] 
Although KINGE had a previous and a direct relationship with the sponsor, the linkages 
between actors were redrawn at this transition stage. Over the training and project 
implementation, the sponsor interacted directly with the CRO’s headquarters, the 
headquarters with the local CRO and these with the site (Figure 6 – KINGE). Then, “if 
                                                          
25 Monitoring is the act of overseeing the progress of a clinical trial, and ensuring that it is conducted, 
recorded, and reported in accordance with the protocol, standard operating procedures, good clinical 
practice, and the applicable regulatory requirements.  
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the sponsor decided to send specific information to the research site or anything, the 
sponsor would send it to the CRO, and then the CRO sends it to the research group” 
[Monitor-CRO, KINGE-Col Nov-27-2014]. So, the sponsor established a linear structure 
to transfer information using the CRO as an intermediary, which is one of the most 
common structures in the pharmaceutical industry nowadays, primarily to coordinate 
the multi-national projects in cases where the sponsor does not have branches in all 
countries. Therefore, in this case, the structure created to train the site in the 
interdependent task had two components: a direct channel sponsor site and the 
intermediation of the CRO to transfer information. 
Although SAVA had branches in Colombia, Brazil and Mexico, the headquarters 
decided to outsource the management of the trial to a CRO like in the KINGE case, but 
in the SAVA case, the objective was to decrease the cost of the monitoring process and 
get the CRO’s support on the management of the local regulation. In addition to the 
CROs, the sponsor decided to outsource the creation of new sites and the training of 
new research staff to SMOs in Colombia and Mexico because of the lack of research 
capabilities in endemic regions (high prevalence of the disease) where SAVA needed to 
implement the trial. Then, the outsourcing of the coordination of the research sites to 
an SMO was the other factor that defined the structure to transfer information from 
the sponsor to the sites to implement the clinical trial. This outsourcing generated a 
structure where multiple channels were employed to transfer information (Figure 6 – 
SAVA) which directly influenced the acquisition of knowledge and information by the 
research teams (a point addressed in section 5.2.3).  
In the case of SAVA, the structure to transfer the information from the sponsor to the 
sites had two ramifications where the CRO was part of the structure. In the first place, 
the headquarters transferred the information26 to their local branches, the regional 
team and the central CRO. Then, the central CRO transferred the information to the 
local CRO (Ramification 1). Locally, SAVA’s local branch and the regional team trained 
the SMOs on the protocol (Ramification 2). Then, in turn, the local branches, the SMOs 
and the CROs cooperated to transfer the information to the sites and train them on the 
                                                          
26 The protocol, vaccine, informed consent, molecular brochure, manuals, Standard Operation Procedure 
and Good Clinical Practices.  
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project (Figure 6 – SAVA). For example, one principal researcher in Mexico said: “the 
training was provided by the three, SAVA, CRO [name], and the team of Dr Agáta 
[SMO-3]” [PI-Site 4, SMO-3, SAVA-Mex, Jul-09-2015]. Then, as it is possible to see, the 
transfer of information from the clinical team to the research sites was complex and 
with the presence of multiple actors providing overlapping training.  
The interviews indicated that the presence of the CROs (SAVA and KINGE) and SMOs 
(SAVA) created difficulties in the information transfer because of the complexity of the 
structures created. One of the shortcomings of outsourcing the transfer of information 
to the CRO is that the CRO’s monitors do not always transfer all the information to the 
sites. In an audit contracted by KINGE, the auditor found that the monitor did not send 
all manuals to the sites to execute specific tasks, blocking the information flow:  
“With the audit, we knew that there were documents that monitors were not given 
to us, why? We don’t know. The monitor had these ones, but we did not even know 
about their existence, so there was a gap in the information.” [PM2 R-IDVI, KINGE, 
OCT-22-2014] 
Moreover, over the course of the trial one project manager reported how she had to 
request information to the monitor because she omitted it: 
“As you get experience and you know which the necessary documents are, then you 
can request these to the monitor. They [monitors] many times don’t send you all 
the information. In my case I had to ask the monitor for many documents because 
she did not send those to me, she forgot it, or she did not have it.” [Project Manager, 
R-IDVT, KINGE] 
These two quotes indicate two important facts about the presence of the monitors as 
intermediaries in the transfer of documents. The first one, the gaps in the transfer of 
information from the CRO monitors to the sites. And the second one, that monitors 
sometimes do not have the information requested, as the last expression of the last 
quote seems to suggest. This delay in the transfer of information seems to be associated 
with the complex structure inside the CRO to transfer information within the 
organisation, affecting the information flow from the sponsor to the site thought the 
monitors, as SAVA’s project manager in Colombia explained:  
“The CRO have their monitors in Colombia [also in Mexico], they [monitors] have 
two bosses. One that is the lead manager that manages all the human resources and 
training and reviews your work locally, and they have a project manager that can 
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be located in Europe, Brazil, Colombia or Mexico, wherever they want, and he is 
responsible for the project advancement. […] Then, they have a structure that is so 
complex, many times the monitor is alone without knowing what to do […] It is 
necessary to review how the structures generated are efficient, most times they are 
not, why are they not? Because negotiations are centralised, I do not do it. 
Headquarters consider ways of work in the United States and Europe, but here we 
work differently; sometimes it works, some other times it does not.” [SAVA-Sponsor 
Col, Mar-24-2015] 
So, in the SAVA case, as this quote points out, the presence of an intermediary 
organisation like the CRO affected the transfer. The fragmented structure within the 
CRO to communicate the information among the personnel working for the project 
distributed geographically seems to explain why the monitors took longer to receive all 
the information sent by the sponsor. The SMO-2’s project manager, Manuela Figueroa, 
in Colombia, also considers that the presence of the CRO does not benefit the project; 
in contrast, it makes the process slower and without the guarantee that sites will 
produce the data under the standards demanded by the sponsor. She worked for Merck 
doing clinical research, and she considers that the sponsors “had developed a series of 
norms and tools to ensure that the sites were complying with their requirements” [OM 
SMO-2, SAVA-Col, Dic-03-2014]. Then, according to her view, there is no need to 
outsource a project to a third party.  
The emergence of the CROs as intermediaries in the transfer of information took place 
in the context of Latin America countries around fifteen years ago. Before this period, 
the pharmaceutical companies had their monitoring departments and controlled the 
training, transfer of documents and all monitoring activities of the trial. However, as 
the sponsor in Colombia explained in the interview, “between the 2009 and 2010 the 
industry in Colombia changed and everything is outsourced to a CRO”. This change in 
the industry demanded from the companies a change in the way in which they 
coordinated projects and how to engage with a third party, the CRO. In SAVA’s view, 
this was not easy, and they lost control over the sites and the monitors because of the 
additional management layers. Before internal monitors established the working 
conditions in the sites, now these activities are delegated to a CRO, and the sponsor 
has low control over the monitors’ training as the next quote indicates:  
“If I [sponsor] say: that the monitor has low performance, the country lead manager 
[CRO] is the one that intervenes. What is the low performance? He does not know 
how to report deviations. So, the lead manager is the one that trains him on how to 
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do reports, but he has to have the project manager over to tell him how we (SAVA) 
need the project. These are complex structures where many times the monitor is 
alone without knowing what to do, and we particularly get involved in the process.” 
[SAVA-Sponsor Col, Mar-24-2015] 
It is a fact that the sponsor’s motivation for decreasing costs associated with labour 
force influenced the outsourcing of monitors to the CRO. However, comparing the 
experience of NUSTAN not outsourcing the project with the experience of KINGE and 
SAVA outsourcing the trial to a CRO, it seems that this change in the industry is 
creating multiple gaps in the transfer of information from the sponsor to the sites rather 
than benefiting the efficiency of the project execution, speeding the transfer of 
information and supporting the work of the research sites. As the last part of the quote 
points out, this outsourcing demands a direct involvement from the sponsor on the 
training of the monitors, which requires an investment in time from the sponsor on 
training monitors; training that the CRO should provide internally to the monitors.  
There is a trend on outsourcing training in organisations for their personnel (Gainey 
and Klaas 2003), and some questions have been raised about how effective it is to 
outsource this activity. Geldenhuys et al. (2012) expressed their fear of outsourcing staff 
training in a clinical trial to a third party where there is a risk that trainers do not 
understand the target audience or they do not identify knowledge gaps in the staff to 
correct them on time. Moreover, Smed and Getz (2013) pointed out how the presence 
of CRO restricts the transfer of lessons learned at the end of the trial between the site 
and the sponsor. The evidence presented in this section shows that the presence of the 
CRO can also have a detrimental influence on the transfer of information and 
knowledge at the beginning of the trial, which is aligned with the concerns expressed 
by Geldenhuys et al. (2012). Complex structures at the intra-organisational level in the 
CROs also create gaps in the knowledge and information that the monitors receive, 
necessary to do their job. Then, the combination of complex intra-organisational 
structures and inter-organisational structures have a negative consequence on the 
transfer of information in the knowledge-intensive project (KIP). So, these gaps, in the 
long term, can have an impact on the execution of the project and the way in which 
information is accepted or not by the research sites, as will be discussed in the next 
section. Therefore, if the presence of the CRO does not contribute to the quality of the 
research and blocks the flow of information between the sites and the sponsor, it is 
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necessary that the sponsor reviews the structure employed to transfer the information 
and to manage the sites over the course of the project. 
5.2.3. Influence of the outsourcing of the management of the 
clinical teams to SMOs 
Continuing with the discussion about the influence of the structural dimension on the 
transfer of information from the sponsor to the sites, the second factor that influenced 
the transfer of knowledge was the outsourcing of the site management to SMOs. This 
outsourcing created a complicated structure to transfer information, as Figure 6 – 
SAVA shows. In the SAVA case, the CRO and the SMO were the primary sources of 
information to the research sites, also having overlapping responsibility for training 
and supporting the sites over the course of the project. On the one hand, the SMOs in 
Colombia and Mexico created the research sites and trained them on all the aspects 
related to clinical research and the execution of projects. The SMOs provided collective 
training and solved any questions about the project before it started, and the sites 
regularly consulted the SMO over the course of the project.  
On the other hand, the sponsor hired the CROs’ monitors with the vision that they 
should be the ‘site manager’, as SAVA’s project manager in Colombia indicated. For 
SAVA, the monitors should provide training and feedback to the sites over the course 
of the project based on the results of the monitoring activities. According to Fernando 
Amatista (Regional Manager, SAVA-Mex), the presence of the CRO and the SMO was 
conceived by the sponsor to provide continuous support to the sites; however, in 
practice, this was not the case. Sites trusted more in the information provided by the 
SMO rather than in the feedback or initial information given by the monitors (this is 
discussed below), and sometimes, sites were confused because they received 
contradictory information via these two channels. The next quotes illustrate part of the 
conflict and clashes in the transfer of information experienced because of this ‘double 
channel structure’: 
Quote 1: “Interviewer: Have you perceived that they doubt your knowledge?  
Monitor: At the beginning, because I did not have experience, also as there was the 
SMO in the middle, always were… we said something and they had to escalate it to 
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the SMO, so there was a clash of opinions, nonetheless, nowadays what we say 
generally has validity.” [Underlining added, Monitor-CRO, SAVA-Col Dic-10-2014]] 
Quote 2: “Then, if you are new [monitor], you are fussier because you doubt 
everything, then everything was a deviation. We said this is not a deviation, we did 
a reflection, and we discussed with the coordination, [SMO said] ‘OK if you don’t 
agree you can tell them’, ah, OK, then they [SMO] started to mediate.” [Underlining 
added, PI-Site 4, SMO-3, SAVA-Mex, Jul-09-2015] 
Quote 3: “You can request advice, but to the monitors not, let’s say that they are at 
a very lower level, they have to do their monitoring work and that is all.” [OM SMO-
2, SAVA-Col, Dic-03-2014] 
The three quotes show, from the perspective of three different organisations, the 
conflict that emerged because the presence of the SMO and the CROs transferring 
information and providing suggestions. The first quote shows how the monitor 
experienced a barrier from the site because the SMO was present in the project. This 
barrier impeded that the research site easily accepted his suggestions. The second 
quote illustrates the perspective of the sites and clearly shows a preference for the 
opinions of the SMOs and a distrust of the recommendations of the monitors. And 
finally, the last quote shows the position of one SMO about the role of the monitors, 
where she considered that monitors did not have the level to provide advice, so in her 
view, they were not qualified to train the sites.  
This last point lets me suggest that the structure designed by the sponsor to transfer 
the information and the trust in the sources modulated the permeability of the research 
sites towards external sources. In this thesis, I proposed the concept of permeability 
based on the discussion in the literature about knowledge acquisition and trust (A. K. 
Gupta and Govindarajan 2000; Katz and Allen 1982; Grosse Kathoefer and Leker 2012; 
Lichtenthaler and Ernst 2006). I defined permeability as the motivation of people 
working in an organisation to accept or not the knowledge and information coming 
from outside its boundaries. The three previous quotes clearly reflect that sites were 
less open to accepting information transferred by the CROs, so they had a low 
permeability towards this source. As quote 1 suggests, the fact that sites received 
information from the CRO, and the SMO, made the site’s staff less permeable towards 
the source in which they trusted less and inspired less confidence; the CRO. As quote 
2 indicates, the staff at the research sites considered the SMO more qualified to provide 
advice, for this reason, the site’s staff trusted on the SMO and were more permeable to 
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their comments and suggestions. Also, the expression, “they are at a very low level” in 
quote 2 indicates how reluctant this SMO was  to the feedback provided by the 
monitors. This quote suggests that, for this SMO, the monitor did not have the 
knowledge or even the responsibility to provide feedback to the site, which in turn 
meant that their sites were less permeable to the monitors. Then, this evidence 
contradicts the vision of the sponsors in Colombia and Mexico, which considers that 
the monitor should be the manager of the site and that a joint work of the CRO and the 
SMO supported the research sites. In fact, the presence of these two actors on the 
ground created a contrary effect. Therefore, this evidence indicates that complex 
structures to transfer knowledge, where more than two channels are employed to 
transfer similar information, creates confusion in the sites because they must decide on 
who to believe and how to raise any issue, as quotes 1 and 2 exemplify. In summary, 
having two different channels of information with overlapping functions rather than 
providing support to the sites created conflicts and insecurities in the sites and affected 
the acquisition of knowledge. Then, the sponsor at the headquarters (they design the 
project structure) must be careful in the structure employed to transfer the information 
to the sites avoiding the outsourcing of related tasks to two different organisations such 
as the SMO and the CRO. In this way, the sponsor enables the acquisition of knowledge 
and makes clear the responsibility of each actor during the training and over the course 
of the trial.  
The evidence collected indicates that the permeability of the research sites towards 
monitors changed over the course of the trial, sometimes shifting from open to closed, 
and other times from closed to open, which indicates that permeability is dynamic over 
the course of the trial. This dynamism depended to a large extent on the trust in the 
sources and the confidence in the knowledge residing within the research team. In 
Mexico, one site working for SAVA explained how the first monitor assigned to be with 
them in the project “inspired confidence” because she had experience, so they followed 
her advice. However, in Mexico at the beginning of the project the turnover of monitors 
was recurrent, so, this monitor left the project. The information transferred by the new 
monitor was accepted and followed at the beginning by the site without being 
questioned, which suggests an openness of the team toward this source. But later on, 
this information was questioned by the site because it contradicted the knowledge 
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acquired from the previous monitor and the knowledge that they had gained in 
practice. Therefore, after evaluating the situation they decided to trust in their 
knowledge, and they did not follow the monitor’s advice anymore. As the principal 
researcher said:  
“At the begging, we said yes, yes, yes to everything, because we didn’t know how to 
say NO. At one point we said that is an excess, then we recognised ourselves, and 
we also had the power to say this is in this way, and I do not agree at all.” [PI-Site 
4, SMO-3, SAVA-Mex, Jul-09-2015, underline added].  
So, this case exemplifies how a team can change the permeability towards the 
information provided by the CRO, passing from open – accepting the feedback 
provided by the monitor – to closed – rejecting his advice and trusting in their 
knowledge – because trust in the source decreased and they started to value their 
knowledge more.  
Data collected in Colombia also show that the staff permeability towards the CRO’s 
monitor also changed from closed – less receptive to the external knowledge – to open 
– being more receptive to suggestions. One of the monitors explained that he was 
determined to prove to the sites that he had the knowledge and skills to provide 
feedback. He was the same monitor that expressed in one of the quotes above that sites 
did not trust in his knowledge at the beginning because of his lack of experience. 
However, it seems that the site reacted to his work and they were more open and 
learned from the monitor, as Dr Perla said when he explained to me the evolution of 
the relationship between the monitor and the site: 
“We have learned a lot from them and they from us. We know the day to day of the 
site, and they have the macro knowledge of the process, then there is a knowledge 
exchange, and this helps us to make sure everything goes well.” [PI-Site-1, SMO-1, 
SAVA-Col] 
Therefore, the data presented indicate that the low permeability of the teams towards 
external information or knowledge is not only associated with not-invented here 
syndrome (Katz and Allen 1982) in which receptors reject knowledge because of envy, 
jealousy or power. Together, these results suggest that receptors’ permeability towards 
external information depends on the evaluation that the receptor does about the 
source, of his experience and on the trust built as the project advances. The positive 
influence of building trust on the evolution of customers’ and suppliers’ 
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communication has been discussed (Gainey and Klaas 2003). These findings are 
consistent with those of Park et al. (2011) and Lee et al. (2008) in the IT industry, and 
the results of Maurer (2010) on engineering projects, which indicates an association 
between trust and the sharing of knowledge and acquisition of knowledge. According 
to the results of Lee et al. (2008), mutual trust increases the confidence among the parts 
achieving common goals, which were the case of some research sites visited, which 
reported that as trust increased in the monitors, the number of deviations decreased 
and the work was harmonic, reducing the uncertainty in the relationship. Also, results 
in this thesis support the results presented by Maurer (2010), which indicate that a 
stable pool of project team members facilitates the formation of inter-organisational 
trust. The fact that CRO’s monitors changed over the course of initial phases decreased 
the possibility of creating stable bonds between the research site and the CRO, affecting 
the acquisition of knowledge. This situation differs to the stability between the SMOs 
and sites where personnel were constant, and the parts built trust. Therefore, sites were 
permeable towards the SMOs. Then, inter-organisational relationships require 
cultivation, and relational investments to achieve sustainable benefits for the project 
and promote the transfer and acquisition of knowledge over the course of the project.  
In this section, I have addressed the structure that each sponsor created to transfer 
information to the research sites and its influence on the acquisition of information 
and knowledge by the research sites. In the first place, in the case of trials in Latin 
America, it is a fact that the presence of the CROs and SMOs has changed the training 
dynamic between the site and the sponsor. The presence of these actors decreases the 
interaction between sponsor-sites and affects the flow of information and knowledge 
across the two parts and the acquisition of knowledge by the sites negatively. Gosain et 
al. (2004) presented how the transfer of a large amount of information is detrimental 
to the vendor-supplier relationship and the creation of mutual understanding. What 
the SAVA case shows is that in addition to the quantity of information transferred, the 
channels selected to transfer this information, the quality of the information and the 
number of channels are critical to ensuring the correct acquisition of knowledge in 
outsourced and interdependent projects. A complex structure to transfer information 
and knowledge with multiple intermediaries representing the sites caused a conflict 
and confusion in the sites because they received contradictory information and they 
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had to select one source in whom to believe. Therefore, a simple structure with direct 
communication between the sponsor and the sites is better to transfer the information. 
Previous research on the transfer of knowledge has suggested that flexibility and 
informal interaction are preferred in the initial stages to give time for the relationship 
to develop and generate strong interpersonal trust across organisations (Narayandas 
and Rangan 2004). The evidence in this section indicates that trust is fundamental to 
the acquisition of knowledge and information. However, to transfer information in 
within a complex structure, it is preferable to establish defined clear roles and 
responsibilities rather than have informal interactions, especially in those cases where 
overlapping responsibilities exist.  
5.3. Previous experience and the acquisition of new 
knowledge 
In a clinical trial, the research sites are those that execute the protocol, and for this, 
they employ the knowledge residing in the organisation. The regulations in Colombia, 
Brazil and Mexico (Ministerio de la Protección Social 2008; Ministério da Saúde- 
ANVISA 2008; COFEPRIS 2012) and the ICH guidelines establish that all workers must 
have the qualifications to be part of the project (ICH Harmonised Tripartite Guideline 
1996:44). The curriculum vitae and/or other relevant documents of each person 
working on the trial had to evidence his/her qualifications to execute the task 
delegated. It is common that sponsors operating in Colombia, Brazil and Mexico recruit 
experienced principal researchers27 or experienced research sites, so they can be sure 
that the personnel working on the project are qualified for the trial. 
In chapter 2, I discussed how people’s previous knowledge is considered a condition to 
acquire and introduce knowledge to an organisation (Li et al. 2014; Nooteboom et al. 
2007; Cohen and Levinthal 1990). The cognitive bases of people are relevant because 
they condition the acquisition of new knowledge in the sites. People learn to associate 
previous knowledge and experiences with the knowledge and information received 
                                                          
27 Information obtained from interviews with clinical trial associations in these three countries: much of 
the protocols do not need a team; individual physicians implement the protocol and have an assistant that 
submits the information. The evaluation of vaccines is different in the fact that these trials demand a large 
population sample. Therefore, these trials are outsourced to research sites with multiple physicians and 
support staff to manage the multiple activities that demand recruiting and following up these populations. 
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(Cohen and Levinthal 1990; Nonaka 1994). There is a group of scholars that argue that 
teams, to some extent, adapt easily to new situations as a result of their shared 
experience (Hollenbeck 2012). For this reason, experienced teams differ from new 
teams in performance and learning because mature teams have more experience as a 
result of a cyclic process of learning and feedback (Savelsbergh, Poell, and van der 
Heijden 2015, 407). 
In this thesis, the teams implementing the protocol receive the name of research sites. 
However, it is important to note that between these research sites there existed 
substantial differences in the level of experience and the size of the team. Also, within 
teams, there existed clear differences in the experience of the personnel. Therefore, in 
this section, I will discuss how the previous experience of team members conditioned 
the acquisition of new knowledge, and how new sites acquired new know-how before 
the clinical trial. In this section, I make a distinction between experienced research sites 
and new research sites and how, in each one of these groups, new personnel acquired 
new knowledge. In the end, I discuss how previous know-how rather than enabling the 
learning of new practices, presented a barrier to acquiring new knowledge and using it 
to execute the trial.  
5.3.1. Experienced research sites and the training of new 
members within the research site 
KINGE and NUSTAN outsourced the execution of the trial to research centres located 
in universities in Colombia (R-IDVI- KINGE) and Brazil (University of Sao Paulo, USP- 
NUSTAN) both led by well-known researchers in the field of infectious diseases in each 
country. The size of the team was between five and ten members, and the number 
varied according to the project stage.28 Both sites had more than 20 years of experience 
conducting clinical trials, and also the site had previous ties with the sponsors, who 
knew about their experience. For example, the research group R-IDVI- KINGE had 
implemented trials for the WHO validating a leishmaniasis drug 22 years ago. 
Moreover, the group at the USP also has more than 25 years of experience working on 
clinical research and has vast experience in HIV research. On both sites, the principal 
                                                          
28 At the recruitment stages the number of physicians, nurses and social workers is higher than at the 
end of the project. 
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researcher, the project manager and quality assurance staff have been working with the 
group over ten years, implementing protocols. Therefore, they knew how to implement 
the project, and they had developed a collective understanding of how to conduct 
clinical research. Then, as Dr Jaime Plata (Sponsor KINGE) said: “The research groups 
have people well qualified with high experience in the implementation of clinical trials. 
Also, they have a knowledge of the disease, which makes it easy to work with them.”  
Experienced staff working at the USP (NUSTAN case) and R-IDVI (KINGE case) had 
the specific medical, technical, and regulatory knowledge that allowed the 
implementation of the trial, fulfilling the regulatory requirements, and producing the 
data with the quality demanded by the sponsor. Expressions like “[previous experience] 
was very instructive because I could understand a lot of the processes and how to take 
a program project forward” [PI-USP, NUSTAN, Apr-01-2015] or “[KINGE] presented to 
us the project and we saw it was viable under the required conditions” [PM R-IDVI, 
KINGE, Nov-05-2014] reflects that personnel at the sites and the principal researcher 
had the knowledge to understand the project, acquire the information transferred by 
the sponsor or the CRO (KINGE case) and also the know-how to implement it. Also, as 
I presented before, the previous experience of personnel at the KINGE site allowed 
them to identify gaps in the information transferred by the CRO. Therefore, this 
previous experience permitted them to understand the project, as the last two quotes 
indicate, and enabled the knowledge transfer and acquisition.  
Nonetheless, both research teams had personnel without clinical research experience. 
The people interviewed in these sites had the professional background to perform the 
task delegated (pharmaceutical chemists, physicians, data managers), having 
knowledge bases to acquire new knowledge. New staff in the USP and the R-IDVT sites 
reported that learning was simple because the academic environment of the group 
enables them to create knowledge bases for the new personnel participating in clinical 
research. In both academic groups, a regular activity was group meetings and study 
groups to discuss academic papers related to the project under execution. Then, in 
these activities, they expanded their conceptual knowledge base, as sub-researcher in 
the USP and R-IDVT group explained: 
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“Every month we have a group reunion, and at the end, we discuss some articles, 
some things interesting in the research program with the coordination of Dr. 
[João].” [Sub-Res-USP, NUSTA, Apr-14-2015] 
 “The medical practice of a general practitioner is very different to (doing) research. 
I as a general physician did not read the results of a new study, but when you are 
doing research you study about how it was done, you analyse the information, and 
you know why you are doing it. But it is only when you start doing this that you 
learn.” [Sub-Res, R-IDVI, KINGE, Nov-05-2014] 
Therefore, as the quotes show, this academic context enables the extension of the 
knowledge bases of the members, to understand the projects in which they are working.  
However, these new staff were not familiar with how to implement the project; then 
they had to learn how to do clinical research. Although the sponsor and the CRO (only 
in the KINGE case) trained them on the protocol and specific procedures of the project, 
these new staff learned the know-how necessary to implement a protocol within the 
research site boundaries. Like Leonardo Silva (data manager working for USP site) and 
GP David Vega (sub-researcher at the R-IDVT site) narrated: 
Quote 1: “Most of the staff working on clinical research did not learn [clinical 
research] at the University, they learn when they arrive to work… they learn 
everything.” [DM-USP, NUSTAN, Apr-13-2015] 
Quote 2: “I didn’t know what a CRF [Case Report Form] was, but since I’m at the 
R-IDVT they trained me on this, and as I have been here from the undergrad, I 
learned it.” [Sub-Res, R-IDVI, KINGE, Nov-05-2014] 
So, these two quotes show that this know-how and also conceptual knowledge was 
acquired in-situ, in the research group, being directly involved in a clinical project. This 
evidence illustrates how inexperienced staff benefit by working with experienced 
researchers and in environments where knowledge and information are exchanged 
continuously. Then, as has been highly discussed in the literature (Davenport, De Long, 
and Beers 1998; Nonaka, von Krogh, and Voelpel 2006), a common space for the 
interaction of team members with different degrees of experience allows the creation 
of a common language to interact and to understand the basic concepts. At these 
experienced sites, the constant interaction enabled new staff to learn the clinical trial 
terminology, such as what is a CRF, how to implement the protocol and the conceptual 
and scientific underpinnings of the project under execution. In this way, experienced 
staff in these academic groups become an important source of knowledge to close the 
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knowledge gap between inexperienced team members. Therefore, the active 
interaction between new and experienced staff enhances the learning process of 
newcomers and facilitates the acquisition of knowledge. It also expands the knowledge 
base, enhances knowledge sharing, promotes learning and improves organisational 
knowledge (Yan 2011).  
However, in Colombia, the national regulations to implement clinical trials determine 
the composition of the research sites and therefore their knowledge-base. The 
Colombian regulation 2378 of 2008 on good clinical practices, unlike the other two 
country regulations (Brazil and Mexico), delimits the professional profiles of the 
personnel working in the laboratory processing the samples or handling the research 
product.29 This fact influenced the configuration of the clinical teams and, therefore, 
the use of the previous knowledge that existed in the team working on the trial in 
Colombia. Specifically, the change in the regulation in Colombia directly affected the 
team configuration in the KINGE site, influencing the staff. The regulation 2378 of 2008 
came into force in 2010 after a transition period (data provided by the regulatory 
agency), which reshaped the configuration of the research team (R-IDVT) between 
phase I (2008) and phase II (2012) trials as the next quote indicates:  
“In the project in Rionegro [Colombia (Phase I)] the person that was doing it 
(preparation of the vaccine) was a microbiologist. Because the new norm required 
that this must be made by a pharmacist, I was hired.” [PQ R-IDVI, KINGE, Nov-06-
2014] 
Although the people interviewed did not mention that the regulation in Colombia 
influenced the performance of the team, the new regulation demanded an internal 
redistribution of responsibilities among the staff. This reallocation, according to 
Leonora Opalo (R-IDVT, Project manager), was “very, very hard” because they had to 
hire new people to fulfil the regulation. For example, because of the new regulation one 
                                                          
292378 resolution states that professionals assigned as responsible for research in the laboratory have to have an 
academic title of the next professions and a professional experience in clinical laboratories of at least two years: a) 
bacteriology b) microbiology c) chemistry or pharmaceutical chemistry, with training in one technical area of clinical 
laboratory d) medicine with specialisation in clinical pathology or a technical area of laboratory clinic, and personnel 
involved in blood samples and its processing, conservation and transport should be : a) bacteriology b) microbiology c) 
chemistry or pharmaceutical chemistry (Ministerio de la Protección Social 2008, 2008:78). 
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pharmacist had to be hired to manage the drugs and vaccines that were managed by a 
bacteriologist before, who could not use her experience in the new project and she had 
to transfer the lessons learned to the pharmaceutical chemistry. 
Additionally, because of the regulation, the person that was working on Phase I 
handling the drugs had to be reallocated to new functions because she was not a 
chemical pharmacist, so this disturbed the team dynamic. In the case of SAVA, in 
Colombia, those that processed the blood samples were bacteriologists and 
microbiologists. Biologists, nurses and clinical technicians were not delegated with 
functions to take, process or transport on blood samples. However, in Mexico and 
Brazil, professionals in these three areas were predominantly part of the research site 
and worked on the project in the positions that the Colombian regulation impede. For 
this reason, in the SAVA case in Colombia, the professional composition of the research 
sites was different than in the other countries working for the same sponsor, so again 
the context, especially the regulatory one, shaped the knowledge-base of the site. This 
data reveals how a regulation that had the aim of standardising, in the country, the 
professionals that are part of a trial, reduced the employability of specific careers on 
these activities and also created variations among the knowledge-bases among sites 
working for the same project in different countries and disrupted the work dynamic in 
research teams already consolidated. As the case of Colombia showed, the regulation 
has a direct influence on the composition of the personnel working for the research. 
Also, although some staff in the organisation possess the knowledge to implement the 
procedure, only people authorised by the regulation to undertake a specific task can 
use it. Then, in Colombia’s sites not only does it matter if personnel at the site have the 
experience to implement the task, having the right to use the knowledge possessed 
defines what of the knowledge-base residing in a firm is really employed to implement 
the project.  
5.3.2. New research sites and the acquisition of knowledge by 
inexperienced staff  
The acquisition of knowledge in the new research sites working for SAVA differed in 
some aspects with the acquisition of knowledge by new people working in academic 
groups working for NUSTAN and KINGE. In the new sites that worked for SAVA, only 
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one principal researcher (these are different to the key opinion leaders who were the 
SMO leaders) of seven interviewed had previous experience conducting clinical 
research. The rest of the personnel at these sites manifested that before the project they 
did not know how to execute the protocol following ethical principles for medical 
research, or how to work according to international standards such as the ICH-GCP, or 
didn’t know the main concepts of clinical research. This gap in the knowledge 
demanded a learning effort to understand the project and especially its 
implementation.  
In the academic context, researchers’ names are equal to brands. Each name has 
associated reputation, value and power within the academic and medical community. 
Because of this, some sponsors try to recruit researchers with strong leadership in the 
fields so they have “the capacity and power to coordinate the study and can generate 
cooperation agreements between institutes and health state authorities” [SAVA 
Sponsor Mex, May-07-2015]. Once trials conclude, sponsors try to use the value 
associated with the name of the principal researchers and use it when they are 
commercialising products. As a person in SAVA said, they were interested in recruiting 
key opinion leaders: 
“Because the key opinion leader will help you to sell the molecule, the good 
researcher that is dedicated to evaluating the patients because the key opinion 
leader does not have time. So, we need to search for key opinion leaders with a good 
research team and the researcher that is dedicated to the research.” [SAVA-Sponsor 
Col, Mar-24-2015] 
Under this logic, the sponsor first identified the key opinion leaders that would help to 
promote the vaccine results, and these leaders configured their own clinical teams and 
created a network of research teams to implement the projects. Then these key opinion 
leaders created temporary SMOs. The reason for this decision was that in the rural areas 
in Colombia and Mexico, where the sponsor required to implement the trial, research 
capabilities to execute the protocol did not exist. Then, these key opinion leaders and 
SAVA established an agreement. In most of the cases, SAVA provided the funding to 
create the research sites, and the key opinion leaders, through their organisations, 
created the research sites and trained staff. Only in one case, the key opinion leader in 
Colombia had a private SMO, so he created new branches where the sponsor required 
to implement the trial, and he evidenced potential to implement other trials with the 
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infrastructure created. The other research sites created by the SMOs in Colombia and 
Mexico were temporal groups of people working together for the first time, so they had 
to learn how to implement a clinical trial together. 
The staff invited by the SMO (key opinion leader) to be on the project had to have at 
least some experience related to the tasks to implement the project. So, the SMO 
“selected personnel with experience with the infection although they did not have 
[experience] on research” [PI-SMO-3, SAVA-Mex, Jun-24-2015]. In this way, at least the 
principal researchers on the site had the medical knowledge about the disease, so with 
this knowledge they could build the rest of the concept required to conduct clinical 
research. Other site members like nurses, technicians or social workers also had specific 
knowledge about the task to implement for the project like vaccination procedures, 
medical evaluations or blood sample management. Employing this technical 
knowledge, the SMO expected that the staff could learn and link the rest of the 
conceptual knowledge about the project, the vaccine and the disease.  
The SMOs and the CROs trained the sites theoretically in every aspect of clinical 
research, explaining the protocol and the Standard Operative Procedures (SOPs) of the 
project. The training received by the new sites is explained in the next quotes:  
Quote 1: “There were meetings with all of us; we all received training, including 
researchers who did not have experience, then we received information from the 
sponsor. The coordination was by telephone, teleconference between all the 
researchers and direct supervision of the sites by SMOs.” [PI 2-Site2, SMO-3, SAVA-
Mex, Jul-01-2015] 
Quote 2: “There were around 10-12 meetings, we had training on the protocol, 
participant recruitment.” [PI-Site3, SMO-3, SAVA-Mex, Jul-08-2015] 
Quote 3: “To be part of the project we had to present a series of evaluations, and 
we had the online training to pass the exams. We had conferences, and we were 
going and coming [reference to another site]. Then, we presented the exams, and it 
defined those that would be part of the site.” [LT-Site-4, SMO-3, SAVA-Mex, Jul-
09-2015] 
Quote 4: “Everybody had to be [at the meeting], so everybody could understand 
what they had to do, about what was the protocol, what was the process order.” 
[OM SMO-2, SAVA-Col, Dic-03-2014] 
As the quotes indicate, this training allowed for the personnel at the site to acquire the 
conceptual basis to implement the project. As quote 3 clearly points out, only the staff 
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that displayed, through an exam that they had to learn the concepts associated with 
the project and procedures to implement were invited to be part of the sites.  
However, although the exams were a method to identify if the staff had acquired the 
knowledge to understand and implement the project, for the sponsor, it was a 
considerable risk to initiate the vaccine trial with inexperienced staff that did not know 
how to implement the project. For this reason, one of the SMOs in Colombia proposed 
the execution of a pre-trial to collect data to identify the serotype circulation30 in the 
studied population. This trial had the primary objective to train the staff in practice to 
close this knowledge gap and level, in all sites, (Colombia, Brazil and Mexico) their 
knowledge before initiating the vaccine trial. The pre-trial implementation sets the 
basis for a new method to create knowledge in inexperienced research sites, which so 
far is a unique case in the pharmaceutical industry. 
The pre-trial consisted of a Prospective Cohort Study with Active Surveillance for the 
disease in a population of 3,000 children between 9–16 years of age (Dayan et al. 2015) 
for ten months. However, the fact that the staff did not have previous experience doing 
clinical research made the acquisition of knowledge difficult, as the next quotes 
illustrate: 
Quote 1: “At that time, we didn’t have the concept or the vision of doing research. 
It was a bit complicated because it was a learning process, and still [it is]. I think 
that research is a continuous learning […], but it was complicated but interesting.” 
[Underline added PI-Site-1, SMO-1, SAVA-Col, Dic-10-2014] 
Quote 2: “At the beginning of the trial, the team does not have the experience to 
know the procedure, how many the [procedures] are, where to do it, where not to 
do it, then at the beginning [deviations] are very recurrent regarding procedures.” 
[Monitor-CRO, SAVA-Mex, Jul-08-2015] 
Quote 3: “Many did not have the experience in clinical research, they find it hard, 
we gave the training, and little by little all of them acquired [the knowledge] 
without a problem.” [PI 2-Site2, SMO-3, SAVA-Mex, Jul-01-2015] 
So, as these quotes indicate, because staff did not have the background and the 
knowledge required to implement the protocol, they struggled to learn the concepts 
and how to proceed. Moreover, the first quote points out that although the personnel 
                                                          
30 With this data it was possible to define which specific viruses’ serotypes were present in the population 
at that time and which serotypes the population had had contact with in the past.  
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reached a level of understanding about clinical research, the learning process was 
demanding and gradual, as the third quote also indicates. Therefore, the cognitive 
distance (Nooteboom et al. 2007, 1017) between the knowledge possessed and the 
knowledge that they had to acquire staff at the new site demanded a strong learning 
effort to learn the practical and conceptual knowledge to implement the project and 
follow up the multiple requirements of a clinical trial. 
Some SMOs expressed that, many times, teams considered that they had understood 
the procedure and implemented the activities, but unfortunately, they were having 
problems with the implementation. A high number of deviations reported in the pre-
trial and at the beginning of the project indicates the struggle lived by the sites to 
implement the protocol according to the ICH as monitors, the sponsor and one 
principal site researcher stated:  
Quote 1: “Question: at the beginning, in which areas did you have deviations?  
Answer: Almost in all areas, they did not document the process, or they left the 
time pass to call people, they did not take note about the date of the visit, or the 
date in which the sample was collected. These kind of details.” [PI-Site3, SMO-3, 
SAVA-Mex, Jul-08-2015] 
Quote 2: “The deviations depend on the stage of development of the study. In the 
beginning, the team does not have the experience about the procedures, how many 
are, when to do it, when not to do them. So, at the beginning, deviations were 
recurrent on procedures. As the study progresses, if there are not big amendments 
and if the team is well trained, the deviations are not repeated.” [Monitor-CRO, 
SAVA-Mex, Jul-08-2015] 
Quote 3: “All of them understood, but over the practice, they thought that was not 
necessary [to collect] so much information, then they stopped to do it [data 
collection], and we asked, why didn’t you do it? [Answer] ‘I thought it was not 
[necessary].” [PI 2-Site2, SMO-3, SAVA-Mex, Jul-01-2015] 
So, as these quotes indicate and the evidence presented in this sub-section reveals, over 
the implementation of the task, personnel not only had to learn and understand the 
information transferred initially by the sponsor and the SMO. This knowledge also had 
to be used to produce the data following the instructions provided, and this was highly 
demanding because they interpreted the instructions in multiple ways that did not 
correspond to the procedures indicated. The reason behind this was the lack of know-
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how to properly implement the instruction and also the lack of a constant example in 
the research site from whom to learn the procedures to implement.  
Personnel at the research site were in contact with the SMOs’ directors (key opinion 
leaders) through email and phone calls. However, these experienced researchers were 
not present in the actual implementation of the activities in the sites, so the know-how 
to implement the project was transferred through instructions rather than with real 
examples, as is illustrated in the next quotes:  
Quote 1: “The monitoring team was not there all time. The coordinator (SMO) is 
the one that had to be in contact day by day with the site. Then, the objective was 
to create that relationship, a link, the closest possible, in this way, if the site had 
doubts it consulted immediately.” [SAVA Sponsor Mex, May-07-2015] 
Quote 2: “Then, the sites had taken that awareness. The people already know, and 
they call me. [Site]: ‘It has emerged this, what do we do?’ Sometimes I don’t know, 
so I have to ask the doctor [SMO], if he doesn’t know, then, we ask the sponsor, so 
this is a chain. The objective is to do the things right, and everybody knows that 
they cannot act without asking.” [PM-SMO-1, SMO-1, SAVA-Col, Dic-10-2014] 
Quote 3: “When there were things that we did not understand, they give us 
teleconferences, then, they explained to us what it was about.” [NRS-Site-4, SMO-
3, SAVA-Mex, Jul-09-2015] 
Because the SMOs and the researcher sites were in different locations, the staff at the 
site who had any doubts had to consult the SMOs via email or phone calls. Personnel 
from the SMO constantly travelled to the sites to provide advice, but they were not 
there working in the sites, teaching how to do the activities. However, they did not have 
a person in situ teaching them with examples of how to implement the projects. Only 
after the results were obtained, through monitoring, was it possible to identify if sites 
implemented the protocol according to instructions imparted, the ICH and SOPs, and 
if personnel really had learned. One example of this evaluation is this quote: “The 
monitor comes and review the files; she reviews if it is good or not and then she explains 
how it should be.” [NRS-Site-4, SMO-3, SAVA-Mex, Jul-09-2015] Then for the sites, 
learning how to implement a clinical trial consisted of a process of trial and error with 
feedback loops, which was demanding and time-consuming.  
As a result of this pre-trial, staff members expressed how they learned how to execute 
a clinical project, including:  how the relationship should be with the monitors; how to 
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introduce the GCP into their professional practices; how to conduct an informed 
consent; how to obtain and send blood samples; how to follow and report adverse 
events to the ethics committees and regulatory authorities; what contracts and 
agreements they had to create with the hospitals to access  information and how to 
interact with the community. Expressions like: 
Quote 1: “I think that without it (pre-trial), we could not have made the trial.” [Luz 
Elena Nuñez project manager SAVA Site1- Col]  
Quote 2: “It was a free university… we learn the practice and the theory together.” 
[PI-Site-1, SMO-1, SAVA-Col, Dic-10-2014]  
And  
Quote 3: “Yes, it was a learning for all of us, it was the way to get involved early and 
in a calm way to the study. The study was calm with few subjects, so it was a very 
good strategy.” [PI 2-Site2, SMO-3, SAVA-Mex, Jul-01-2015]; 
reflect the relevance that this pre-trial had for the learning of new knowledge. In this 
way, this pre-trial allowed them to implement, in a real project, the concepts acquired 
over the training provided by the SMOs. In the end, those that acquired the knowledge 
to implement the trial were invited to be part of the vaccine clinical trial as this quote 
from the paper published with the pre-trial results indicates: 
“The teams at all sites showed their ability to capture and follow up acute febrile 
episodes within the timeframe specified in the protocol to confirm symptomatic 
dengue cases, which confirmed the feasibility of implementing an active 
surveillance system to detect and diagnose symptomatic dengue cases in multiple 
countries in Latin America.” (Dayan et al. 2015, 22) 
With the execution of this pre-trial, the sponsor decreased the risk of implementing a 
trial in sites without the experience where mistakes would cost the project’s success.  
In the literature, it has been discussed which approach is better to learn know-how, if 
learning from experience or learning from example (Pentland 1995). Based on the cases 
of SAVA, NUSTAN and KINGE, I argue that in the case of clinical research, learning 
from example enables the acquisition of know-how in a less traumatic way compared 
with the evidence presented by SAVA. In SAVA sites, the trial and error process lived 
by the research sites was demanding and it required long cycles of feedback loops. 
Although SAVA implemented a pre-trial where this learning by doing took place, in a 
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clinical trial the implementation of procedures wrongly has direct consequence for the 
data quality as it was present and therefore on the final results. Then in the context of 
clinical research and the training of new staff, sites without additional experience of 
learning by doing need a physical accompaniment that provides the example and 
guidance on how to proceed. Moreover, it has been found that the more interaction 
with experienced staff, the more information is learned (Park, Im, and Kim 2011) where 
training might involve, in the long-term, transferring personnel to the provider’s 
location (Roy and Sivakumar 2012). Therefore, if there is not a rule that impedes the 
presence of the trainers on the execution of the project, experienced staff should have 
responsibilities delegated in the sites and execute initial parts of the project with the 
personnel until they learn the fundaments of the procedures. The acquisition of know-
how requires constant interaction and learning from example. 
As was mentioned, researchers with previous experience in research working for the 
NUSTAN and KINGE sites manifested that the process to collect data was routine 
because they already know the procedures and how to write good medical notes. Young 
physicians working for NUSTAN, KINGE and SAVA sites participating for the first time 
in a clinical trial found the procedures easy to follow and logical; for them, it was not 
complicated to introduce the GCP and the procedures indicated in the protocol into 
their medical practices. This openness to learning is explained by the fact that they had 
not developed a consolidated work routine that they had to reshape, so the acquisition 
and integration of this know-how were simple. In contrast, physicians working for 
SAVA who had substantial clinical experience, but did not have a research background, 
found it complex to include the GCP into their medical practice, as the next quotes 
illustrate:  
Quote 1: “The project required a personal and professional re-engineering, this had 
some difficulties, it is much easier if you are trained since the beginning compared 
if you need to straight up yourself on the road, that happened to me.” [PI-Site-1, 
SMO-1, SAVA-Col, Dic-10-2014] 
Quote 2: “You need to teach people, the resistance to change ‘hijole’ it is one of the 
biggest problems that you are going to see everywhere.” [PI-Site3, SMO-3, SAVA-
Mex, Jul-08-2015] 
Quote 3: “This way of collecting the data and be attached to the norm, it is not easy, 
sometimes you forget a point, and they call you, ‘you forgot to write this’. 
Sometimes, I feel that some things do not affect so much, but maybe they do, so we 
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try to follow the project, avoiding deviations, doing the things correctly, the truth 
is that it is hard, at least for me that is the first time.” [Sub-Res-Site 4, SMO-3, SAVA-
Mex, Jul-09-2015] 
Then, as these quotes indicate, having rooted know-how, rather than enabling the 
acquisition of new ways to implement a task and learning new procedures, it obstructs 
this acquisition of this new knowledge. The proof is that young researchers with fewer 
experiences manifested that learning new procedures was easy for them compared with 
highly experienced researchers, as the ones quoted above. This difficulty in adopting 
the operative procedures and following the GCP by the staff has also been reported in 
other vaccine clinical trials in Asia and Africa, where periodic monitoring visits by 
CROs – not coordinators – were necessary to insist on complying with SOPs (Acosta et 
al. 2007; Geldenhuys et al. 2012). This evidence reflects an early resistance of researchers 
to adopt the practices and follow up the procedures of the project. These findings of 
the acquisition of new know-how are consistent with the argument raised by 
Ottevanger et al. (2003) who stated that the harmonisation of routines among 
physicians could be difficult because physicians that are not familiar with these 
routines face more challenges to acquire them in practice. But also, these findings 
reveal that previous experiences can be an obstacle to learn new practical knowledge, 
as Cook and Brown (1999) suggest. They stated that: “Many people experience a period 
when explicit knowledge about how to move one’s feet or hold one’s shoulders can 
actually impair one’s ability to acquire the tacit knowledge necessary to perform the 
skill in a fluid or masterful way.” (Cook and Brown 1999) Acquiring know-how takes 
longer, especially where their previous knowledge is profoundly rooted.  
In conclusion, the evidence presented indicates the relevance of the knowledge-base of 
the people working on the project on the acquisition of knowledge. The analysis of the 
knowledge-base and its influence on the acquisition of knowledge requires a distinction 
between conceptual knowledge (know-what) and practical knowledge (know-how), as 
the data indicates. In the three cases studied, mainly all people interviewed had the 
conceptual base to learn about the disease and the clinical trial; physicians, lab 
managers, nurses, data managers had a profession related to the activity to be 
undertaken. Using this knowledge, people build the theoretical knowledge about the 
project. In contrast, only those that had previously worked in clinical research had the 
know-how to understand how to implement the procedures according to the protocol, 
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as was the case of some of the personnel working on the NUSTAN and KINGE sites. As 
it was presented, the environment and the constant interaction with experienced 
people influenced the acquisition of the know-how. In academic research sites, 
experienced and less experienced staff cohabited, where these last ones could learn 
from experienced personnel because of the constant interaction that took place at the 
research site. In contrast, in new sites managed by the SMOs, personnel in the research 
sites interacted less with experienced researchers, so the acquisition of the know-how 
was slow. Also, the data presented reveal that having a practical knowledge-base 
associated with the knowledge that must be acquired not always enables the acquisition 
of new know-how. Physicians with long experience as a general practitioner (but not 
on research) were reluctant to acquire and integrate the new know-how into their 
medical practices compared with young researchers, who had less rooted know-how 
and, therefore, were more flexible in learning new procedures to conduct a medical 
consultation. Then, this differentiation between practical knowledge and conceptual 
knowledge lets us better understand the relevance of previous knowledge in the 
acquisition of knowledge, leading me to argue that only previous conceptual knowledge 
allows the building of new concepts and, in contrast, previous practical knowledge can 
be a factor that decreases the ability to acquire new know-how. Then, practical and 
conceptual knowledge-bases cannot be considered the same on the analysis of the 
relevance of the knowledge-base in the acquisition of knowledge.  
5.4. Conclusion 
This chapter meant to answer the research question: To what extent does the 
structure designed by the sponsor to transfer knowledge, the permeability of the 
research sites, and the previous experience of people working on the project 
influence the acquisition of knowledge in the research sites? The evidence 
presented indicates that in interdependent activities that take place in multi-
organisational projects, these three factors directly influence the acquisition of 
knowledge by the staff working in the research sites. These factors defined what 
knowledge and information the personnel received, and affected the disposition and 
capability to receive, understand and implement the transferred knowledge. A 
summary of the three factors and levels of analysis are summarized in Figure 7. 
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Figure 7. Summary of factors influencing the transfer/acquisition of knowledge between 
the sponsor and the research sites. 
In the first section of this chapter, I discussed the influence of the structure designed 
by the sponsor on the acquisition of knowledge or information by the personnel 
working on the research sites (Figure 7). The data presented showed how a direct 
communication between the sponsor and the site’s staff has a positive effect on the 
acquisition of knowledge by the personnel, ensuring that sites receive all the 
information needed to execute the project. In contrast, structures to transfer 
knowledge and information that had the presence of intermediary actors/boundary 
spanners (CROs, SMOs) showed to be less efficient, slowing down the communication 
between the parts, creating gaps in the transfer of information or blocking the 
acquisition of information to the sites. The fragmented structure within the CRO to 
transfer the information across multiple personnel working in the trial decreased the 
speed in the communication, and in some cases impeded the flow of information from 
the sponsor to the sites. Regarding this point, I presented how the presence of 
experienced staff decreased the risk of loss of information over the transfer because 

















personnel at the site is vital to overcoming the slow flow of information or the gaps that 
could emerge.  
A structure with multiple intermediaries, rather than providing continuous support to 
the sites and enabling the acquisition of knowledge, created fragmentations in the 
transfer of information and confusion in the sites. The evidence also indicates that as 
the number of intermediary actors increases, the acquisition of knowledge is affected, 
and sites start to develop a high permeability for one of the sources. This permeability 
at the end defines which knowledge is acquired and which is not by the sites. So, in this 
way permeability also influenced the acquisition of knowledge and information. Trust 
in sources was reported as a key factor mediating the permeability of the staff towards 
external sources, and this trust depended to a large extent on the experience of the 
person transferring the information. Personnel at the site easily accepted information 
communicated by the SMOs or experienced CROs rather than novice CROs. Another 
element discussed was the permeability of the research sites. The permeability of the 
teams towards a source is not static, so this one can shift from open to closed or vice-
versa, according to how the personal relationship and trust among parts evolve over 
the course of the project. Then, this evidence contributes to the discussion about the 
concept of permeability developed in this thesis. 
In the last section of this chapter, I discussed how the experience of the personnel 
working in the research sites influenced the acquisition of knowledge to implement the 
clinical trial. In the research sites, the staff had the professional background which 
provided the conceptual bases from which they could build the concepts required to 
understand the project. However, the level of previous experience doing clinical 
research directly influenced the acquisition and use of the concepts acquired over the 
initial training. As the NUSTAN and KINGE cases show, in these sites personnel had 
the knowledge bases to understand the project and implement it. Also within these 
sites, personnel without previous research experience learned directly from their 
colleagues the bases to implement the project, so learning from example was relevant. 
One of the findings in this chapter is the role of the regulatory agencies determining 
the professionals that can work on a clinical trial, which conditions the knowledge-base 
of the site. The SAVA case shows how a low level of previous experience slows down 
the acquisition of knowledge and its implementation, but most importantly, this case 
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shows how personnel with vast experience on related activities were reluctant to learn 
new know-how to implement clinical research. This situation is explained by the fact 
that to acquire new practical knowledge people must modify, replace or reshape the 
old knowledge to introduce the new practical knowledge, which demands a 
tremendous effort. Therefore, this evidence indicates that previous practical knowledge 
or similar activities, rather than enabling the acquisition of new practical knowledge, 
can create an obstacle for it. Then, the next step to continue studying the flow of 
knowledge in multi-organisational projects is to understand how the knowledge 




Chapter 6: Opening the black box of 
the research sites. Implementation of 
the protocol and clinical data 
production 
6.1. Introduction 
Previous studies about knowledge management in the pharmaceutical industry have 
been limited to the relationship between the pharmaceutical company and the CROs 
(S. Gupta and Polonsky 2014), the hierarchies in the transfer of knowledge and 
knowledge creation between CROs and the pharmaceutical (Azoulay 2004) and the risk 
of losing knowledge by the pharmaceutical company and their dependency on external 
suppliers (S. Gupta et al. 2009). However, practitioners in the industry have broadly 
discussed the work and contributions of the research sites and this topic has been less 
addressed in the literature of management. This chapter aims to address this gap. 
Using the model proposed in Chapter 2 to study the flow of knowledge across 
organisations and its use within the firm, in the last chapter, I discussed in depth the 
acquisition of knowledge, data and information from the research sites working on the 
three case studies. This chapter addresses the other two steps of the model at the intra-
organisational level. The use of the knowledge to solve productive inquiries and 
evaluate the results, and the storage and transfer of results to an interdependent 
organisation requiring this information to conduct their work. In this way, this chapter 
provides an answer to the third research question of this project, which is: How is 
knowledge employed in the clinical research sites to solve the productive 
enquiries related to the production of clinical data and transfer the results to the 
sponsor? 
As it was proposed in the conceptual model in Chapter 2, at the use phase organisations 
create their knowledge products and these products are stored and shared in different 
formats with other organisations (M. H. Meyer and Zack 1996). In this phase, 
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knowledge is employed to analyse and integrate information to the organisations, and 
standardise procedures (Evans, Dalkir, and Bidian 2014). This chapter separately 
addresses the production of clinical data from the transfer of results to answer this 
research question. In this way, this chapter is divided into three sections. In the first 
section, I discuss the integration and use of knowledge within the research site. For 
this, I address the operationalisation of the knowledge acquired through the creation 
of the standardisation of procedures within the research site, the use of knowledge in 
practice to recruit volunteers for the project, to produce the clinical data and contribute 
to the protocol implementation. In this section, I explain how physicians used their 
medical knowledge, about the disease and the project, and the information gathered 
from volunteers to produce the clinical data. This section is central because physicians 
are the ones that capitalise all the previous effort to design, training, standardisation 
and recruitment in the diagnosis of the infection; this means the production of clinical 
data. Also, I discuss the relevance of knowing how to produce the clinical data 
according to the standards of the industry and the sponsor to ensure the quality and 
validity of the clinical data collected. It is in this section that I analyse the integration 
of knowledge in the activities of the research sites to implement the protocol in which 
the ‘epistemology of possession’ and the ‘epistemology of practice’ (Cook and Brown 
1999) converge in the execution of the task. 
The second section discusses the learning loops that took place over the course of the 
trial and their relevance to improving the staff performance. The third section 
addresses the transfer of clinical data to the sponsor and the strategies designed by 
research sites to ensure participants' adherence to the project using the integration 
framework proposed by Anderson and Parker (2013). Also, because of the frequent 
turnover of personnel in the research sites, I discuss the relevance of storing the lessons 
learned over the course of the trial. In conclusion, this chapter aims to explain the use 
of knowledge in the implementation of the clinical trials in each one of the steps, where 
not only the medical knowledge of physicians was essential, but also the work and 
knowledge of other staff members were crucial to the project success. 
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6.2. Integration and use of knowledge within the 
research sites  
In outsourced projects contractors need to integrate the knowledge received with their 
local knowledge and operationalise it to create the product demanded (Jackson and 
Klobas 2008). In this process, the outsourced organisation develops new organisational 
capabilities to manage all knowledge and information: the old one, the one received 
and the new one, when the capabilities are oriented to learn, apply, merge, create, 
record and transfer the knowledge (Dalkir 2005). In a clinical trial, sites integrate the 
acquired knowledge constantly into their knowledge-base and create the capabilities 
to implement the project.  
In the first section, this integration process is addressed (Figure 8). Here it is argued 
that integration was not linear and in some cases the integration gave explicit 
documents as a result; in other cases, outcomes consisted of the actions of other people. 
In this dynamic process of integration and use, in this thesis two mechanisms to 
integrate knowledge and use it were identified. The first mechanism was the 
standardisation of procedures through the SOPs manual (Figure 8-1). In this process, 
each site integrated the knowledge received with their knowledge of their local 
dynamics, the regulation and the community to define how to operationalise the 
protocol. The second mechanism is the actual use of the acquired knowledge in 
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standardised activities (Figure 8-2.). In this scenario, personnel in the sites used the 
knowledge directly to produce the clinical data (Figure 8-2.a), to present alternatives 
to optimise the strategies proposed by the sponsor (Figure 8-2.a) or to overcome the 
challenges associated with the implementation and recruitment of participants (Figure 
8-2.b). In this way, the knowledge, information and data acquired are employed to 
execute the activities, and produce the knowledge products (M. H. Meyer and Zack 
1996), give a solution to problems (McElroy 1999) or, as it will be presented, to 
contribute with alternative proposals. Below I address each one of the two mechanisms 
to integrate knowledge and its associated activities. 
6.2.1. The creation of operational documents  
In international projects the standardisation of the protocol and procedures among 
participants is a challenging activity because of the variation in practices among 
organisations (Sprague, Matta, and Bhandari 2009). In addition, the integration of the 
knowledge acquired into the organisation requires its operationalisation (Jackson and 
Klobas 2008) and integration into daily routines (Maier 2004). One effective and 
efficient mechanism to integrate knowledge and standardise procedures is the creation 
of standard operating procedures to ensure consistency of actions of individuals within 
organisations helping to coordinate clusters of actions and drive decision -making 
(McIver et al. 2012). 
In the clinical trials, one way to operationalise this knowledge is standardising the 
procedures indicated in the protocol. For this, each research site must create Standard 
Operating Procedures (SOPs) manuals. The SOPs definition is: “detailed, written 
instructions to achieve uniformity of the performance of a specific function” (ICH 
Harmonised Tripartite Guideline 1996, 8). These documents have the step-by-step of 
each procedure and the delegated responsibilities of each staff member according to 
the protocol. As one project manager indicated, these SOPs must be very specific, and 
clear so that “if a person must make the process and does not have instructions, with 
that [SOP] he can reproduce the process” [PM R-IDVI, KINGE, Nov-05-2014]. The SOPs 
are exclusive for each protocol. One clear example of this is that although the research 
site R-IDVT executed the clinical trial Phase I and Phase II for KINGE, they could not 
employ the SOPs designed for Phase I on Phase II. The research site had to “modify the 
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SOPs for the Phase II” [PM R-IDVI, KINGE, Nov-05-2014]. Then, the knowledge and 
information acquired about the project are transformed in detailed procedures 
consigned in the SOPs manuals, which guide the actions of people working on the 
project. This fact clearly indicates the degree of relevance of SOPs for governing the 
actions of the personnel participating in the clinical trial and setting up the day-to-day 
activities and indicating how staff must perform procedures. 
The process to integrate the acquired knowledge and the knowledge of the site to create 
the SOPs differed in the three cases studied. However, the conceptual bases and 
information and knowledge employed to create the SOPs were similar among cases. In 
the first place, the person to create the SOPs had to use her/his knowledge to adapt the 
procedures indicated in the protocol and the manuals transferred by the sponsor to the 
context of the research site and the local regulation, as the next quotes indicate for the 
different cases:  
Quote 1: “The protocol establishes clearly the clinical aspects. Then, you don’t have 
to invent anything. You have to take the protocol to create the manuals; you can 
create a unique operational manual including the clinical follow up. In our case I 
did the manual for the Morelo sites, we evaluated it and then we shared it with the 
other sites.” [PI-SMO-3, SAVA-Mex, Jun-24-2015]  
Quote 2: “The SOPs are building with the study coordinator, because [it] depends 
on the structure that you have, [it] depends on the team. So, we could not borrow 
one SOP or flow chart, not, it is impossible because we have differences between 
institutions.” [PM-USP, NUSTAN, Apr-01-2015] 
Quote 3: “They [Morelos team] send us a guideline, but each one had to adapt them 
to its unit, to the culture, to the operations. It is not the same in Temizco that they 
have 1000 and more [participants] than us that we have the half.” [PI-Site 4, SMO-
3, SAVA-Mex, Jul-09-2015] 
Quote 4: “Each site has its manual, each one with its particularities because any 
SOP works for all. That would be a big mistake; we had to individualise it [manual] 
because each site has different characteristics.” [PI- R-IDVI, KINGE, Oct-15-2014]  
Quote 5: “The informed consent process is not the same in all parts of the world. 
Then, you need to adjust it [procedure] depending on the country and the site.” 
[SAVA Sponsor, Col, Mar-24-2015] 
In the first place, as quote 1 indicates, the manuals were designed based on the protocol. 
The person responsible had to use the knowledge acquired previously about the 
protocol and had to complement this knowledge with his/her knowledge about the 
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team (quotes 2-4), the culture of the communities (quote 3) (i.e. what activities can be 
implemented to contact people and to recruit them) and local regulation (quote 5). For 
example, among countries, there existed differences in the procedures to sign the 
informed consent. For this reason, the sites in Colombia and Mexico had to adapt the 
process indicated in the protocol to the requirements of the country, such as the 
number of identification copies to obtain and the signing of the informed consent by 
two parts. Therefore, the person responsible for creating the SOPs to operationalise the 
protocol in executable tasks needed to know the protocol, the requirements of the local 
regulation, the technical procedures required to execute the project, and the team 
members’ responsibilities. In this way, multiple pieces of knowledge that are 
complementary are brought together and externalised in one consistent document to 
be shared with the rest of the personnel, as Landry et al. (2006) also suggest. It is in the 
standardisation of procedures that the protocol reaches its full potential as a boundary 
object (Star and Griesemer 1989), being plastic enough to be adapted to the site 
dynamics, work practices and local regulation, conserving its essence across sites over 
the standardisation of procedures.  
In most of the research sites and SMOs, one person created the manuals, which 
evidences how the vision of one person about how the protocol should be implemented 
prevails in this standardisation process. The person who creates the SOPs using this 
knowledge made explicit his or her mental model about how procedures should be 
implemented, unifying practical criteria around the trial (Maier 2004). In the cases of 
KINGE and NUSTAN, the vision of the project manager in the sites was the one that 
defined the actions in the SOPs. In both cases, the project manager had better 
knowledge about the process to implement procedures compared with the principal 
research, which was usually absent from the physical site space. In the cases of SAVA, 
the principal researchers working for the SMO-1 (Colombia) and SMO-3 (Mexico) were 
the ones that added the modified initial version of the SOPs to their sites, adapting the 
protocol to their local contingencies. In the case of the private SMO in Colombia, the 
operational manager created the SOPs for each one of their research sites.  
The SAVA case evidences two different degrees of control of the SMOs over the 
research site, modulating the contribution or not of the site’s personnel to the 
standardisation. In Colombia, all the sites managed by the SMO-2 belonged to the 
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company, so the control of this SMO over these sites was direct and strong. The 
operations manager designed the manuals and trained the sites, giving small room for 
local researchers to contribute to this activity. In contrast, the sites managed by the 
SMO-1 (Colombia) and SMO-3 (Mexico) did not belong to the SMO. Sites were created 
and managed by the SMO, and almost all sites had independent teams configured by 
local hospitals only for the clinical trial. The control established by these two SMO was 
flexible and gave authority and control to the local researchers to adjust the SOPs to 
their local dynamics; even though being new research sites. The principal researcher in 
each site working for the SMO-1 (Colombia) and SMO-3 (Mexico) modified initial 
version of the SOPs (Quote 3), adapting the protocol and procedures to their local 
contingencies. Therefore, the SAVA case provides a new light about how standardising 
activities take place in research sites managed by SMOs; a rising figure in the clinical 
trial industry, and the control that SMOs manager exercise on the research sites.  
In summary, the data presented for the three cases elucidates how one person 
dominates the integration of knowledge into the site routines, either the project 
manager or the principal researcher in the research site, or the operations manager in 
a private company. In most of the cases, the manager or principal researcher shared the 
SOPs with the staff members to learn and understand the action, creating, in turn, a 
shared understanding of how they should follow the procedures over the course of the 
project and extending his/her vision about the task and the protocol. It was through 
the socialisation of these SOPs that protocol procedures, once adopted by people, are 
institutionalised into the standard routines of the research site (Bruni, Gherardi, and 
Parolin 2007).  
However, the creation of the SOPs and its implementation in the sites does not mean 
a full standardisation of procedures. Some key opinion leaders in the SAVA case 
suggested that regulatory authorities or the sponsor should evaluate the manuals 
created by the sites before initiating the project. For one of these researchers: 
“It was a mistake that manuals were requested only once you concluded the active 
phase and you initiated the hospitality phase; this should be since the beginning, 
this is a mistake from the laboratory and the principal researcher.” [PI 1-Site2, SMO-
3, SAVA-Mex, May-15-2015]  
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Then, although sites created manuals at the beginning of the project, a validation of 
the coordinating firm is desired to ensure a correct standardisation. Then it is not only 
relevant to create the manuals according to the protocol, but it is also essential to verify 
if the SOPs addressed the procedures correctly. In this manner, it is possible to verify if 
the knowledge acquired about the project is integrated into the organisation properly 
through the creation of manuals that have to be followed by the rest of the team.In the 
literature, concerns have been realised about the strong standardisation of knowledge 
process, as this can decrease the importance of tacit knowledge in practice and people’s 
capability to generate ideas and contribute to the project (Maier 2004; McIver et al. 
2012). This concern is totally valid; however, the data collected indicates that high 
control of the routines through the standards and a central managerial organisation are 
the factors that reduce the opportunities for staff to contribute to the project. In those 
cases where personnel had more freedom to propose, they could contribute to the 
project and the process implementation, as will be discussed in the section 6.2.2.2. In 
addition, the implementation of activities such as the clinical evaluation of participants 
demands the use of the tacit knowledge of physicians and their medical expertise to 
provide the diagnosis. Then, although the SOPs standardise some activities, the 
implementation of these tasks gives room for the personnel to contribute and reflect, 
as I will present in the next sub-section.  
6.2.2. Use of knowledge to implement the project activities  
As the introduction of this section presented, the other mechanism to integrate 
acquired knowledge into the project activities is applying the knowledge possessed 
(Dalkir 2005), giving a solution to problems (McElroy 1999). In all cases, the creation 
of the SOPs was the first step to integrate the knowledge into the organisations; 
however, all the procedures indicated in the guidelines had to be executed to recruit, 
follow up and evaluate participants to obtain the data. Then in this section I address 
the actions and how knowledge was implemented to execute critical activities of the 
protocol, how local researchers, using their knowledge, contributed to improving the 
procedures indicated in the guidelines and addressed the challenges that emerged over 
the trial.  
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6.2.2.1. Implementation of tasks 
One of the key activities in a clinical trial is the recruitment of participants. In this 
activity the staff are required to actively use the knowledge about the project to explain 
the project to potential volunteers. A key moment is the signing of the informed 
consent: without volunteers there is no project. In this activity the transfer must be 
clear to ensure that through the informed consent process, volunteers understand the 
project, their rights and responsibilities. This transfer is vital for the project because 
the informed consent is an ethical requirement and the legal contract between the 
principal researcher and the volunteer. Once volunteers sign the informed consent they 
have officially entered the clinical study as a subject31 and they declare that they 
understand their role as a “subject of research”, their rights, benefits and even 
responsibilities (Nijhawan et al. 2013; Robertson and Gan 2001). For this reason, the 
signing of the informed consent by volunteers is considered one of the most critical 
activities in the execution of a clinical trial. 
As the ICH-GCP indicated, personnel delegated in the site, and the physicians, had to 
explain the project carefully to the participants, resolve their doubts and give them 
enough time to review the information to decide if they wanted to participate in the 
trial, as the next quotes show:  
Quote 1: “We, for example, read with them the informed consent, with the parents, 
the subject. We read everything, and we explain all, there are documents with 10, 11 
pages. Sometimes people felt sleepy; they do not understand, so you need to ensure 
that they understand what I read, for me, it is the most complicated process.” [PM-
Site-1, SMO-1, SAVA-Col, Dic-10-2014] 
Quote 2: “We need to provide to them the [informed] consent to read, the assent, 
we give time. Then, they pass to me, and I answer all doubts, we ask them if they 
want or not to participate, and all that procedure corresponds to me.” [Sub-Res, 
Site2, SMO-3, SAVA-Mex, May-15-2015] 
Quote 3: “Before the patient signs the consent, I need to be sure that he has really 
understood, that he is willing, that there are no interests in between.” [Sub-Res, R-
IDVI, KINGE, Nov-05-2014] 
                                                          
31 “Prior to a subject’s participation in the trial, the written informed consent form should be signed and 
personally dated by the subject or by the subject's legally acceptable representative, and by the person who 
conducted the informed consent discussion.”(ICH Harmonised Tripartite Guideline 1996, 15) 
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Quote 4: “The people vaccinating speak Maya. Although the woman come and she 
was illiterate, or she did not speak Spanish, she always was with her kids, husband 
or someone and we explained the project.” [Nurse-Site4, SMO-3, SAVA-Mex, Jul-
09-2015] 
So, as these quotes indicate, personnel at the site and, in particular, physicians had to 
use their knowledge about the project to explain it to volunteers, families and 
witnesses, including their rights benefits and responsibilities. The community-
recruited mostly did not have the theoretical knowledge-base to understand the 
technicalities of the project. Then, the person explaining the informed consent had to 
develop skills to explain the project in a non-technical language without affecting the 
message and identify if the personnel had comprehended the project. This activity 
reveals the deep understanding that they had about the project and the disease, and 
analytical process that staff performed to transform and link technical concepts to daily 
life language to transfer the information, even in a different language such as Maya, as 
quote 4 indicates. In this way, through the project socialisation with volunteers 
(Nonaka 1994), personnel in the site displayed competence about the project, and used 
their knowledge in practice showing integration and appropriation of the project to 
socialise it with the community to achieve one of the most critical steps in the clinical 
trial, the subjects’ recruitment.  
Another key task in implementing the clinical trial is the production of clinical data. In 
this activity all previous efforts implemented by the site staff are summarised. 
Physicians are the only ones that implement this activity, who evaluate the medical 
condition of volunteers. Each protocol establishes the number of visits of the 
participant to the site and the variables that physicians need to investigate. In this 
activity, physicians had to evaluate the participants and identify if the participant had 
experienced any symptom associated with the disease under investigation. It is relevant 
to point out that physicians were autonomous in their diagnosis and they were not 
questioned about their medical conclusion, as Dr Macias indicated: “We have not had 
the case where a diagnosis is called into question.” (PI-Site 4, Mexico) Then, despite the 
standardisation of procedures, in the privacy of the interaction between physicians-




In the process to integrate the acquired knowledge into the medical practice, physicians 
narrated that in the three cases, they had to know the procedures indicated in the 
protocol for each visit, so they could collect the data required by the sponsor, as the 
next quotes for each one of the cases indicate: 
Quote 1: “My work here has been examining the participants those days that are 
stipulated in the protocol and meet each one of the points indicated for each one 
of the visits.” [Sub-Res-Site2, SMO-3, SAVA-Mex, May-15-2015] 
Quote 2: “At the point that the person receives the vaccine, we have to consider all 
the adverse events [that the] vaccine [is] responsible [for]. So we fulfil the term of 
adverse events, and then after the research or the clinical research or the laboratory 
results, we define if it was related to the vaccine or not related to the vaccine.” [Sub-
Res-USP, NUSTAN, Apr-14-2015] 
Quote 3: “[Disease] is a febrile illness. The first thing is to discard if they had had 
dengue; any type of fever, since dengue goes from nothing to severe symptoms. 
Then, we emphasise on it, if they have had fevers at each visit. Then, I do the control 
of the patients every time they come, that they did not have adverse events, and I 
do the monitoring and follow-up that is typically done with a vaccine.” [Sub-Res, 
R-IDVI, KINGE, Nov-05-2014] 
As quote 1 points out, the researcher or sub-researcher following the instructions in the 
protocol knew what procedures to implement to collect the data in each one of the 
visits. Quote 3 presents an example of the process to produce the data, which shows 
that data production was not a mechanical action. This evidence contradicts some 
papers and guidelines that have suggested that physicians follow a checklist to conduct 
the procedures (Knatterud et al. 1998), and that the SOPs rationalise the medical 
knowledge to control the margins of mistakes derivating from medical reasoning 
(Bruni, Gherardi, and Parolin 2007). Data production required a deep analytical 
capacity of the physician, who is using his knowledge about the disease to analyse the 
biological evidence32 (if it is necessary) and the narrative provided by the participant 
about his/her symptoms, which becomes a source of information for the physician for 
the analysis, as quotes 2 and 3 clearly illustrate. In the interaction between physician-
participant, the clinical research context seems to disappear, and only reminds a 
physician that he is providing a service to a patient to determine his health status. At 
this moment, the project acquires a new character and the physician becomes the 
protagonist, using his previous medical knowledge as a ‘tool’ to transform the 
                                                          
32 Physicians required blood tests to provide a diagnostic.  
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information obtained from the participant and the laboratory results in a medical 
diagnosis. At this stage, the physician’s thinking is flexible, versatile and invisible, 
where much of the analysis is tacit, fast and individual, at the same time addressing 
multiple variables and possible solutions based on the evidence collected, and he/she 
has the freedom to question and define what evidence is required to support his/her 
conclusion. As the physician narrated, at this intimate moment of reflection, he 
obtained a diagnostic through an internal process of propositions and associations 
guided by questions and answers; as a kind of flow chart that directed the mental 
process to provide the diagnosis. Wiig pointed out that “thinking will also rely on some 
of the reasoning strategies that are second nature to us” (Wiig 1993, 235). At this point 
the collected information triggers, priming memory, previous concepts and previous 
experience to provide a diagnosis. Once physicians culminated the diagnosis, the 
context of the project newly emerged. All the thinking processes that they conducted 
had to be externalised in the shape of clinical data in the medical records following the 
GCP and the sponsor standards. 
The national regulation and the Good Clinical Practices (GCP) guide the writing of the 
medical evaluation in the context of clinical research. These practices emerged with the 
intention of standardising clinical research, increasing efficiency in the procedures, as 
a result of distrust in medical practices (Bijker, Sauerwein, and Bijker 2016). Then, to 
produce the data, physicians had to know what information to collect and how to 
externalise it on paper following these norms, which shaped the actions of physicians 
to report their results, which provided the data with a character of “correctness” to be 
employed to the sponsor. In the first place, physicians had to create a medical record 
for each volunteer, where its content was determined by the national regulation and 
not by the sponsor,33 as the health secretary in Antioquia stated:  
“You like an IPS34 needs to fulfil the norm, independently of what the sponsor 
request, you need to meet the requirements of the medical record. We started to 
visit them, and they said, ‘I don’t have that because the sponsor receives it in this 
                                                          
33 In Colombia, the resolution 3374 of 2000 determines the management and minimal content of a medical 
record.  
34 Institutional Health Service Providers: All institutions in Colombia that provide medical, hospital, 
clinical and intensive care services. 
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way’, ‘Sorry, the norm that you need to meet to get the certification is this one.’” 
[Rep-Health secretary Antioquia, Colombia Feb-10-2015] 
Then, as this quote clearly indicates, physicians working on a clinical trial must collect 
the information indicated in the local regulations, and not only the data requested by 
the sponsor. This point was corroborated by physicians, who indicated that they had to 
register the data as the country’s normative demanded:  
“The template of the clinical record was the classic one because they are patient 
and we have to be within the official normativity. So, we made some adjustments 
in the project, for the protocol, but the principal support, the core of the medical 
record is what is established in the Mexican official norm.” [Sub-Res, Site2, SMO-3, 
SAVA-Mex, May-15-2015]  
In addition to the national normativity, to produce the data physicians had to add to 
the records the information specified by the sponsor, and they had to be more 
consistent and explicit, as the following quote indicates:  
“We are accustomed to being governed by norms. We all, despite the level of which 
we are at, we have to document in the record […] here it has to be more detailed. It 
has to be more punctual at the beginning and at the end to avoid omissions and 
apply the good clinical practices.” [PI-Site 4, SMO-3, SAVA-Mex, Jul-09-2015] 
Then, to externalise the results of the medical evaluation of participants, physicians 
had to know what information to collect based on the protocol and the local 
regulations, and they had to know how to collect the data according to the GCPs, which 
are the standards of the industry. According to the GCPs, “the investigator should 
ensure the accuracy, completeness, legibility, and timeliness of the data reported to the 
sponsor in the CRFs and in all required reports” (ICH Harmonised Tripartite Guideline 
1996, 18). As the last quote shows, physicians had to externalise as much information 
as possible about how they analysed the information, what evidence they employed and 
what conclusion they reached. Therefore, although the analytical process for making 
the diagnosis was flexible and researchers had the freedom to collect evidence, the 
writing process was governed by rules and standards decreasing the flexibility of 
physicians to report the results, demanding from them an effort to be rigorous and 
concise in the way in which they externalised data.  
The process to codify their diagnosis correctly was not straightforward, as was 
discussed in the last chapter, which presented how physicians with extensive 
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experience in clinical practice found it challenging to introduce the procedures to 
collect information indicated in the GCPs. Nonetheless, as was reported by monitors 
and physicians, as the project advanced, physicians learned how to collect the data 
according to the GCP:  
“As you repeat, you are more precise; you make a better note, you write the data 
better informing an adverse event. In the beginning, I made a partial note, not now. 
Now I know which is the item that I have to consider, when the symptoms started, 
when they ended, what medicines he took, how often, concomitant medication, all 
those aspects that I didn’t consider.” [PI-Site-1, SMO-1, SAVA-Col, Dic-10-2014] 
“I had to write everything in my notes following the GCPs and each one of the 
mistakes to avoid suspicions that maybe I was manipulating the information.” [Sub-
Res, Site2, SMO-3, SAVA-Mex, May-15-2015] 
Therefore, physicians, through practice, could externalise their medical knowledge in 
the shape of the clinical data according to standards of the industry, including all the 
aspects of the evaluation, the analysis and the evidence that they employed over the 
visit to make their conclusions. In this way, physicians writing long and detailed notes 
generated credible data and decreased any suspicion that they or any other site’s 
members were manipulating the information. As Zollo & Winter (2002) point out, the 
codification of knowledge, writing down, requires a cognitive effort, especially when 
individuals codify their understandings. Writing becomes a mechanism to make causal 
links explicit and clarify ideas. In the case of writing the clinical evaluations in the 
medical records, physicians, in addition to writing their analysis, they had to be 
conscious about how they did it. Therefore, although the analytical process for making 
the diagnosis was flexible and researchers had the freedom to collect evidence, the 
writing process was governed by rules and standards decreasing the flexibility of 
physicians to report the results, demanding from them an effort to be rigorous and 
concise in the way in which they wrote the medical records.  
Once this knowledge had been mastered, the know-how of writing according to the 
GCP standards became part of physicians’ routines. As the SMO-2 director and some 
practitioners working for SAVA and KINGE mentioned, they considered that physicians 
working in clinical trials improved their performance in their professional practice, 
becoming more accurate in their notes, and they also translated the knowledge 
acquired in the trial about data production and data management into their daily life. 
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This fact has also been highlighted by other researchers, who have discussed the 
influence of the experience gained in the clinical trials into the standard clinical 
practices of physicians with benefits for their patients because the level of detail paid 
to information gathered (Robertson and Gan 2001; Goodarzynejad and Babamahmoodi 
2015). Then, the acquisition and use of know-how associated with clinical research not 
only has a positive impact on the data collected over the course of the research, but it 
also has a positive influence on the daily work of researchers beyond the boundaries of 
the research sites and the context of the clinical research.  
6.2.2.2. Contribute and improve established procedures 
In addition to implementing the task indicated in the project to produce the clinical 
data, research sites contribute with their knowledge to improve the procedures 
established by the sponsor or proposing their own alternatives in those cases where 
room exists for it (Figure 8). One action through which sites contribute strongly to the 
project is in the recruitment and keeping the adherence of participants to reach the 
number of participants calculated by the sponsors to be enrolled in the project. Low 
recruitment rate has different repercussions for a trial; the length of the trial could be 
extended, increasing the costs; the probability of committing a type II error increases; 
the trial’s statistical power, internal validity, and external validity of the trial decline; 
and finally, if participants’ adherence is not good, the trial may be concluded without 
published results (Thoma et al. 2010; Bower et al. 2014). In contrast to the creation of 
the SOP, where an explicit document is created, the results of the recruitment strategy 
are reflected in the signing of the informed consent by the volunteers. In this case, the 
action of a third party (the volunteers) evidences the success of the productive enquiry 
(participant recruitment). This represents an extra challenge because the mobilisation 
of the community towards the project required a deep knowledge about the 
community, the project and the disease.  
In theory, the personnel on the research site have the autonomy to propose the 
recruitment strategy with the conditions that the researcher “should be able to 
demonstrate (e.g based on retrospective data) a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period” (ICH Harmonised 
Tripartite Guideline 1996, 13) and the rights, integrity, and confidentiality of trial 
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subjects should be protected (ICH Harmonised Tripartite Guideline 1996, 4). Therefore, 
in this aspect, the research sites can contribute, proposing the recruitment strategy that 
they consider more convenient.  
In the cases of NUSTAN and KINGE, the research sites proposed their recruitment 
strategy, as Dr Pablo Esmeralda [NUSTAN Chair] said: “We do not impose to the 
researcher how to do it […] the researcher can do it differently since it satisfies the 
protocol criteria.” In both cases the site elaborated a programme and created alliances 
with strategic organisations such as hospitals (KINGE), social leaders (KINGE), and 
public TV channels (NUSTAN) and newspapers to recruit the population indicated in 
the protocol. In both research sites, previous experience in engaging with these allies 
existed, and within the research group it was considered that these strategies allowed 
the targeting of the specific population that they were searching for the trial. In both 
cases it manifested, that these strategies were successful; “the project was like a clock” 
– volunteers contacted the site to participate and they were committed to the project 
[PM R-IDVI, KINGE, Nov-05-2014]. In this way, the freedom and the experience to 
create a recruiting strategy to address protocol requirements allowed the site to 
contribute with their knowledge to create a recruiting strategy to the most critical 
activities of the clinical trial, the recruitment of participants and their adherence. 
In contrast, in the SAVA case, the sponsor designed a recruitment strategy followed by 
almost all sites, excepting two in Mexico, who proposed alternative strategies based on 
their knowledge about local health programmes that could speed up the recruitment 
(details provided below). The sponsor’s strategy consisted of visiting the local schools; 
there, the medical team asked parents if they would like their children to participate in 
the research, and they collected the data of those interested to be contacted later. Those 
sites implementing the sponsor’s strategies did not contribute to the design of the 
recruitment. Nonetheless, their knowledge about the communities and about the 
project was fundamental to the implementation. As the sponsor in Colombia said: 
“They (SMOs) searched for investigators from the population, close to the people, that 
the people could feel identified with them; they (physicians) needed to know the 
problems in the region.” [SAVA-Sponsor Col, Mar-24-2015] And this close relationship 
allowed them to maintain the adherence of the participants to the project. 
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The two sites that decided to propose an alternative recruitment strategy were in the 
state of Yucatan. I consider their experience valuable because they used their in-depth 
knowledge about the community to create one of the most successful recruitment and 
adherent strategies of the SAVA case. In these two sites, Dr Maria Cristina Macias (PI-
Site 4, Mexico) and Dr Gabriel Valderrama (PI-Site-2, Mexico) knew about the state 
programme to promote and closely follow up the health status of the population. This 
programme consisted of the assignment of one physician, nurse and one health 
promoter to communities. These two researchers proposed a recruitment strategy, 
creating an alliance with the local health promoters to include their knowledge about 
the community in the project, as both indicated in the next quotes: 
Quote 1: “Health promoters have special relevance for me because the one [health 
promoter] that has less time working in his area has been there for 12 years. They 
know perfectly the people in each sector… They have a census, and they know which 
people have factors that would help us to select the subjects.” [PI-Site 4, SMO-3, 
SAVA-Mex, Jul-09-2015]  
Quote 2: “One of the biggest advantages of doing this is that health promoters of 
the health centre actually know the entire population. They were an essential part 
to implement the recruitment, not only for the seroprevalence trial, but also for the 
clinical trial. People already know them, and they are identified with them because, 
for years, the health secretary has worked with them… So, it was easier because 
existed trust, communication, etc.” [PI-Site3, SMO-3, SAVA-Mex, Jul-08-2015] 
Quote 3: “First, we received training from the doctor [PI Site 4] and the team, then 
in the information about the community structure that we have organised about 
the population, I review the age group that was necessary for the project.” [PH1-
Site-4, SMO-4, SAVA-Mex, Jul-09-2015] 
The inclusion of personnel with knowledge about the community was an advantage to 
recruit the volunteers. As the first quote points out, the fact that the health promoter 
had demographic information35 about the population enabled the principal researchers 
to stratify their message and direct it to the potential candidates that fulfilled all the 
criteria to be part of the trial (i.e. age, complete vaccination schedule, two parents). 
Social workers were trained on the project and considered that the project benefited 
the communities. They employed their knowledge about the communities to direct the 
message to the heads of the family, as they knew their decision-making process, as one 
                                                          
35 In these records there is information about the medical background of each person, the enrolment of the 
subject into health programmes, the vaccine schedule, health reproduction, pregnancy, diarrheal 
programmes among others. 
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health visitor indicated: “I visited the house personally when the husband was there, 
because here many decisions are taken by the spouse, and the people invited never was 
insecure.” [PH2-Site-4, SMO-4, SAVA-Mex, Jul-09-2015] Then, the fact that health 
promoter used their knowledge about the community and integrated this with the 
knowledge received about the project, and that they believed in the benefits of the 
project for the communities, enabled the participants’ recruitment. 
Another way in which these researchers working for SAVA in Mexico contributed to 
the project using their knowledge about the community was reducing the recruitment 
age of participants. In this way, they ensured the adherence of participants over the five 
years of the project. In this specific case, Dr Macias (PI-Site-4, Mex) knew that young 
males tend to migrate to the USA after high school and in the community there existed 
a high level of teenage pregnancy. Therefore, Dr Macias modified the inclusion criteria, 
as she stated: “although the project said [kids] between 9 and 16 years old, we decreased 
the age from 9 to 11 or 12 years to ensure the follow up” [PI-Site 4, SMO-3, SAVA-Mex, 
Jul-09-2015]. In this way, she anticipated the potential loss of participants as the kids 
grew over the course of the trial. This case shows how previous knowledge allows 
thinking far beyond the present conditions, proposing action to anticipate outcomes 
without passing through a trial and error process, as Wiig suggests (1993). 
As a result of this modification, her site had the lowest levels of desertion among all 
research sites working for the project in Latin America, as was reported by the SMO 
coordinator, and this was recognised by the sponsor, who invited her to share her 
experience with the other sites. In this site they did not have as many desertions of 
pregnant women like in Colombia or the other sites in Mexico, where the index of 
pregnant teenagers was high36 and which affected the participants’ adherence, as was 
reported by these sites at the interviews:  
Quote 1: “We recruited 4500 participants, we have lost less than 5%, half of it 
because of teenage pregnancy.” [PI-SMO-2, SAVA-Col, Apr-01-2015] 
Quote 2: “Recruitment was between 9 and 16 years old, some women turned 17-18 
or even with 16 years old they were pregnant, we have had a good number of 
                                                          
36 In Mexico, according to the National Institute of Geography and Statistics, 7.8% of teenagers between 12 
and 19 years have had at least one child (Instituto Nacional de Estadística y Geografía 2017). In Colombia, 
for 2017, 20.5% of those aged between 10 and 19 years have had at least one child (DANE 2017).  
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pregnant teenagers […] for the third dosage they were pregnant, so they had only 
two dosages or one dosage because we could not apply it. We continue the analysis 
and follow up depending on the vaccines that they received and the evolution and 
to the baby too.” [PI-SMO-3, SAVA-Mex, Jun-24-2015] 
The evidence in this sub-section is aligned with the lessons learned by Geldenhuys et 
al. (2012) in clinical trials after they had low recruitment rates, where they suggest that 
“enrolment rates should be based on accurate baseline data available on the targeted 
study population” (Geldenhuys et al. 2012). The data presented in this section 
complements their conclusion, evidencing how the use of demographic information 
about the community and a good understanding of their culture and decision-making 
process benefit the recruitment of participants into the study, complying in time and 
number of participants. Using knowledge about the community influenced and 
directed the recruitment strategy; this knowledge provided a vision of the possible 
outcomes of the project and its use allowed the anticipation of events. However, it is 
not only having the information about the community that makes a difference in the 
recruitment. A deep, trustworthy relationship between the parts, and good knowledge 
about the way in which families make decisions, and the social dynamics of the target 
population are fundamental to recruit the participants and ensure the adherence of the 
subjects in the long run. Then, the use of deep knowledge about the communities is 
essential to implement the socialisation and recruitment of the volunteers in a clinical 
trial. 
6.2.2.3. Address challenges 
The other mechanism that evidences the integration of knowledge into the work of the 
research site is using it as problems emerge. One challenge usually narrated by sites 
was the emergence of negative rumours in the communities; the other challenge that 
took place in the SAVA case was the recruitment of minors for the project. In this last 
case, sites had to search and acquire additional recruits to the project to overcome the 
impasse.  
Regarding the first challenge, physicians and site staff, over the project’s socialisation, 
had to present the project to the community. In these activities they had to already 
possess a good understanding of the project to solve the questions that emerged from 
the community and clarify any doubts that may arise. However, over this process, there 
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emerged “epidemiological gossip” about the project, as was constantly reported in 
Colombia in the SAVA case and also, I evidenced, in the case of KINGE. One example 
of these rumours is the next quote: 
 “We detected a woman that was defaming, saying that we will experiment with the 
kids, we went and visited her, and we said, ‘you don’t need to enrol your child in 
the project’, but we explained everything.” [PI-Site-1, SMO-1, SAVA-Col, Dic-10-
2014] 
This rumour, in the case of this site, decreased the recruitment rate and, as one 
researcher manifested, “gossip destroys a lot”. Therefore, to address this situation, 
physicians, using their contact within the community, identified the source of the 
stories and explained the project to them to overcome the myth and stop its diffusion. 
Then, through the active use of their knowledge about the project, physicians 
addressed this challenge and the project achieved the recruitment targets. So, this 
shows how once people introduce knowledge, its use is flexible, and they employ it 
according to the need of the project and the task to be undertaken. 
The recruitment of minors in a clinical trial demands that the legal representative of 
the minor signs the inform consent accepting its inclusion in the project.  The 
personnel at the site had to know the procedures and the local regulations to enrol the 
participants in the project. In the cases of KINGE and NUSTAN, the sites and the 
sponsor followed the national normativity, and they did not manifest any 
inconvenience over the signing of the informed consent. However, in the case of SAVA, 
the sponsor harmonised the informed consent process across all countries. SAVA’s sites 
were enrolling minors between 6 and 16 years old into the project. The regulations in 
Colombia and Mexico indicate that the minor’s parent or legal representative – in the 
singular – should provide consent allowing the minor to be a volunteer (Ministerio de 
la Protección Social 2008, 2008:28; COFEPRIS 2012, 4). Nonetheless, in the protocol, it 
was established that “after the subjects’ parents/legally acceptable representatives have 
signed a current IRB-approved ICF/AF, inclusion and exclusion criteria will be checked” 
(L. Villar et al. 2014b) - in plural. So, the recruitment established by the sponsor was 
stricter than the national regulations in Colombia and Mexico because either parents 
or legal representatives had to sign the informed consent form (ICF). This discordance 
between the local regulations and the protocol obstructed the enrolment of the 
participants in the selected communities, as the next quotes indicate: 
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Quote 1: “Both [parents] have to allow the subject to participate in the study. That 
complicates the situation [recruitment] because sometimes both can’t, or in these 
communities, 50% of women are abandoned or are single mothers where they 
[children] never had a father, so this is more complicated.” [SAVA Sponsor Mex, 
May-07-2015] 
Quote 2: “We know that we need to apply it [informed consent] but at the time of 
executing the procedures and meet it is difficult, it is very complicated, especially 
in this community.” [PI-Site-1, SMO-1, SAVA-Col, Dic-10-2014]  
Quote 3: “The protocol says that it must be both mother and father, you can’t, what 
do you want? The study? Or do you adjust yourself to someone that is sitting at a 
desk who wrote it?” [PI 1-Site2, SMO-3, SAVA-Mex]. 
In the first place, as the quotes indicate, the lack of knowledge by the sponsor of the 
social dimension of the communities made the recruitment process more rigid and 
complicated for the site personnel and created frustration, as the third quote reflects. 
In these communities, more than 20 % of the women exercise their motherhood 
without a partner37 and Colombia registers the highest number, where 84% of the 
children have only their mother (Social Trends Institute 2015). Numbers that support 
the challenge that represented the recruitment of this population of the sites in Mexico 
and Colombia under this context, because in many cases, both parents were not there 
to sign the informed consent. The research site could not enrol participants without 
the consent of both parents, otherwise the site could be at risk of being closed because 
they violated the protocol. The research sites, knowing this context and barriers, had 
to acquire knowledge about how the legal system works and transfer it to the subject 
to overcome this juncture and ensure the correct enrolment of the participant in the 
project, ensuring the validity of the process without committing any deviation over the 
recruitment. To meet these requirements, personnel at the sites provided alternatives 
to the participants to demonstrate their legal status, like obtaining an extra-judicial 
statement38 indicating the legal relationship between the parents and the kids, or 
providing legal documents that stated that kids did not have one parent. Then, 
personnel, using their acquired knowledge about the legal system, guide the 
                                                          
37 In Mexico 27.8% women exercise their motherhood without a partner. Of them, 21.3% at one point had 
a partner, while 6.5% are single mothers (Instituto Nacional de Estadística y Geografía 2017). 
38 It is a free and spontaneous manifestation, where a person in a notary under oath attested or provided 
information about an issue. Where the mother had to testify that the minor hadn’t had a relationship with 




participants through the legal procedures to allow the participation of more children 
in the trial.39 Also, the staff at the site had to be proactive in searching for alternatives 
and learning about the legal system to face the situation, showing once again the 
relevance of their work in the context of a clinical trial. Based on the evidence presented 
in the last part, I suggest that sponsors conducting multi-national projects should 
follow what the local regulations indicate, rather than harmonise procedures increasing 
the requirement indicated in the local regulations.  
In conclusion, the evidence presented in this section 6.2.2 contradicts the argument 
raised by Fisher (2008) about the use of knowledge of physicians in clinical trials and 
in their learning over the course of the trial. The results of her study in the USA indicate 
that “pharmaceutical clinical trials are offered to physicians as pre-packaged studies in 
which they choose to participate or not” where they contribute with their practical 
clinical skills, but not with knowledge, and they receive little training to implement the 
project before or over the course of the project. The data presented to this point differs 
from these conclusions and presents a different view about the flow and use of 
knowledge in vaccine clinical trials by physicians and clinical sites in Latin America.  
The critical point to understand the differences in the results is in how both studies 
define knowledge. For Fisher (2008), physicians’ contributions are only considered if 
they participate in the design of the trial with ‘scientific knowledge’, which rarely occurs 
in an industrialised context like in the USA. Excepting if the trials are conducted by a 
National Health Institute, where physicians are more involved in the trial (Kagan et al. 
2009, 6). In Fisher’s discussion, knowledge about the communities and participants and 
the use of their medical training is not considered as the knowledge that physicians use 
actively in the clinical trial or benefit the project. Whereas in this thesis, the 
contribution of physicians to the project is not only associated with the design of the 
project or the scientific knowledge that they can provide. In this thesis, I consider that 
people use different types of knowledge over the trial’s implementation, knowledge 
that involves the know-how that people use to implement the activities, the conceptual 
knowledge that people previously have and acquire as part of training, and also the 
                                                          
39 Personnel at the site could not be with the parents over the legal declaration because that could be 
considered as a coercive action. Then, the personnel at the site had to trust the will of the volunteers to 
carry out all the legal procedures and get the documentation, to then be part of the project. 
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knowledge about community, which is vital for the recruitment and adherence of 
participants. Researchers contribute with other knowledge for the correct 
implementation of the trial and data collection; they are not pre-programmed 
machines to produce data using a code provided by the sponsor. Therefore, reducing 
the knowledge contribution of physicians to only the ‘scientific knowledge’ is very 
simplistic and diminishes the daily contributions of the principal researchers and sub-
researchers to the project to make it a success, as has been presented in this section. 
6.3. Learning loops through the trial 
The last section discussed how physicians employed their medical knowledge about the 
infection’s symptomatology to conduct their diagnosis. This knowledge was not static, 
and researchers continued learning and used the new knowledge in their medical 
activity, as one sub-researcher in Mexico said: “we need to be always updated, it is 
decisive”. In the three cases, researchers and sub-researchers indicated how, over the 
course of the trial, they continuously learned about masked symptoms of the disease 
and the management of the disease from their experience, the sponsor or the local 
health authorities. Physicians incorporated this new knowledge in their medical 
evaluation to produce the data, as this quote indicates:  
Quote 1: “The knowledge has come from all sources. In the beginning, we only had 
to search for patients with fever. As the sponsor’s knowledge and our knowledge 
evolved, we started to search not only for patients with fever, but also if [they] had 
petechiae,40 if they had problems of bleeding in any mucous membrane, or hidden 
bleeding manifested in the laboratory with haemoconcentration, anaemia. General 
data that orient you towards a process a little masked. In that way, we were 
searching. However, from all sources have come the knowledge, including the one 
that is transferred, the one that we get or the one that we receive from the health 
secretary.” [Sub-Res-Site 4, SMO-3, SAVA-Mex, Jul-09-2015] 
Quote 2: “Well, firstly we said that dengue was fever, bone pain, muscle pain and 
that was all we knew about dengue. No, the problem with dengue is that it can 
cause other types of disorders, it can cause diarrhoea, it can be a urinary infection, 
what is a more masked picture, abdominal pain that can be confused with acute 
abdomen, with a shock for example. Then, you say good it’s a very polymorphic 
disease and we have had to adapt this to what you are finding. So, really, we have 
modified the criteria regarding dengue a lot.” [Sub-Res2-Site 4, SMO-3, SAVA-Mex, 
Jul-09-2015] 
                                                          
40 It is a small red or purple spot (1–2 mm) on the skin, caused by a minor bleed from broken capillary 
blood vessels (Gikonyo et al. 2008). 
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Therefore, these two quotes illustrate how medical knowledge about the disease was 
not the same and it got more robust and detailed. Showing a learning loop, where they 
acquired knowledge from external sources such as the sponsor and the health 
secretaries and introduced it into their medical activity to diagnose the disease.  
One of the principal loops that takes place over the trial is the feedback provided by 
monitors. Loops that have been widely reported in the literature (Knatterud et al. 1998; 
Minisman et al. 2012; Ukwu et al. 2011a). What happens over these loops is that monitors 
evaluate the quality of the data produced by physicians and, usually, if too much 
variation is identified, additional training is provided to solve these issues and minimise 
the probability of future occurrences of deviations, as the next quotes illustrates:  
Quote 1: “Yes, they need the training if they have deviations, or they are not 
accomplishing the times. We need to remain them the regulation, all that.” 
[Monitor-CRO, SAVA-Col Dic-10-2014] 
Quote 2: “If there is a mistake we need to train the site to avoid its occurrence 
again.” [Monitor-CRO, SAVA-Mex, Jul-08-2015] 
Quote 3: “Where there is an amendment in the protocol we need to retrain, when 
we detect on a visit or through monitoring a failure on the process, we need to 
retrain.” [SAVA-Sponsor Col, Mar-24-2015] 
Quote 4: “We had meetings with the monitors, and they gave us training about 
modifications in the project, and if they detected that there were things that were 
not according to the protocol then they trained us about that.” [Sub-Res-Site2, 
SMO-3, SAVA-Mex, May-15-2015] 
Quote 3: “What is expected is that those amendments and changes improve the 
project dynamic, improve the results and, improve the quality of the research.” 
[Monitor-CRO, KINGE-Col Nov-27-2014] 
These loops meant that the physicians and the staff had to include the feedback 
provided into their work. As was presented in the last chapter, researchers working in 
SAVA were less permeable to the monitor comments. Therefore, the introduction of 
the feedback provided by the monitors was not accepted positively in all cases, and sites 
questioned it. However, these loops were constant and sites received regular updates 
of their work to improve their performance. Then, over the course of the project, a loop 
exists between the CRO and the site, which has the objective of improving the project 
quality and improving the work and diagnosis capabilities of personnel at the research 
site. Therefore, the lack of knowledge to implement actions is not the only trigger of 
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loops (Cook and Brown 1999), evaluations of external actions and reception of external 
knowledge trigger learning loops and constant communication to transfer the new 
knowledge among parts.  
6.4. Data transfer  
In the model presented in Chapter 2 the step that connects the organisations working 
on the interdependent project at the inter-organisational level is the transfer of 
knowledge and products (Ngai, Jin, and Liang 2008; M. H. Meyer and Zack 1996). In 
this section, I address this stage and present how sites transferred the clinical data 
produced to the sponsor. For firms working at a distance in knowledge work projects, 
the mobilisation of fragmented knowledge across firms (Bruni, Gherardi, and Parolin 
2007) and the integration of data are fundamental to ensure the project’s success 
(Anderson Jr. and Parker 2013). Also, one important element at the intra-organisational 
level is the storage of results or lessons learned within the firm (McElroy 1999) so the 
research site can increase its internal capabilities to be implemented in further 
research.  
6.4.1. Transfer of clinical data to the sponsor 
Anderson and Parker (2013) developed a framework to research the integration of 
knowledge in distributed knowledge work (DKW), like the clinical trials, where parts 
of the project results are produced by multiple organisations such as the clinical sites 
and have to be integrated by the lead firm such as the sponsor. This framework suggests 
that the two aspects that firm leaders must consider when designing the project are 
information infrastructure to promote integration and the organisational network 
design. These two aspects are addressed in this section to understand how the sites 
transfer the data to the sponsor and this sponsor, in turn, integrates the knowledge 
produced in multiple locations. 
Although physicians collect the clinical results in the medical records, data is 
transferred to the sponsor in a document denominated CRF - Case Report Form. In the 
GCP it is established that all data collected for the study is transferred to the sponsor 
employing the CRF. The CRF is “a printed, optical, or electronic document designed to 
record all of the protocol required information to be reported to the sponsor on each 
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trial subject” (ICH Harmonised Tripartite Guideline 1996). Nonetheless, the sponsor, 
as head of the project, has the freedom to define the channels to collect the data, the 
data to obtain, the frequency of the transfer and the procedures to receive the data 
produced in multiple locations. In other words, sponsors have the autonomy to define 
the information structure and organisational network design to collect and integrate 
the data; however, the boundary object to transfer the data is the Case Report Form.  
In the three cases studied, the organisational network and information structure 
differed, which shows that in the industry this procedure is not entirely standardised. 
The information structure in KINGE was different to the SAVA and NUSTAN cases. 
KINGE was the only one that employed a combination of paper CRF and an electronic 
data capture software; in the other two cases the CRF was virtual. This difference had 
deep implications on the process to transfer data, integrate it and verify its integrity. In 
the KINGE case, the physician, after each consultation, based on his notes in the 
medical record, filed the CRF on paper manually following the ICH-GCP, a document 
that had three copies made with carbon paper. One of the copies was collected by the 
CRO monitor, as the project manager said: “CRO come [to the site] and collected it 
[CFR] and take it. She passed it to the data management group [sponsor]” [PM R-IDVI, 
KINGE, Nov-05-2014]. The CRO’s monitor was responsible for comparing if the 
information in the CRF complied with the ICH and it was similar to the information in 
the medical records. For posterity, the CRO transferred the data to the sponsor 
transcribing the information into the sponsor’s Electronic Data Capture software 
(EDC). Subsequently, the data management team verified this data. The problem with 
the information structure and network design were that any requirement and 
clarification requested by the data management team (sponsor) had to be 
communicated to the research sites through the monitor who, in turn, had to transfer 
the corrections and clarifications to the sites. This procedure created a working 
distance between the data management team and the research site to provide any 
explanation and feedback about the data. The collection of data on paper CRFs is 
disappearing in the industry and data is submitted directly to the sponsor data 
management team directly using software, which decreases the intermediation of the 
CRO transferring data to the sponsor, and all clarifications are requested directly 
through the software, as the SAVA and NUSTAN cases indicate. 
155 
 
In the NUSTAN and SAVA cases, the sponsor employed an eCRF (electronic Case 
Report Form) directly managed by the research sites, which enables a direct transfer 
and integration of the data. In both cases, once physicians filed the medical record 
electronically or physically, the data manager was the one that transcribed the data 
demanded by the sponsor in the eCRF. The presence of the data manager indicates how 
the work distribution varied in these two cases compared with the KINGE case, where 
the physicians and the CROs did not have responsibility for the transfer of data to the 
sponsor. The next quote indicates how the transfer to the sponsor was presented in the 
NUSTAN and SAVA cases:  
Quote 1: “It is manual; I do the manual part [creation medical record]. Then, we 
have Natalia and Leandro, they put in the software; it is easy, it is not hard.” [Sub-
Res-USP, NUSTA, Apr-14-2015]  
Quote 2: “The procedure was relatively simple, there was a person that was 
dedicated to that, that collected the information from the medical record and 
transferred it to the format that the sponsor had designed. Only they had access to 
that, only they. I did not have access to that database because it was not my job.” 
[Sub-Res-Site2, SMO-3, SAVA-Mex, May-15-2015] 
Quote 3: “When I receive the case file, I submit what the system requests, for 
example, the date of the visit, if the volunteer arrived, if the specific sample was 
taken […], everything has to match. The process is not tedious, it is information 
about specific visits, but you need to be looking for the information because 
otherwise, you have many queries [errors] accumulated in the systems.” [PM-Site-
4, SMO-3, SAVA-Mex, Jul-09-2015] 
Quote 4: In the beginning, all the data that they [physicians] collected, we 
introduced it at INFORM [software employed by the sponsor]. Right now, the only 
thing that comes up regarding the subjects are cases of pregnancy and SAEs or 
terminations in a given case, but I think we only have one or two casualties. 
Moreover, now almost the only information updated are about the visits.” [SW-
Site4, SMO-3, SAVA-Mex, Jul-09-2015] 
In these two cases, physicians did not have access to the databases, so they did not 
control what was sent to the sponsor, although they produced the data. As quote 4 
states, the information transferred to the sponsor varied according to the stage of 
development of the project, and the data manager was the one that had to know what 
data the sponsor requested. The staff transferring the data had to be quite careful in 
sending only the information recorded in the file without modifying the physician’s 
narrative, as a project manager delegated with this responsibility indicates: 
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 “I upload to INFORM (software) what is in the file [medical record], I cannot 
upload anything that is not there…it is not complicated, but you have to be aware 
of the information to submit.” [PM-Site-4, SMO-3, SAVA-Mex, Jul-09-2015].  
Then, although this activity is manual and mechanical, it demanded attention from the 
data managers to transfer the data. Although the transfer of data from the site to the 
sponsor was directly through the software, in the transfer process within the site there 
existed an intermediary. Consequently, the data presented about the organisational 
network and information infrastructure indicates that the transfer data produced by 
physicians is not direct to the sponsor, and there are intermediaries, either an external 
organisation, such as the CRO or an internal staff member, such as the data manager. 
In both cases there is a risk that the data produced suffer changes as a result of the 
transcription. In other studies, the transfer of information from the file to the CRF as 
the primary source of data error has been reported (Vantongelen, Rotmensz, and Van 
Der Schueren 1989). It has been suggested, in the literature of clinical trials, that data 
submitted by people that have not been delegated with this responsibility may be 
rejected from the database or considered with suboptimal quality because the person 
does not have the knowledge to do it (Knatterud et al. 1998). Therefore, the delegation 
of the transfer responsibility in research sites must consider the knowledge of the 
person to address with the software and understand the information that is transcribed 
to avoid misinterpretation and mistakes.  
Although the process to transfer the data from the site to the sponsor varied among 
cases, in the three cases the sponsor employed software to integrate the data produced 
by the sites. This information infrastructure allowed the data to be centralised and 
enabled the data analysis. However, the process to evaluate the data transferred by the 
research site and provide feedback to the sites differed in the KINGE case compared 
with SAVA and NUSTAN. In the KINGE case, as was presented above, the CRO monitor 
was the one who communicated to the sites the amendments in the CRF and he also 
had to return to the original files to identify if he made a mistake in the transcription. 
In the cases of SAVA and NUSTAN, a person remotely connected to the database 
reviewed the data transferred to the site and requested clarification directly to the staff 
through the software. This procedure is highly shared in the industry to ensure data 
quality (Ottevanger et al. 2003; Gassman et al. 1995). The process to review the data by 
the data management team (sponsor) is presented below:  
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“The verification consists in identifying if there exists a mistake in the database; 
sometimes there are logic mistakes or other times are mistakes of consistency. Logic 
mistakes are, for example, that I receive a man with a pregnancy test. A consistency 
mistake is that a person has a headache and I name it in five different ways, which 
is a huge work to fix those consistencies. Sometimes the center takes time to send 
the data and that delays our work. For example, we request a correction, and the 
center is late providing the correction because the staff is busy with other activities, 
that is what takes most time.” [NUSTAN Chair, Apr-13-2017] 
“There is monitoring of INFORM staff [actually it is SAVA data management team] 
who check queries [mistakes], they verify the data we submit.” [PM-Site-4, SMO-3, 
SAVA-Mex, Jul-09-2015] 
Comparing the NUSTAN and SAVA cases with KINGE, in the two first cases the site 
personnel received direct feedback and questions about the data directly through the 
software, and they could directly solve any issue without the need for the 
intermediation, as in the KINGE case. Then, as it is possible to see, among cases 
differences also existed on the structures and mechanisms to transfer the data from the 
sites to the sponsor. The role of intermediaries, like in the case of KINGE, determined 
the accuracy by which data is transferred, but also the speed by which corrections are 
implemented by the sites. The use of software allows communication in real time 
among the parts, speeding the corrections. Then in a project where a reciprocal 
interdependence exists (Thompson 1967), where sub-task outcomes and inputs 
continuously interact, the organisational structure and communication channels 
established between the sponsor and the sites are fundamental to provide feedback and 
ensure the timely corrections of the data.  
6.4.2. Turnover of staff and the loss of knowledge  
The lessons learned in the clinical trial by the personnel at the site becomes one of the 
most important capitals that the organisation has for future projects. In the literature 
of knowledge management, the relevance of storage the knowledge acquired by people 
in the organisation has been intensely discussed (Rubenstein-Montano et al. 2001; 
Prencipe and Tell 2001). For this, multiple authors have suggested the implementation 
of knowledge systems that consist of the creation of software that allows to the workers 
to externalise their knowledge, contacts and information into a big warehouse (Mas-
Machuca and Martínez Costa 2012; Maier 2004; Pentland 1995). In the context of the 
research sites visited, only the R-IDVI site had implemented a kind of system to store 
the knowledge acquired by their workers. And I say kind of, because there was no 
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software to centralise all the information and it was not directly related to the clinical 
trial. What existed were paper formats that people filed, explaining the techniques that 
they had learned as part of the academic exchange. However, practical information 
about the clinical trial, for example, was not part of the routine. In the rest of the 
research site there was no software or any mechanism to at least collect the lessons 
learned by the workers.  
This lack of mechanisms to store knowledge has an impact on the knowledge capital of 
the organisation for a future project, especially when there is a constant turnover of the 
staff over the course of the trial or between projects. For example, the Brazilian group 
working for NUSTAN did not have any mechanisms to ensure the transfer or 
codification of knowledge of the people leaving the groups, as is evident in the next 
fragment of the interview:  
“Interviewer: How do you retain the knowledge that they (people leaving) have? Do 
they train new people, or do they document the process in a notebook or lab book? 
Project Manager: No, we don´t have that at this time […] We have a final meeting 
with this person to hear his voice, to understand why and to say our impressions to 
this person, but we don´t have a formal document, but we have plans to have more 
formal documents.” [PM-USP, NUSTAN, Apr-01-2015] 
Therefore, the lack of strategies to ensure the storage of lessons learned or other forms 
of knowledge to be transferred inside the group when a person leaves the project 
creates a loss of information and experiences that is impossible to recover. The project 
manager in R-IDVT also manifested, “The difficult thing is that the experience stays, it 
[experience] does not stay, the person that leaves, leaves with the experience that he 
had […] the experience is not transferable. It is very hard.” Although in this research 
group the person leaving the project trained the new physician, enabling continuity in 
the process, the new physician revealed that although he received information about 
the project from the previous sub-researcher, he had a limited understanding of the 
initial stages of the project and activities conducted. So, the knowledge gained over the 
first part of the project was no longer part of the research group. Thus, all the lessons 
learned about these initial stages by people leaving cannot be employed on the site for 
a future project.  
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In two of the three cases studied, the research sites had lost staff over the course of the 
project. This implied that the knowledge acquired by the people leaving was no longer 
part of the project and the new staff had to acquire knowledge about the project, and 
the sponsor had to re-train personnel. In the case of sites working for NUSTAN, it was 
reported by the sponsor how challenging was to re-train constantly new personnel. The 
turnover created a problem for the continuity of the project, as Dr Esmeralda (NUSTAN 
Chair) indicated:  
“The biggest problem has been the personnel turnover in the research sites; many 
people left the site, so we have to do quite often re-training… The academic work 
in Brazil does not allow that people have formal and competitive employment 
contracts in terms of salary.” [NUSTAN Chair, Apr-13-2017] 
Then, although the NUSTAN case had the advantage of having a direct training channel 
with the sponsor to acquire knowledge and information (Chapter 5), the personnel 
turnover becomes into one of the grey areas of the project because people always had 
to be re-trained and the project on the ground did not have continuity. Because 
knowledge was dispersed across all the people that worked on the project at the 
different stages, the staff turnover meant that once the project concluded, the 
knowledge employed did not remain in the organisation and it was no longer available 
for other projects. Then, as  Zhao et al. (2004) argue, outsourced companies should pay 
attention to how to retain, utilise and create knowledge, to improve their corporate 
memory and core capabilities, and develop a culture to promote knowledge sharing 
across the organisation. Some strategies suggested are the articulation and codification 
of knowledge at the project level and the creation of a mechanism for people to review 
the lessons learned by their partners (Newell and Edelman 2008).  
The reason for this turnover in Brazil, as one of the previous quotes indicates, is the job 
insecurity of people in the research groups. As Laura Ferreyra (Project Manager, USP-
1) explained: “we are ‘scientific bolsistas’,41 we receive peer protocols, we don´t have a 
legal contract, it is for the project, so for technical people is more difficult to 
understand; they receive another opportunity, salary, and leave the project”. So, this 
job insecurity in the academy represents a difficulty to guarantee the continuity of 
                                                          
41 Expression employed in Brazil to make reference to the people that work with funding coming from 
scholarships provided by the university of the government which are denominated “bolsas”.  
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personnel that were already trained in the project and, therefore, to get the benefit of 
the experience gained over the execution. Although NUSTAN implemented formal and 
fixed contracts with the sites to guarantee certain salaries to the personnel working on 
the project, this did not resolve the issue. Each research group had the power to 
redistribute the incomes of the project and re-assign salaries. As a sponsor explained: 
“One of the things that we need to respect, and it is a bit delicate, is the next one. I 
cannot generate a distortion within the research site. One nurse of my project cannot 
earn one and a half times (more) than a nurse working on a routine service.” Then, 
because the sponsor didn’t want to create competition between the people working for 
the clinical trial and those that were not, they did not fix a wage for the people working 
on the project. Then, besides salary, some incentives and strategies should be 
implemented to ensure the permanence of staff in the project and the research site.  
In contrast to these two cases, in SAVA’s sites, it was reported that sites’ staff were 
stable. Personnel had direct contracts with the SMOs, with all the social benefits, like 
one of the principal researchers in Colombia said: “we are directly contracted by the 
foundation; that generates labour stability, and that makes people perform better”. In 
Mexico, for example, in Site-3 in Yucatan it was reported how, at the end of the day, the 
team had meetings to evaluate together the results of the day, what problems they faced 
and how they could improve for the next days. Although they did not record on paper 
the lessons learned, the staff stability and the constant transfer of knowledge within 
the site encouraged the team to learn and improve their work dynamic. These results 
concord with the findings of Zollo & Winter (2002), where the socialisation of 
knowledge promotes the development of the group competences,  although it could be 
more beneficial if staff or managers document these lessons.  
In summary, the working conditions of the personnel are essential to avoid that all the 
effort made at the beginning of the trial to train staff and create a shared understanding 
of the project will be lost because of the turnover of staff. Therefore, both academic 
sites in Colombia and Brazil indicate that the labour instability in academic research 
sites is a threat to the project. People with the knowledge and training without optimal 
labour conditions are prone to leave the project to pursue a different profession, taking 
with them the knowledge acquired to execute the protocol. 
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Turnover was also frequent among CRO monitors, which is a problem in the industry 
in Latin America, as was highly testified by the clinical trials associations, and industry 
analysis indicates this too (Shuchman 2007). In Latin America, the CROs compete with 
each other for the best staff (Ukwu et al. 2011a). This situation creates an environment 
where monitors continuously look for better job opportunities, leaving the projects that 
are under their responsibility. This industry dynamic affected the SAVA and KINGE 
projects directly. In both cases, monitors changed continuously over the course of the 
project, which affected the projects’ continuity. The person leaving the project took not 
only the knowledge acquired about it but also the connections and interactions that he 
or she had developed with the sites. So, the new monitor had to rebuild the 
communications channels and trust with the site’s staff, as was presented in Chapter 5, 
and this influenced the permeability of the sites towards the information and 
knowledge transferred by the new monitors (Chapter 5). Then, this evidence supports 
the argument raised by Azoulay (2004), where he expresses a concern for the low 
expertise that a monitor can build about a particular project; concern that also can be 
extended to the turnover that takes place in the academic research organisations.  
The fact that monitors and staff spend a short time in a position in a clinical trial means 
that they do not develop a deep understanding about the project and they do not know 
the previous work, so engaging with the project takes longer. It has been suggested that 
when people arrive as a replacement they are prone to make more mistakes in data 
execution, which is linked to inadequate training of the new personnel because they 
come late (Gassman et al. 1995). Therefore, one of the challenges in the clinical trials is 
to guarantee the continuity of the staff from the beginning to the end in academic 
research sites and CROs, which requires attention to ensure that the knowledge 
acquired at the beginning of the project remains in the organisation. 
In conclusion, in this section, I have discussed the relevance of the know-how of the 
data managers in the research sites to transfer the clinical data to the sponsor. Although 
this activity is manual and does not require an analytical effort, it is crucial to ensure 
the correctness of the data transferred. Achieving this demands practice, dedication 
and constancy. Also, I presented how the transfer of data to the research sites consists 
of an interdependent activity, where the product (data) obtained in the site is 
transferred to the sponsor to be analysed and gather the evidence about the vaccine. In 
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this section, the importance of storing the lessons learned over the course of the trial 
was also discussed, and how the constant turnover of personnel in academic research 
sites decreased the accumulation of knowledge and experience in the site, so the 
knowledge capital that the site could have accumulated over the project is lost. Based 
on the evidenced collected, I discussed how, in the case of Latin America, the 
contractual conditions in the research sites were one of the reasons for people leaving 
the project and promoted the turnover (evidence about Brazil and Colombia). But also, 
in the case of the CROs, this turnover was discussed; however, in this case, the highly 
competitive environment of the CROs to attract the best talent creates the migration 
of people across firms, which also affected the projects, as was discussed in this section 
and in Chapter 5.  
6.5. Conclusion  
In Chapters 1 and 2, I presented how the clinical trial literature and the literature of 
knowledge management have broadly discussed the contributions of the research sites 
to projects. For this reason, this chapter aims to address this gap answering the research 
question: How is knowledge employed in the clinical research sites to solve the 
productive enquiries related to the production of clinical data and its transfer to 
the sponsor?  
The model proposed in Chapter 2 guided the answer to the research question. This 
answer has an intra-organisational perspective to analyse the use of knowledge in the 
research sites, and this answer also has an inter-organisational perspective to address 
the transfer of results to the sponsor and the loops that emerged over the project 
execution. The main productive enquiries in the clinical trial discussed in this chapter 
were: (1) the standardisation of procedures to execute the project; (2) the recruitment 
and enrolment of participants; (3) the medical evaluation of participants (data 
production) and (4) the data transfer. In this answer, I provide evidence of the positive 
contributions of the research sites to the execution of the clinical trial project and how 
they employed their previous knowledge to solve the productive enquiries. In this way, 
I presented how the ‘epistemology of possession’ and the ‘epistemology of practice’ 
(Cook and Brown 1999) converge in the execution of the project tasks. 
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In the first section, I presented how knowledge was integrated and employed in the 
research site to standardise procedures, recruit participants and produce the clinical 
data. In this section, I discussed two mechanisms to integrate the knowledge and 
information received with the knowledge of the organisation (Figure 8) to produce the 
knowledge products (M. H. Meyer and Zack 1996) and to give a solution to problems 
(McElroy 1999). The first mechanism was the standardisation of procedures through 
the SOPs manual. The second mechanism was the actual use of the acquired knowledge 
in practice of each one of the standardised activities either to produce the clinical data, 
to optimise the strategies proposed by the sponsor, or to overcome the challenges 
associated with the implementation and recruitment of participants. The integration 
of knowledge and its use was gradual, and it depended on the activity under execution. 
For example, the recruitment of participants demanded a deep understanding of the 
project and procedures to socialise this with the volunteers and their families, to 
simplify the message, and transfer it in a different language to the community. 
Although the protocol defined the activities to implement, and the ICH-GCP 
established a group of practices to develop the activities, the evidence presented 
indicates that the standardisation of operations was different between cases. The 
person standardising procedures interpreted the protocol under the light of the 
community dynamics and the site dynamics to propose alternatives to optimise the 
protocol implementation, and to address challenges that emerge over the course of the 
project execution. 
The conceptual bases and information employed to create the SOPs and produce the 
clinical data were similar among cases. In all cases, the person creating the SOP had to 
use its knowledge about the project, the task to perform and had to know how to write 
the manuals according to the GCP guidelines, detailing step-by-step the procedures for 
each task. In this way, the person externalised her knowledge in the shape of a manual. 
However, the standardisation of procedures in the three cases differed considerably 
according to the degree of freedom that the sites had to create their manuals and the 
experience of the research site. Nonetheless, it is a fact that the creation of the SOPs 
was dominated by one person at each site or SMO where her/his vision about how 
procedures should be implemented prevailed, unifying practical criteria and 
conceptual knowledge around the trial. 
164 
 
The other critical task is the production of clinical data, which was an individual activity 
implemented by physicians. The evidence presented contradicts some of the arguments 
in the literature, which argue that physicians are limited to following a checklist to 
conduct the procedures (Knatterud et al. 1998; Fisher 2008) or that the protocols and 
SOPs rationalise the medical knowledge to control the margins of mistakes (Bruni, 
Gherardi, and Parolin 2007). Although physicians had to follow the procedures in the 
protocol, they had the freedom to conduct the clinical evaluation; for this, they used 
their medical training and knowledge about the disease, and analysed the biological 
evidence and the narrative provided by a participant about their symptoms to produce 
the clinical data. What the data presented indicates is the cognitive effort that 
represented for physicians to externalise the results of their medical evaluation and 
reasoning in the shape of clinical data that fulfilled the requirements of the ICH-GCP 
and local regulation. As the project advanced, physicians learned and mastered the 
know-how to report the clinical data according to the industry standards. Even though 
the evidence indicates that as researchers become more consistent and detailed in the 
way in which they recorded the medical files which benefited their medical practices 
beyond the trial context. Also, the evidence indicates that the principal researcher 
employing his knowledge about the community contributed to the project by 
proposing the recruitment strategies and tailoring the protocol to the community’s 
social dynamics, such as the case in Mexico. The use of this knowledge is highly relevant 
to achieve the adherence rates in the long term. Then, not only conceptual and 
technical knowledge is essential to implement the project task, deep knowledge about 
the communities is highly positive in clinical trials. Therefore, reducing the knowledge 
contribution of physicians to only the ‘scientific knowledge’ is very simplistic and 
diminishes the daily contributions of the principal researchers and sub-researchers to 
the project to make it a success, as this section indicated. 
The second section in this chapter addressed the learning loop in the project execution; 
these loops are at the inter-organisational level between the CRO, the sponsor or health 
authorities, increasing the conceptual knowledge of physicians and providing feedback 
on the know-how of the activity. As I presented, if sponsors identified variation in the 
clinical data, they or the monitors provided feedback. This situation demanded 
additional training or modification of procedures to solve these issues and minimise 
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the probability of future occurrences of deviations (Knatterud et al. 1998; Minisman et 
al. 2012; Ukwu et al. 2011a). Research proposing other KM models has argued that loops 
are a trigger because people in the organisation lack the knowledge to implement 
actions (McElroy 1999). However, the evidence presented indicates that in multi-
organisational projects the external evaluation of results creates a learning loop 
induced by external actors involving a constant transfer of knowledge among parts. 
Therefore, the internal demand for knowledge or external knowledge induced loops. 
The last section of this chapter explained, at the inter-organisational level, the transfer 
of data to the sponsor and the strategies designed by each sponsor to centralise the 
data, and at the intra-organisational level, I discussed the relevance of storing the 
lessons learned for future projects. Regarding the data transfer, I evaluated two aspects 
proposed by Anderson and Parker (2013) to integrate knowledge in distributed 
knowledge work (DKW): the information infrastructure and the organisational 
network design. This last aspect corresponds to the structural dimension to transfer 
knowledge to the research sites addressed in Chapter 5. In the different cases, the 
sponsor defined the channels to collect the data, the data required, the frequency of 
the transfer and the procedures to receive the data produced in multiple locations and 
integrate it. These four elements differed among the three cases, showing that the 
integration of data is not entirely standardised in the industry. In the first place, the 
information structure in the KINGE case differed to the NUSTAN and SAVA cases. In 
the KINGE case, a combination of physical documents and electronic platforms to 
transfer information was employed, where the CRO monitors played an important role 
in the data transfer. This last element created a distance between the sponsor’s data 
managers and the site to determine any variation in the data and provide feedback. In 
contrast, SAVA and NUSTAN employed a bi-nodal software, where the sites directly 
transferred the data to the sponsor. In these two cases, the intermediaries transcribing 
the data were on-site personnel and feedback provided by the sponsor was direct and 
in real time. As I presented, these differences had implications on the transfer and the 
process to verify it. Then in a project with reciprocal interdependences (Thompson 
1967), where sub-task outcomes and inputs continuously interact, the organisational 
structure and communication channels established between the sponsor and the sites 
are fundamental to provide feedback and ensure data corrections on time. This 
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evidence indicates that in the model proposed to study the flow of knowledge in a 
multi-organisational project, it is necessary to consider the loops that emerge across 
organisation when organisations transfer interdependent products. 
Finally, this chapter discussed how the turnover of personnel and the lack of knowledge 
system to store the lessons learned decreased, over the project, the capacity to use the 
experience gained in future activities. None of the sites visited had a proper strategy or 
procedure for recovery and transferring the knowledge developed by people working 
on the project before leaving, creating gaps and loss of knowledge to the organisation, 
impacting the organisation’s knowledge capital. This section evidenced how the labour 
conditions of the researchers and staff members incentivise staff turnover. It was 
evident that in countries such as Colombia, Brazil and Mexico a competition exists 
between CROs for qualified personnel, which promotes the turnover, which affected 
the relationships between the CRO and the sites and the transfer of information, as I 
discussed in Chapter 5. Also in countries such as Brazil, the high demand for trained 
physicians in clinical research promotes turnover, especially in an academic context, 
where salaries are not as competitive as the industry. Therefore, the staff turnover in 
the organisation becomes a threat for the creation of knowledge capital in the 
organisations, and outsourced organisations should consider a mechanism to retain 
their staff and create a culture to promote knowledge sharing across the organisation, 





Chapter 7: Discussion and 
Conclusions  
7.1. Introduction 
With the last empirical chapter, I concluded the study of the flow of knowledge across 
organisations participating in multi-organisational clinical trials in Latin America. In 
this journey, I have paid attention to the transfer, acquisition and use of knowledge, 
information and data in the clinical trials to produce their respective knowledge 
products. I studied the design of the project with the creation of the clinical protocol, 
addressing its transfer to the research sites, the acquisition of knowledge by these 
actors and the integration and use of knowledge to produce the clinical data and its 
subsequent transfer to the sponsor. In this final chapter, I will bring together the 
empirical, theoretical and practical findings presented in the chapters above to answer 
the principal research questions that started this doctoral journey: How does 
knowledge flow across organisations and is employed by people in their firms 
to implement the clinical trials and obtain their respective results?  
As a result, studying three clinical trial projects, I explained the analytical process that 
led to the transformation of initial knowledge (conceptual, contextual, practical) on 
tangible results, “boundary objects” later transferred either within the organisation 
(SOPs) or across organisations (protocol and data). The knowledge acquired was 
consistently involved in the action of research site staff, in activities such as the 
enrolment and adherence of individuals over the course of the clinical trial or the 
contribution and reshaping of initial actions that allowed them to face emerging 
challenges. Also, in this mapping process, I informed the factors that influence the 
transfer and acquisition of knowledge at the inter-organisational level, such as the 
structure to transfer and integrate data, knowledge and information, the knowledge-
base of people to acquire knowledge, and the permeability of people to acquire 
knowledge. This last factor is a concept proposed, elaborated and evaluated over the 
course of the empirical chapters.  
168 
 
In this thesis a three-step model was proposed based on models reported in the 
literature of ‘knowledge models, work and processes’ (K. Grant 2011, 121), the concept of 
interdependency proposed by Thompson (1967), and the three factors that influence 
the transfer of knowledge across organisations to study the flow of knowledge, data and 
information. The three steps are: (1) The acquisition of knowledge, data and 
information by people. (2) Integration of knowledge and its use in the practice 
(knowing) to solve the productive inquiry and evaluate results. (3) Storage and transfer 
of results to other organisations. Then, I identified the products that created 
interdependency across organisations and were directly linked to the production of the 
clinical data in the clinical trial. The clinical protocol and the clinical data were 
identified as the primary products. Then, I formulated three questions to understand 
how the sponsor and the research sites employed, acquired or transferred knowledge, 
data and information to produce the protocol and the clinical data. These three 
research questions guided this research, and the three empirical chapters of this 
document addressed each question separately. 
The conceptual framework proposed in the theoretical framework was robust, to follow 
the flow of knowledge, data and information in different organisations participating in 
the project, from the design of the protocol until the production of the clinical data. 
However, the analysis of the data collected also pointed out that the model proposed 
initially had to consider another dynamic to better explain and study the knowledge 
flow in a multi-organisational project. In this chapter, in the first section, I will provide 
a summary of the main empirical findings associated with the production of the 
protocol and clinical data and the flow of knowledge in a clinical trial for vaccines in 
Latin America. In the second section, I present several noteworthy contributions of this 
research to the study of knowledge management in outsourced projects or services. 
Here is proposed a model that brings together the intra-organisational and inter-
organisational dimension of the knowledge flow, and simultaneously shows the 
transformation of the knowledge in different interdependent knowledge products that 
leads, at the end, to the expected result.  
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7.2. Main empirical findings 
The discussion about the development of new vaccines or medicines in developing 
countries has focused strongly on the mechanism to develop the product, its 
introduction into the market (Srinivas 2006), the development of capabilities either for 
the drug evaluation (Hanlin 2008) or their production (Chataway, Tait, and Wield 
2007). Nonetheless, the understanding about the clinical evaluation of the new product 
and the challenges of the clinical trials on the ground, especially in endemic rural areas, 
has been less discussed. Although there have been papers narrating the experiences or 
lessons learned by physicians and companies implementing clinical trials (Campbell et 
al. 2007; John 2006; Zaman et al. 2012), these studies have focused only on one of these 
two actors. These studies have paid less attention to the relationship among the parts, 
and the knowledge employed by the actors in the trial. Moreover, the implementation 
of clinical trials in Latin American countries has been under-studied compared with 
other regions such as Africa (Geldenhuys et al. 2012; Vischer et al. 2016; Gikonyo et al. 
2008) or Asia (Abbas 2007; Zaman et al. 2012), where sponsors share their experience 
implementing trials in these countries. Therefore, this study addressed these gaps and 
provided an understanding of how knowledge is transformed in clinical trials taking 
place in Latin American countries. 
7.2.1. Empirical findings, the first research question 
The first sub-research question of this thesis was: How did the sponsor acquire and 
use knowledge, data and information to design the clinical protocol? 
This question emerged because of the gap in the literature about the acquisition and 
use of knowledge to design the clinical protocol. Researchers have extensively discussed 
the need for a multidisciplinary perspective to design the protocol (Chin 2012), the 
interaction of people writing the protocol, the physical writing of the protocol process 
(Eapen 2007; Gennari et al. 2004; Weng et al. 2004; Weng et al. 2007) and the need to 
address aspects such as scientific and logistic issues, data management, 
implementation and data analysis (Ottevanger et al. 2003; Goodarzynejad and 
Babamahmoodi 2015; Pocock 1980). However, the need for external sources of 
information and knowledge and the use of knowledge residing within the clinical team 
boundaries were less discussed. From the literature, it was possible to infer that one of 
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the challenges is to integrate multiple versions over the writing process (Eapen 2007; 
Gennari et al. 2004; Weng et al. 2004; Weng et al. 2007), and that the protocol creation 
has been considered a routine activity where clinical teams have the knowledge and 
experience to do it. However, the evidence provided in Chapter 4 provides new 
evidence to the protocol creation process, showing how clinical teams required 
constant interaction with external sources to acquire data, knowledge and information 
to use in their analysis to create the protocol. 
The empirical findings in this study provide a new understanding of the knowledge 
employed to design the protocol. This study has found that five groups of data, 
knowledge and information are critical to designing the protocol. (1) The knowledge 
and experience of the clinical team. (2) The previous results of pre-clinical and clinical 
phases. (3) The guidelines designed by the WHO to evaluate the vaccine and 
implement laboratory tests to measure antibodies in humans (two different guidelines). 
(4) Sponsor’s commercial interest. (5) Operative and social information and 
epidemiological data about the disease incidence and prevalence in the locations when 
the trial took place (Table 3). In all cases, sponsors employed these pieces of knowledge 
and information in the design of the protocol. What varied among cases was the 
availability of this knowledge and information within the boundaries of the clinical 
team, which triggered the acquisition of this missed information and knowledge. 
The evidence from this study suggests that in Latin America, research institutions lack 
the knowledge and experience to lead clinical trials for new medical products, which 
makes it challenging to recruit personnel with this knowledge to close knowledge gaps. 
The evidence suggests that once firms identify individuals with the background to 
design the protocol and lead the project, this personnel, in turn, translated their 
personal experience to the project design and closed their knowledge gaps through a 
learning effort (Akbar 2003), employing, as a base, the conceptual bases possessed by 
individuals. The NUSTAN case illustrates how, in cases where the personnel do not 
participate in the previous trial, ensuring a communication channel with personnel 
involved in earlier stages allows access to the knowledge that the team cannot recreate 
internally (Powell, Koput, and Smith-doerr 1996).  
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The use of guidelines to design clinical trials is a shared practice in the clinical trial 
industry. However, the use of the guidelines is usually not reported in the literature as 
part of the knowledge and information employed by clinical teams to design protocols 
and the clinical trial, it is taken for granted. These findings suggest that, in general, 
sponsors employed published guidelines as starting point to design their protocol for 
the vaccines evaluated. In the three cases, it was evident how the guidelines developed 
by the WHO were the backbones to design the protocols and conduct the laboratory 
tests. Then, all three cases shared this same information to create their protocols. As 
one researcher said, it was a “template” to create the protocol. Which clearly indicates 
its relevance for the study design. However, not all the guidelines were similarly 
accepted and used in all cases. The NUSTAN case evidences how critical positions 
about these documents reduced the use of materials widely accepted in a community 
and it generates a resistance to use its content under the light of the scientific premises 
of their clinical research. Therefore, the results of this investigation show that 
knowledge of the teams to interpret the guidelines reshaped the use of the guidelines, 
despite its standardising role to create knowledge products.   
Another aspect that is usually neglected by those discussing the protocol creation is the 
influence of the commercial interest of each sponsor on the design of the clinical trial. 
Findings reported in Chapter 4 indicates that the commercial interest defined the 
population included, the sample size and if the clinical trial would be multi-national or 
in a single country. So, the commercial interest reshaped the information required to 
design the protocol. Also, this interest demanded efforts to consolidated coordinating 
teams in multiple countries (SAVA case in Brazil) and outsource the project to CROs 
in multiple countries which later had a repercussion on the knowledge transfer. Then, 
this aspect must be considered as a factor to reshape the protocol design and goes 
beyond scientific interests. 
Continuing with the answer to the research question, to create the protocol clinical 
teams acquired knowledge, data and information from external sources. This 
acquisition was mediated by two factors the channels employed to access to the sources 
and the permeability of the clinical team towards requested and not requested 
information and knowledge. As the cases studied indicated, the geographical distance 
between the source and the clinical team, and the previous linkages among the parts, 
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determined if the clinical team accessed the information directly or the clinical team 
required the use of boundary spanners. In those cases where a geographical separation 
existed, but a direct communication channel with the source existed, sponsors 
requested the information directly. However, as the SAVA case illustrated, if there were 
no communication channels among the parts, the use of boundary spanners was 
necessary to support the search of information and data and help with the transfer of 
data. Also, the data indicate that geographical separation gives place to the emergence 
of boundary spanners-in-practice (Levina and Vaast 2014), who assume a boundary 
spanning role not delegated by the sponsor, which creates fragmentation in the 
knowledge and information transfer. As the evidence indicated, boundary spanners are 
active actors who interact with the data and process it before being sent.  
In summary, in Chapter 4 I provided new evidence about the protocol creation process, 
showing how clinical teams constantly interacted with external sources to acquire data, 
knowledge and information and used it to create the protocol. Also, I provided 
empirical evidence about how they employed or criticised guidelines in the design of 
clinical trials, a topic that scholars usually do not report and is a shared practice in the 
industry. 
7.2.2. Empirical findings answering the second research 
question 
The second research question in this thesis was: To what extent does the structure 
designed by the sponsor to transfer knowledge, the permeability of the research 
sites, and the previous experience of people working on the project influence 
the acquisition of knowledge in the research sites?  
Within the clinical trial community, researchers have associated data’s validity with the 
level of training that the sponsors provide to the personnel working in the clinical trial 
about the protocol (Gassman et al. 1995; Subramaniam and Dugar 2012), or training on 
the GCP and the project documentation (Ukwu et al. 2011a). However, the discussion 
has been limited to highlight its relevance, but the literature has not discussed or 
presented empirical evidence about the training implementation and the factors that 
influence the knowledge acquisition. Also, in a changing context, with the presence of 
new actors like the CROs and SMOs, little has been researched about the influence of 
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these actors on the acquisition of knowledge, with few exceptions that discuss the 
knowledge losses for research and technology because of the presence of CROs 
(Lowman et al. 2012). For this reason, studying the training and transfer of knowledge 
becomes relevant to analyse the flow of knowledge between the sponsor to the research 
site and the creation of an understanding about the project and the task to undertake 
to produce the clinical data across research sites. This chapter addressed three factors 
that played a role in the transfer and acquisition of knowledge. Firstly, the structure 
designed by the sponsor to transfer knowledge. Secondly, the permeability of the 
research sites, and thirdly, the previous experience of people working on the research 
sites.  
In the first place, the chapter presented evidence that the structure designed by the 
sponsor to transfer the information about the project to the research sites had a direct 
influence on the acquisition of knowledge by the site. In the clinical trials, three key 
elements defined the structure of the network: direct communication between the site 
and the sponsor, the outsourcing of the project to a CRO, and the outsourcing of the 
creation and management of research sites to SMOs. Direct communication between 
the site and the sponsor allowed a simple transfer of knowledge and information 
required to implement the project. In contrast, the data presented elucidates how the 
decisions of the sponsor to outsource activities related to the transfer of information 
and training to the CRO and SMOs had a clear implication on the flow of information 
between the sponsor and the site. The consequences of the presence of the CRO in the 
transfer of information were (1) the slowing down in the communication between the 
parts, (2) the emergence of gaps in the transfer of information and (3) the co-presence 
of the SMO and the CRO to transfer information created confusion and lack of trust on 
one of the sources. A bifurcated structure to transfer information rather than provide 
continuous support to the sites to acquire the knowledge and information created 
confusion on the sites because each source offered different versions regarding how to 
implement the trials. This chapter also contributed to the discussion about 
permeability initiated in this PhD and shows an association between structure and 
permeability. This study has found that trust in the source was the key enabling factor 
that modulated the permeability of the staff towards external sources, and this trust 
depended to a large extent on the experience of the person transferring the 
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information. Therefore, the empirical evidence indicates that a reduction in the 
number of sources employed to transfer information increases the efficiency in the 
acquisition of knowledge and increases the permeability of the sites to receive the new 
information.  
The data presented about the outsourcing of the project to CROs elucidated a deeper 
problem in the industry in Latin America. Although outsourcing can give results on 
decreasing costs, the evidence presented indicates that this intermediary, rather than 
contributing, represents an obstacle to the management of knowledge over the course 
of the trial, especially in the initial stages, where staff at the research sites build their 
knowledge about the project and the work to undertake. The distribution of 
responsibilities within the CROs to train the monitors and transfer the information to 
the sites has a direct consequence on the efficiency to transfer knowledge and 
information to the sites. The fact that information sent by the sponsor passed through 
multiple staff inside the CRO affected the final information received by monitors 
responsible for the final delivery. Therefore, if any information was missing on the way, 
it was likely that the sites did not receive all the information. 
The evidence in this chapter presents a new scenario, what does happen when the local 
researchers do not have the experience to implement the protocol? Usually, it is 
reported, in the literature of clinical trials, how sponsors work with trained physicians 
that have the experience to conduct the project (Cruz and Gagnon 2011; Kennedy 2001; 
Petryna 2006). However, in the SAVA case, this was not the case in most of the project 
sites, which gave the opportunity to understand the relevance of the knowledge-base 
on the acquisition of knowledge in a clinical trial and explore a new scenario. All the 
staff interviewed in all cases at least had a technical or professional knowledge from 
which they built and reinforced the concepts required for the project, so they had a 
conceptual knowledge to build new knowledge. However, the process to build the 
practical knowledge to implement the trial following the procedures indicated in the 
ICH-GCP and the sponsor was more complex in new research sites compared with 
experienced sites.  
In the cases of NUSTAN and KINGE, the opinion leader had a research group to execute 
the project, and a large part of the personnel had the conceptual basis and the 
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experience to understand the new project and implement it. This previous knowledge 
allowed the identification of the gaps in the information transferred by the CROs and 
enabled the training of new personnel. Experienced personnel constantly shared their 
knowledge with new staff, and within these research groups, spaces exist to socialise 
and learn from another project and members; in these cases, learning practical 
knowledge had a strong component of example. In the case of SAVA, the new sites 
learned from experience (Pentland 1995) thanks to an innovative pre-trial that allowed 
the integration of the acquired knowledge into their routines and practices, a learning 
process that had a large component of learning by doing and trial and error. 
Unfortunately, staff in new research did not coexist with experienced researchers and 
the interaction with experienced personnel was limited to training visits, and the 
learning in practice was alone. Then, the possibility to solve doubts immediately and 
replicate a practice was low; only after the results were obtained was it possible to 
identify if staff followed the instructions and the guidelines – only at this point 
corrective actions took place. Therefore, the constant presence of a person with the 
experiential knowledge transferring this knowledge and providing examples makes a 
difference to the speed of the knowledge acquisition of new learners, especially in those 
cases where an entire team lacks the practical knowledge to implement a clinical trial.  
One empirical finding in this chapter was the influence of the local regulation to 
implement clinical trials in Colombia on determining the professional profiles of the 
people working in clinical trials. This regulation demanded a redistribution of 
responsibilities in an experienced research site, which disrupted the team dynamics. 
The staff that had, in the past, implemented activities associated with blood and drug 
handling could not employ this accumulated knowledge in the new project because the 
regulation excluded their professions from the list of professions that can process 
samples or handle the research product. Then, this situation demanded an internal 
exercise of hiring new personnel and training them to do the work of personnel that 
already had the knowledge to do it. Then, in the case of Colombia, the local regulations 
had a direct influence on how the previous experience and knowledge could not be 
employed directly in the execution of the clinical trial. 
In summary, in Chapter 5 I provided new empirical evidence about the influence of the 
structure created by the sponsor to transfer knowledge and information to the research 
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sites, showing the impact of intermediaries in this activity. Also, this chapter provided 
evidence about how CROs influence the transfer of information and their internal 
distribution of responsibilities affects the information flow directly. Another empirical 
aspect highlighted was the acquisition of knowledge in newly constituted research 
sites, which is an atypical case in the context of clinical research. This evidence 
presented the process of learning by doing lived in these organisations and how the 
strategies designed by the sponsor to develop practical knowledge in these sites had a 
positive effect on the acquisition. Notably, the empirical evidence indicates that, in 
Colombia, the entry into force of new clinical research regulation influenced the 
knowledge-base available to implement the trial and demanded a re-distribution of 
responsibilities and training of new personnel.  
7.2.3. Empirical findings answering the third research 
question 
At the transition stage, before initiating the clinical trial, the transfer of knowledge by 
the sponsor and the acquisition of this by the research site was discussed. Then, in this 
study about the flow of knowledge and its use to produce knowledge products over the 
course of the clinical trial gave place to the third question: How is knowledge 
employed in the clinical research practice to solve the productive enquiries 
related to the production of clinical data and its transfer to the sponsor? 
One of the main contributions that I’m doing is opening the black box of the research 
sites, explaining how physicians produce clinical data and how personnel at the site 
contribute with their knowledge to the project execution. Previous studies about 
knowledge management in the pharmaceutical industry have discussed: the 
relationship between the pharmaceutical company and the CROs (S. Gupta and 
Polonsky 2014); the hierarchies in the transfer of knowledge and knowledge creation 
between CROs and the pharmaceutical (Azoulay 2004); the risk of losing knowledge by 
the pharmaceutical company and their dependency on external suppliers (S. Gupta et 
al. 2009); the influence of the staff behaviour on the integrity and safety of the subjects 
and the procedures to recruit participants (Ottevanger et al. 2003; van Dongen 2001; 
Ippoliti 2013; Barnes and Florencio 2002b; Barnes and Florencio 2002a; Geldenhuys et 
al. 2012; Goodarzynejad and Babamahmoodi 2015). Also, researchers have documented 
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the problems emerging in the trial implementation, including protocol violations, 
consent violations, fabrication of data, falsification of data and financial conflict of 
interest (Habermann et al. 2010; Gardner, Lidz, and Hartwig 2005; George 2016). To 
address these problems, the literature has proposed multiple strategies to improve data 
quality in clinical trials in general (U.S. Department of Health and Human Services 
Food and Drug Administration 2006; Friedman et al. 2015; Chan et al. 2013; Gassman et 
al. 1995; Knatterud et al. 1998; Meinert 2012). However, the work and contributions of 
the research sites have been broadly discussed by practitioners in the industry and less 
addressed in the literature of knowledge management. One of the reasons to focus the 
discussion on the CRO is the way in which private funded clinical trials are 
implemented in the USA and Europe. In these regions, the biggest CROs have their 
own research sites to implement the trials, which differs from the operational model of 
the CROs in Latin America, where CROs do not have their own research sites and need 
to re-outsource the project implementation to local research sites or principal 
investigators. Then, it is in the context of Latin America and specifically vaccine trials 
that the discussions in this thesis have been taking place.  
The integration of the protocol to the research site activities took place through two 
complementary mechanisms. In the first mechanism, personnel at the research site 
created SOPs manuals to operationalise the knowledge acquired from the sponsor. In 
the second mechanism, people directly used the acquired knowledge in practice to 
recruit volunteers for the project, to produce the clinical data, to overcome the 
challenges associated with the implementation and to optimise procedures proposed 
by the sponsor. However, this integration with the previous knowledge and use of 
knowledge transferred was not straightforward: the organisational context and the 
context of the communities in which the trial took place influenced this integration.  
In the cases studied, one person per site created the SOPs. The vision of this person 
about how procedures should be implemented dominated the integration of knowledge 
into the site routines. People creating the SOPs in the three cases shared three 
elements. They had the complete understanding of the research sites, and how to 
execute the project task, they had experience in clinical research, and they had a good 
understanding of the protocol. The evidence indicates that although the SOPs governed 
the actions of the personnel participating in the clinical trial and settled the day-to-day 
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activities, these documents were not perfect and their implementation in the sites does 
not mean a full standardisation of procedures. Even though key opinion leaders have 
suggested that regulatory authorities or the sponsor should evaluate the manuals 
created by the sites before initiating the project. The deviations on procedures are an 
indicator of why creating SOPs is not enough to standardise procedures and how the 
full understanding and implementation of the procedures in practices is necessary to 
standardise the procedures. The standardisation of procedures in all cases did not mean 
a high control of the routines or a reduced number of opportunities for staff to 
contribute to the project. However, if there is a central and rigid managerial control, 
such as in the case of the SMO-2 in Colombia, the freedom of the site’s staff to 
contribute to the project and the standardisation of procedures decreased. 
Physicians had the freedom to use their knowledge to provide their diagnosis despite 
the standardisation of procedures. In the cases studied, the production of clinical data 
demanded an understanding of the protocol. However, the main knowledge capital to 
produce the clinical data was the medical experience of physicians, their analytical 
skills and their practical knowledge to externalise the clinical data following the 
industry standards. Data production required a deep analytical capacity of the 
physicians to evaluate the biological evidence and the narrative provided by a 
participant about their symptoms. As the evidence indicates, physicians had the 
experience to provide a medical diagnosis, but the practical knowledge to externalise 
the data according to the ICH-GPC was developed over the course of the trial through 
a feedback loop process between the monitor, the sponsor and the physician. The 
evidence indicates that physicians to externalise data had to follow the national 
regulations and, in second place, procedures indicated in the ICH-GCP. The procedures 
established by the sponsor cannot be above the procedures and information required 
in the national regulation. The fact that experienced physicians faced more difficulties 
to follow the GCP to collect the data compared with less experienced physicians 
indicates that if a practice is deeply rooted and practitioners have established working 
routines, the introduction of new practices or modification of the old ones takes longer 
than if the person hasn’t developed a routine to implement an activity. Therefore, this 
study shows how beliefs and resistance to change are elements that influence the 
activities performed and caused bias in the results, as Knatterud (1998) suggests.  
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The evidence from this study suggests that, in the design of the recruitment strategy 
and its implementation, the use of the knowledge about the social dynamics of the 
population by the researchers contributes enormously to the project success. The 
evidence about the two research sites in Mexico working for SAVA showed how using 
the accumulated knowledge about the community (migration patrons, teenage 
pregnancy) and a good understanding about the project favoured the recruitment of 
volunteers. In the long term, this knowledge minimised the risk of lost participants over 
the course of the project. Also, the creation of alliances with local health programmes 
allowed the integration of local health workers, who had profound knowledge about 
the community. So, their experience and contextual knowledge became an advantage 
to create an alternative recruitment strategy that better addressed the project needs.  
Also, the deep knowledge about the communities allowed sites to face threats that 
emerged because of the presence of rumours or the limitations raised, because the 
social realities of the communities intervened. For example, the knowledge about the 
social context from the leaders and the members of the community allowed the 
building of trust between the communities and the research sites and dismantled 
chains of gossip that emerged in the community about the project. The social reality in 
the territories has consequences for the project implementation if these are not 
considered in advance. The lack of contextual knowledge by the sponsor to establish 
the inclusion criteria gave place to a series of challenges to recruit participants. Local 
researchers faced this situation using their knowledge about the local legal system and 
guiding the parents through the process without intervening directly in it. Therefore, 
the present study enhances our understanding of how research sites, especially 
physicians, employ the knowledge about the communities in the clinical trials to create 
and implement the recruitment strategy. 
The transfer of data from the research site to the sponsor marks the end of the 
productive work of the research sites and the initiation of the data analysis by the 
sponsor to obtain the clinical evidence. This fact creates a reciprocal interdependency 
between the sponsor and the research sites, where the sponsor constantly requests 
clarification on the data from the sites. In the three cases studied, each sponsor defined 
a different organisational network and information structure to integrate the data, 
showing that, in the industry, this procedure is not entirely standardised. The presence 
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of intermediaries to transcribe data from the medical records to the CRO or the 
electronic data capture induced mistakes and created feedback loops to clarify the 
information. The presence of the CROs in this transfer process showed, once again, a 
negative effect, as they did not have the original sources on hand, decreasing the speed 
of reviewing the data. In contrast, a direct communication site sponsor to transfer the 
data enabled a direct feedback loop and a faster evaluation of the data.  
The evidence collected also suggested the negative effect of personnel turnover on the 
continuity of knowledge in the clinical trial. The lack of a mechanism in the research 
sites to manage the knowledge acquired by the staff and to ensure the transfer of 
knowledge to the team creates a loss of information and experiences that is impossible 
to recover. One of the reasons for the staff turnover was the labour stability in the 
research sites in Latin America. The job insecurity in the research sites represented a 
barrier to guarantee the continuity of personnel that were already trained in the project 
so the site could not get the benefits of the experience gained by the staff over the 
training and the execution. Therefore, ensuring the working conditions of the 
personnel in the clinical trial is essential to avoid the loss of staff and of all the effort 
made at the beginning of the trial to train staff and create a shared understanding of 
the project. 
The results of this study have shown how knowledge, data and information flows across 
organisations, and it is used by the sponsor and the research sites to execute their parts 
in the project, in this way answering the main research question of this thesis. How 
does knowledge flow across organisations and is employed by people in their 
firms to implement the clinical trials and obtain their respective results? This 
research extends our knowledge in the first place about the use of knowledge within 
the research sites to collect the clinical data. The evidence presented indicates that 
teams employ knowledge acquired from external sources in the various tasks associated 
with the project implementation. Nonetheless, the process to incorporate the new 
knowledge by people in their routines was not straightforward and demanded an 
additional effort before it was fully integrated into the routines and combined it with 
the know-how that personnel already had. Also, this work dived, for the first time, into 
the knowledge about the social context that research sites have and how the use of this 
contributes directly to the project implementation and its success. Therefore, these 
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findings enhance our understanding of the use of knowledge within the research sites 
and contradicts the vision that research sites are only data makers and do not 
contribute with their knowledge to the project.  
7.3. Theoretical discussions 
This study proposes a model to study the flow of knowledge, data and information and 
its transformation in multi-organisational projects at the intra-organisational level and 
inter-organisational level. The model proposed in the theoretical framework was built 
based on three previous models of the literature of knowledge “models, work and 
processes” (K. Grant 2011, 121) introduced by Meyer and Zack’s cycle (1996), McElroy 
(1999), and Ngai (2008). These models have three stages in common: the acquisition of 
knowledge, the task execution, and the transfer/storage of the results which were 
adopted in this research as a base to create the model to study the knowledge flow 
(Table 4). The three steps were complemented with the concept of interdependency 
proposed by Thompson (1967) to explain the relationship between outcomes and 
inputs among firms that takes place in the context of outsourced projects or multi-
organisational projects. Also in this model the critical enabling factors that mediated 
the acquisition and transfer of knowledge were considered. Regarding knowledge 
acquisition, the factors identified were the previous experience of the organisation and 
the permeability of individuals to external information. Regarding the knowledge 
transfer, it was identified that the structure established by the sender to reach the 
receptor could be a relevant factor in the transfer of information (Blumenberg, Wagner, 
and Beimborn 2009). In this section, I discusses separated each one of these steps and 
the emergence of new facts that I consider relevant to include in a reviewed version of 
the model proposed.  
7.3.1. Knowledge transfer and the role of intermediaries 
The work on interdependency has focused on the interaction between two nodes, the 
flow of work, the complementarities of the different work products, communication, 
control and interaction between the unit executing pieces of work (K. Kumar, van 
Fenema, and von Glinow 2009). However, to my understanding in this field of work, 
the presence of intermediaries as a mechanism to reduce costs and communicate with 
other organisations in distributed work has not been considered. Then, this work is the 
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first one in the context of sequential interdependencies that addresses and develops 
this issue, showing the role of these actors in these activities.   
Table 4. Summary of the conceptual model proposed to study the flow and use of 
knowledge over the course of a multi-organisational project. 

























• Use of knowledge 
to produce the 
product.  
• Structural dimension 
to transfer the product 
and other information. 
• Interdependency. 
 
Scholars such as Samoilenko and Nahar (2011) have argued that the client is the one 
responsible for planning and conducting the training and transferring specific and 
generic42 information about the tasks to be implemented for the project to the 
contractor. The evidence presented in this thesis supports this argument. However, it 
shows that the transfer is not always direct between the source and the receptor, as 
Samoilenko and Nahar (2011) suggest, and it is implicit in the model proposed based on 
Meyer and Zack’s cycle (1996), McElroy (1999), and Ngai (2008) (Table 4). The data 
presented shows that the delegation of this responsibility to a third party has a direct 
consequence on the transfer of information and its acquisition by the receptor. 
Although, the evidence collected indicates that the sponsor directly transferred 
information related to the protocol, the outsourcing of training to intermediaries such 
as the CROs and SMOs affected the information transfer. Therefore, in outsourced 
projects, the actors transferring knowledge and information to the same receptor in 
multi-organisational projects simultaneously is evident, which, as I have highlighted 
multiple times, had direct consequences on the transfer process.  
                                                          
42 Zack defined general explicit knowledge as a broad knowledge that is independent of particular events, 
while specific knowledge or information refers to knowledge that is context-specific, where specific 
categories and descriptions should be provided (Zack 1999).  
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The literature names these intermediaries as boundary spanners. It has been argued 
that these actors emerge as a solution to manage the boundaries (Levina and Vaast 
2014), linking groups separated by location, hierarchy or function (Ansett 2005; S. 
Gupta and Polonsky 2014; Levina and Vaast 2014; Alavi and Leidner 2001). However, the 
evidence presented indicates that the role of these boundary spanners does not always 
benefit the transfer of knowledge and information across organisations. The emergency 
of boundary spanners-in-practice decreased the interaction among organisations, and 
these spanners were active actors who interact with the data, processing it before 
sending it. Then, as Meyer (2010) suggests, boundary spanners or knowledge-brokers 
do not only move knowledge, they also produce “brokered knowledge” and transfer it 
across boundaries. 
Delving into the discussion about the presence of intermediaries at the inter-
organisational level, Blumenberg et al. (2009) suggested that the transfer of knowledge 
from the outsourced to the contractors has two dimensions: a contain dimension and 
a sender-receiver dimension (structure dimension). This last dimension explicitly 
defines in a document how the interaction between the parties should be. The structure 
dimension proposed by Blumenberg et al. (2009) has its roots in the hierarchical 
structures to transfer knowledge within the firm proposed by Nickerson and Zenger 
(2004). These authors agree that the efficiency of the transfer of knowledge is related 
to having a defined interaction structure to transfer the information and, in turn, this 
helps to create a high level of shared knowledge. Also, the literature suggests that in 
interdependent tasks the amount of communication and coordination effort among 
parts is highly relevant (K. Kumar, van Fenema, and von Glinow 2009). The findings of 
this project indicate that not only is it necessary to have defined structures and clear 
rules, as Nickerson and Zenger (2004) and Blumenberg et al. (2009) suggest. The 
complexity of the structure also has implications on the transfer of the results from one 
firm to another. Chapter 5 evidenced how simple structures with direct communication 
between the parts were the best mechanism to transfer information about the project 
between the sponsor and the research groups. In contrast, structures with one or two 
intermediaries between sites and the sponsor affected the transfer process despite the 
existence of written down protocols of communication. Moreover, if the intermediary 
organisations have a complex internal structure to transfer information, or there are 
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multiple intermediaries with overlapping responsibilities on the transfer of 
information, the transfer is negatively affected.  
The results of this research strongly indicate that the presence of intermediaries in 
outsourced projects, rather than enhancing the transfer of information, data and 
knowledge, it slows down the transfer process. Their presence creates knowledge gaps 
and misunderstandings, and makes the entire transfer process inefficient compared 
with the case in which communication between the sponsor and the sites was direct. 
Also, as the SAVA case illustrates, these complex structures have profound implications 
for the acquisition of knowledge by the research sites, also having a direct link to the 
receptor’s permeability towards the source and the information and knowledge 
received (this discussion continues below). Therefore, the existence of defined and 
documented interaction structures between parties like Nickerson and Zenger (2004) 
and Blumenberg et al. (2009) suggest, is not enough. These interaction structures 
should be as simple as possible, and the sender must have control of the knowledge 
transfer process. Otherwise, the transfer of the results from one organisation to another 
one can turn into a game of Chinese Whispers. The receptor does not get all the 
information, the message is distorted, and each intermediary includes their own 
“touch” in the information, affecting the transfer process completely.  
These findings have important implications for designing strategies to transfer 
knowledge in multi-organisational projects, especially when geographical separations 
exist among actors. If the use of intermediaries is necessary, it is important that the 
team coordinating the project at the lead firm considers the capabilities and internal 
structures of the intermediaries. Coordinators should avoid delegating overlapping 
responsibilities, and most importantly, the lead firm must verify if the person 
responsible for the intermediation has the knowledge-base to understand the 
information and transfer it. If there are already communication channels between the 
source and the receptor, as in the KINGE case, the results of this research strongly 
suggest avoiding the inclusion of an intermediary and opting for a direct transfer of 
information. 
Sveiby (2001) proposed a framework at the organisational level to acquire knowledge 
to raise its knowledge-base and induce the creation of capabilities. In his framework, 
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he considered internal and external sources. He identified three levels of sources: 
individuals (employees), who have the “primary intangible resources”; external 
structures such as partners, competitors, suppliers, or others; and internal 
organisational structures such as repositories of explicit knowledge existing in the 
organisation (patents, concepts, models, and computer and administrative systems). In 
his framework, he assumed a direct interaction between the three sources at the intra-
organisational and inter-organisational level. However, based on the evidence 
presented above, the presence of boundary spanners can complement this framework. 
A complemented framework should consider the intermediation of these boundary 
spanners between individuals in different organisations or between individuals and 
external sources of explicit information, such as external databases; sources that 
Sveiby’s (2001) framework did not consider and are present, as Chapter 4 showed, such 
as the Ministry of Health databases. With this contribution, the framework is more 
robust and can be employed in new scenarios such as multi-organisational projects.  
7.3.2. Knowledge acquisition, permeability and people’s 
knowledge-base 
The acquisition of knowledge and the task execution (Table 4) are the two components 
at the intra-organisational level proposed in the model. In this section, I will address 
the discussion about the acquisition of knowledge. The demand for knowledge and 
information, teams’ permeability towards external knowledge and people’s knowledge-
base were three relevant elements identified in this research that mediated the 
knowledge acquisition.  
The acquisition of knowledge in the previous models consists of the search for internal 
or external knowledge to implement the activities, either to increase the organisation’s 
“knowing” (McElroy 1999; Ngai, Jin, and Liang 2008) or to acquire data and information 
to be analysed or transformed into products. In these models, people already know how 
to process this information and data (M. H. Meyer and Zack 1996). As Gupta and 
Govindarajan (2000) indicated, people’s motivation to acquire and receive knowledge 
influences the acquisition of knowledge. However, the information presented in 
Chapters 4 and 5 shows that in addition to motivation, the need for the information 
and knowledge is a key factor that mediated the acquisition. In the case of sponsors, 
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they acquired knowledge and information that they needed to design the protocol 
(Chapter 4). And in the case of the research sites, they acquired the information and 
knowledge about the protocol and procedures to implement from the sponsor, the CRO 
or the SMOs because they needed this knowledge and information to execute the task. 
In both types of organisations, the permeability towards the information requested was 
high, and teams were open to receiving and using it to implement their productive 
enquiries. However, in those cases where the team did not request knowledge and 
information, the permeability of the teams varied and they were not always open to 
receiving and using the information and knowledge. This permeability varied according 
to the trust in the source and the valuation of the internal knowledge versus the 
knowledge received. Teams were less permeable if they did not request the information, 
they doubted the validity of the external knowledge, they did not trust the source of 
information, or intermediaries were filtering the information for them (Chapter 5). On 
the contrary, they were more open to not requested information if they trusted the 
source and considered the knowledge and information received as valid.  
The role of trust between firms is widely acknowledged, and it has great importance in 
the success of inter-organisational projects (Kadefors 2004; Wong and Cheung 2004). 
Trust promotes the sharing of knowledge among parts, enabling the acquisition of 
knowledge from external partners (McEvily, Perrone, and Zaheer 2003). In previous 
research, Maurer (2010) concluded that in inter-organisational engineering projects 
trust between partners promoted knowledge acquisition. However, in their study, the 
association between trust and acquisition was not as strong as they expected. 
Therefore, they suggested that other drivers should probably be mediating the 
acquisition of knowledge in inter-organisational projects. The results of this PhD 
suggest that a combination of drivers under the concept of permeability, which 
includes the need for the information, the valuation of the internal knowledge versus 
the knowledge received and the trust in the source, can much better explain the 
acquisition of knowledge from external sources by the firms working on the project.  
Also, the results of this research suggest that the permeability of the teams towards 
external sources is dynamic. This one can shift from open to close or vice-versa as trust 
evolves among parts over the course of the project. In the first place, if trust in the 
source is lost, the permeability can change from open to close. In contrast, permeability 
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can change from closed to open if the receptor begins to trust the source and a 
relationship based on trust and cooperation emerges. Then, trust can be built or can 
decrease among the parts as the project progressed, enabling or blocking the 
acquisition of knowledge. The data presented clearly indicates that the low 
permeability of a person towards external information or knowledge is not only 
associated with not-invented here syndrome (Katz and Allen 1982), in which knowledge 
is rejected because of envy, jealousy or power (Ngai, Jin, and Liang 2008; Maier 2004). 
The permeability of a person towards external information depends on: 
1) The evaluation that the receptor conducts on the source  
2) The experience displayed by the sender. 
3) The experience that the receptor develops over the course of the project  
4) The trust generated in the relationship  
In summary, this work contributes to existing knowledge about the acquisition of 
knowledge, developing the concept of permeability. The results provide important 
insights into four key factors that defined the clinical team’s permeability towards 
external knowledge and its dynamism over the course of the project. The first factor is 
the demand for knowledge. The second factor is the trust in the source and the 
validation of its knowledge. The third factor is the presence of boundary spanners-in-
practice, which act as a filter that regulates the information flow among parts. And the 
fourth factor is the experience of people to make an informed decision about the 
acquisition. So, this discussion about the factors that influence the permeability of the 
clinical teams makes an initial contribution to the development of the concept of 
permeability formulated in this thesis. 
This thesis considered the previous team experience or knowledge-base as one factor 
that influenced the acquisition of knowledge. A significant number of authors have 
suggested that previous knowledge (basic skills, shared language and knowledge of 
scientific or technological developments) modulates the potential to acquire and 
introduce knowledge or information in collaborative networks or outsourced activities 
(Li et al. 2014; Nooteboom et al. 2007; S. A. Kumar and Thangavelu 2013; Cohen and 
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Levinthal 1990). And it is an important condition for the recipients of information (Dwi 
and Alon 2017). Nonetheless, most of these discussions were oriented on understanding 
how the knowledge-base of individual organisations allows knowledge acquisition to 
be more innovative. Then, this research contributes to expanding our knowledge about 
the relevance of knowledge-base in multi-organisational projects where not all 
organisations have the same level of experience.  
In multi-organisational projects, it is a fact that no organisations have the same 
knowledge-base and previous experience. The internal knowledge residing within the 
organisation and the team is unique and totally specific to the group of people at a 
specific point in time. And it is from these experiences that each team builds their 
knowledge to implement the task. The stability of project members through interlinked 
projects emerged as a principal element that enables the acquisition of knowledge, not 
only because people had the cognitive bases to translate previous experience to the new 
project, but also because the team had established an understanding of how to work 
and coordinate actions. These results are aligned with the discussion in project 
literature that highlights the relevance of team’s stability for the project success 
(Savelsbergh, Poell, and van der Heijden 2015) and also facilitates coordination of 
interdependent work (Edmondson, Dillon, and Roloff 2007). The accumulation of 
specialised knowledge allows the addressing of complexities that emerge over the 
project (Tseng et al. 2004). The access and use of previous results are critical for its 
further use in interdependent projects (Formentini and Romano 2011; Owen and 
Burstein 2006).  
In those cases where teams lack previous experience, professional backgrounds are the 
base to acquire knowledge and implement the task, despite the organisation to which 
they belong (sponsor, or research site). In these teams, knowledge acquisition is cyclic, 
where knowledge possessed is constantly evaluated in practice and the results can 
trigger learning loops if knowledge is not enough. It is the use of knowledge in practice 
that reveals the complete internalisation and the integration of the knowledge acquired 
into work (Cook and Brown 1999). Two mechanisms are employed to learn practical 
knowledge in multi-organisational projects. The first one is learning from example and 
the second one is learning by experience through a trial and error process. In the first 
scenario, I presented how a constant interaction with experienced staff benefited 
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learning (Park, Im, and Kim 2011) and the co-location of experienced personnel with 
inexperienced personnel enabled the acquisition of practical knowledge (Roy and 
Sivakumar 2012). Nonetheless, learning by experience was highly demanding and could 
compromise the results, especially because this learning took place over the course of 
the project. 
Contrary to what most of the literature on knowledge management suggests about the 
positive role of previous knowledge on the acquisition of knowledge, the evidence 
presented in Chapter 5 seems to suggest that the previous knowledge is not always a 
catalyst to acquire new knowledge. On the contrary, the evidence presented about 
experienced clinicians working for the first time in clinical research showed how their 
previous background becomes a limitation to learn new processes and procedures to 
implement the task. Then, although previous knowledge allowed them to acquire new 
concepts and understand the project, the acquisition of new practical knowledge was 
complex if the person had rooted practice associated with the activity. 
These findings take us to a less developed discussion about the knowledge-destruction 
capability that professionals must have to acquire and create new knowledge. 
According to Kaplan et al. (2001): “The destruction capability constitutes the capacity 
to eliminate elements of knowledge or disassemble the interconnectedness of 
knowledge.” Then, to acquire new knowledge, the old one has to be destroyed and 
replaced by the new one. Authors like Landry et al. (2006), based on medical literature, 
have suggested that, for physicians, it is difficult to destroy old knowledge and replace 
it with new knowledge. The evidence collected in Chapters 5-6 supports this 
interpretation and provides qualitative evidence about the evolution of the destruction 
capability of physicians working in clinical trials, extending our understanding about 
the destruction-creation process in the acquisition of practical knowledge. Findings in 
Chapters 5-6 suggest that the destruction of knowledge is not a straightforward process, 
and not all members of research sites manifested a capability to change their previous 
medical practices and routines easily. In the first place, the destruction of knowledge 
requires that the person recognised value in the new knowledge. Secondly, destruction 
is a process where people introduce, day-by-day, the new knowledge into the new 
routines, so the old knowledge is progressively replaced with the new one. Thirdly, the 
person must realise the impact that the introduced knowledge has on his work. And 
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finally, it requires determination and motivation by the practitioner to acquire the new 
knowledge, and it also requires patience by the person supervising the acquisition, who 
has to be willing to repeat the information until the old knowledge is replaced by the 
new one. Therefore, these results clearly evidence that, on the acquisition of knowledge 
in the context of a project, previous knowledge is also destroyed to give place to the 
creation of new knowledge that is the result of the acquisition of the transferred 
knowledge and the implementation of this in the medical practice.  
7.3.3. Use of knowledge to produce the product 
At the intra-organisational level, the execution of the task is the most important part 
of the project. Knowledge, information and data acquired are employed to execute the 
activities and produce the knowledge products (M. H. Meyer and Zack 1996), give a 
solution to problems (McElroy 1999), or, as it will be presented, to contribute with 
alternative proposals. In this thesis, the use of knowledge took the approach proposed 
by Cook and Brown (1999), where they suggested that in the execution of productive 
enquiries two epistemologies of knowledge exist: the “epistemology of possession” and 
the “epistemology of practice”. The epistemology of possession sees knowledge as 
something that people have in their heads, and they can acquire and transfer it; which, 
in my view, is in accordance with the model this thesis proposed. The epistemology of 
practice is focused on what people know and do in certain contexts; this means bringing 
the knowledge possessed into action. Otherwise, the knowledge possessed is not 
contributing to people's work. In this way, both epistemological approaches come 
together in work and help to explain how people employ knowledge in the productive 
enquiries.  
I identified the knowledge, data and information employed by the research sites and 
the sponsor to execute the respective productive enquiries. In both scenarios, the 
accumulated experience/knowledge of team members was the base to execute the 
respective parts of the project integrated with the newly acquired knowledge. However, 
in knowledge-intensive projects, knowledge products are the result of the summation 
of the individual analytical process, where workers interrogate data, information and 
knowledge and create new connections to produce new knowledge. This new 
knowledge is then externalised in a document. However, because this process is 
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individualised, abstract and mental, the study of the acquired knowledge 
transformation is not easy. All information collected about this activity depends on the 
person’s interpretation and narrative about its own analytical and logical process, 
which is a limitation to more clearly explain the creation of new knowledge by people.  
The evidence also supports the argument that knowledge produced as a result of the 
project must be stored and lessons learned must be available to the rest of the 
organisation or at least for other project members (Markus 2001). The storage of 
knowledge has been, in part, the base of the knowledge management systems theory, 
whose base is the storage of the organisational knowledge to make the firm more 
competitive. Evidence presented in Chapter 6 indicates that research sites are not good 
at storing the lessons learned by workers. So, the storage of the knowledge acquired 
and created by the people over the course of the trial about how to execute the project 
is one of the weaknesses of clinical sites and the management of knowledge within 
these organisations.  
It is important to point out that most of the previous research about the data 
production has studied clinical trials for chronic diseases, which are the most common 
in the pharmaceutical industry where recruitment is competitive between countries 
and physicians, and individual physicians implementing the project. Then, one of the 
most prominent contributions of this research is that it addresses, for the first time, the 
use of knowledge in the research sites and makes an in-depth analysis of how the 
researchers contribute with their contextual knowledge to the project. In this analysis, 
the need for integrating knowledge to the organisations through the standardisation of 
procedures and the use in practice of the knowledge acquired was evident. The 
integration takes place over the acquisition and use of knowledge, which makes the 
study of this activity harder, as it is disconnected from the other two steps. Based on 
the evidence presented, I argue that physicians and principal researchers in clinical 
sites contribute with their knowledge to the trial. They contribute not only to collecting 
the clinical data and transferring it to the sponsor or the CRO, but also maintaining the 
project’s stability, and guaranteeing the enrolment and adherence of the participants 
over the entire project, which is fundamental for the project’s success (Chapter 6). 
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7.3.4. A conceptual model to study the knowledge flow in 
multi-organisational projects 
Multi-organisational projects are composed of a leading organisation and various 
external project teams from specialised partner firms or sub-contractors (Maurer 2010). 
In previous studies about inter-organisational projects such as outsourced projects, 
services and inter-organisational relationships, scholars had provided valuable insights 
into the management of knowledge. For example, they have discussed how outsourced 
firms create new knowledge and store it to make the firm competitive (Yan 2011; Zhao, 
Yim-Teo, and Yeo 2004; Matinheikki et al. 2016); how knowledge is transferred across 
companies; the need to create a shared knowledge among the actors (Samoilenko and 
Nahar 2011; A. K. Gupta and Govindarajan 2000); and the relevance of interpersonal 
relationships among people working on the projects (M. Jensen et al. 2007). However, 
despite the attention paid to the transfer of knowledge in inter-organisational projects, 
limited research has been conducted about the interdependency of knowledge among 
organisations in the project and how each one of the firms uses their internal 
knowledge and external knowledge to implement the tasks.  
Based on the discussion in this thesis, it seems that the model proposed initially in the 
theoretical framework was robust to follow the flow of knowledge, data and 
information in different organisations participating in the project, from the design of 
the protocol until the production of the clinical data. However, the analysis of the data 
collected indicated that the model proposed can be complemented with the new 
evidence presented through this chapter (Figure 9). In the initial model proposed, the 
knowledge acquisition implies an internal-external orientation. However, in the 
context of multi-organisational projects, it is important to consider the perspective of 
the receptor, as they do not actively search for the knowledge to implement the tasks. 
So, considering the directionality of the acquisition is critical, especially because it 
affects the permeability of people towards knowledge. People were highly permeable 
or non-selective toward information and knowledge if they requested the information. 
However, they were less permeable if the information or knowledge was not demanded 
being reluctant to employ this knowledge in the production of the knowledge products. 
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Regarding learning new activities, this research has shown how the presence of strongly 
rooted medical routines decreases the flexibility to learn new practices, like research 
practices. This analysis revealed how the level of experience of researchers in medical 
consultation, rather than being an enabling factor to introduce the new knowledge to 
do clinical research, it was an obstacle. Then, the knowledge-destruction capability of 
people is important to acquire knowledge and should be considered as part of the 
factors that influence the knowledge acquisition (Figure 9). The presence of 
intermediaries plays an important role in modulating the transfer of knowledge among 
parts. The presence of boundary spanners should be considered in a model to study the 
knowledge flow in multi-organisational projects, either nominated boundary spanners 
and boundary spanners-in-practice (Levina and Vaast 2014) because, as I discussed, the 
delegation or emergence of these actors has a direct consequence on the flow of 
knowledge across interdependent actors.  
Figure 9. Complemented model to study the flow of knowledge and its use in multi-





Compared with other models proposed in the literature of KM, this model differs 
considerably on the order of the stages and, in turn, on the study of knowledge flow. 
For example, previous models propose that the use of knowledge is possible once this 
one is stored and shared in the organisation (Evans, Dalkir, and Bidian 2014). This 
perspective is logical in models that address the use of lessons learned in organisations, 
a field dominated by the literature of knowledge management systems, which analyses 
the use of informatics infrastructure to manage the knowledge in organisations. 
However, the model proposed aim to address dynamics at the inter-organisational 
level, where knowledge acquisition and use takes place before storing and sharing 
lessons learned, offering a different starting point to study knowledge management in 
the organisations.  
So, in this section, I discuss the pertinence of the model proposed to study the chain of 
interaction and dependencies that take place in multi-organisational projects, 
discussing step-by-step the steps proposed. In conclusion, I present several noteworthy 
contributions that this study makes to the field of knowledge management, specifically 
to the literature of knowledge models and the studies of outsourced project or services. 
First, proposing a model that brings together the intra-organisational and inter-
organisational dimension of the knowledge flow and simultaneously presents the 
transformation of the knowledge in different interdependent knowledge products. And 
secondly, evaluating and complementing the proposed model. 
7.4. Conclusions, shortcomings of the work and 
avenues for further work 
This is the first study to undertake a longitudinal analysis of knowledge management 
in multi-organisational projects, advancing our understanding about the flow and use 
of knowledge in this kind of project. The study offers some important insights into the 
knowledge management at the inter-organisational level and intra-organisational level 
in these projects. In this thesis, I highlighted the lack of a model to study and map the 
flow of knowledge over the course of a multi-organisational project, addressing its 
implications for theory and practice. This study aimed to contribute to this growing 
area of research by elaborating a conceptual model to study the flow of knowledge, and 
its use across organisations that participate in KIP and are working on outsourcing KIP. 
195 
 
The proposed model was evaluated and complemented based on the evidence collected 
from three multi-organisational projects to evaluate vaccine candidates in Colombia, 
Brazil and Mexico. The analysis of the results allowed me to complement the model 
initially proposed and also allowed me to expand my own knowledge of how 
knowledge, data and information flow and are used to produce knowledge products 
though interdependent productive enquiries. This study has shown that knowledge 
flow across the organisation is not direct and linear. The results of this study indicate 
that the presence of intermediaries, the permeability of receptors and integration of 
knowledge in practice are fundamental not only to ensure knowledge flow but also to 
transform knowledge into knowledge products, such as boundary objects. This study 
proposes and elaborates on the concept of permeability increasing the understanding 
of the knowledge acquisition in teams and organisations. The insights gained provide 
researchers and clinical trial practitioners with valuable understanding about how 
clinical trials in a new fragmented landscape are developed in Latin America, where the 
presence of intermediaries is highly relevant to manage clinical trials. So, this research 
extends our knowledge about clinical trials in Latin America; a topic under-studied 
until now. Nonetheless, more research in other contexts employing the proposed 
model is required to determine its applicability in other contexts. 
Due to practical constraints to gain access to biological laboratories where sponsors 
implemented blood tests, and to statistical teams, this research cannot provide a 
comprehensive review about the production of biological data and the integration of 
this data with the clinical data to obtain the final results.  For this reason, analysis and 
conclusions are limited to the production of clinical data and its review by the sponsor. 
A further study with more focus on the participation of these actors is therefore 
suggested to comprehend how sponsors analysed and refined data collected by sites 
and the biological data to have a whole picture of the clinical trials.  
In this research, I pointed out the relevance of the knowledge that research sites had 
about the communities. However, I consider it relevant to explore the understanding 
that communities have about the projects and their responsibilities for it. As I 
presented, rumours emerged in a clinical trial, and some communities created their 
own collective perception of the project and the procedures. Therefore, learning how 
communities generated these perceptions became relevant to address at the planning 
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stages of large clinical trials. Moreover, in Mexico in one of the clinical trial industry 
conventions, I witnessed how some volunteers publicly showed a low understanding of 
their rights if they experienced associated side effects. So, further research needs to 
more closely examine the transfer of knowledge to participants and its understanding 
by volunteers, as the acquisition of knowledge by people has direct implications for 
participants’ health and claiming of their rights.  
I consider it relevant to address, in future research, the transfer of knowledge, not only 
clinical data, from the research sites to the sponsor. Research sites develop a rich 
understanding of clinical research and a profound practical knowledge that can benefit 
the sponsor in the planning and execution of future research. Then, in the transfer of 
lessons learned from the site to the sponsor, there is a potential to gain knowledge that 
has been unexplored by sponsor companies and future research should address this. 
The translation of results in this research to other multi-organisational projects, even 
clinical trials for chronic diseases, should be with caution, because in these last cases 
trials are not outsourced to research sites; they are outsourced to individual 
practitioners, which changes the dynamic in the project and the work of the CRO is 
much more relevant. A natural progression of this work is to compare results of multi-
organisational projects in multiple fields to determine the robustness of the proposed 
model in multiple research contexts.  
Although I collected data about the clinical trial industry in Colombia, Brazil and 
Mexico, the current research was not specifically designed to evaluate factors related to 
knowledge production in the entire clinical trial industry in the three countries. The 
constant reshaping of local regulations was beyond the scope of this study, which had 
a project level. Then, future research derived from this work can investigate the results 
of the regulatory changes on the quality of the clinical research, its influence on the 
project execution and the industry dynamic, passing from a project level to an industry 
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Appendix 1.  
Questions to the Sponsor  
1. Interviewed personal details 
Can you tell me about your academic background? 
For how long have you been working in the institution?  
What are your core responsibilities here in the company? 
 
2. Project planning 
Who designed the protocol? 
What is the criteria to select the outsourced companies? 
Could you explain me, how is the process to you agree a contract with other 
organisations?  
Did any regulatory authority participate/contribute to the protocol design? 
 
3. Transition stage 
How was the process to implement the protocol in each centre?  
What information did you transfer to the site? Did you train staff? How did you 
do it? 
How do you make explicit to the research group the type of data that you need 
to produce?  
How do you guarantee that all procedures are standardised?  
How do you ensure reproducibility of the results among research groups?  
Did you visit the research site? 
 
4. Control over the project 
What channels of communication do you establish with the group to follow up 
the progress? 
 Can you monitor the progression of the trial in real time?  
Do you use some metrics such as patient enrolment to evaluate the contribution 
of the research group to the project?  
Is the language a barrier in the clinical trials? 
 
5. Data integration  
Once recruiting is taking place and data is produced, how do you compile that 
information?  
How do you ensure that data and information is protected?  
Can you describe to me how the process of integrating data coming from 
different centres or countries has been for your company? 
 
6. Offshoring of clinical trials 
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Which ones are the main barriers that you find to conduct the trial in 
collaboration with other organisations? 
Have you noticed that some organisational culture or local culture practices 
have an effect over the clinical trial? 
How do research sites manage the production of data under the context of 
transnational offshored clinical trials? 
 
Question to personnel in the site 
 
1. Research site background 
Can you tell me a bit about your background as a researcher?  
For how long have you been conducting clinical research? 
What are the main areas of research in your research group?  
Why did you start to conduct clinical trials?  
Who is responsible for obtaining the ethical approval to conduct the trial?  
 
2. Knowledge transfer  
 What technical information do you receive from the PC before starting the trial? 
 How are the people who are going to conduct the trial trained?  
Once you receive the protocol, who has access to it?  
Do you receive formularies and informed concerns by the PC?  
 It is there a process to standardise the production data among different research 
groups? 
What other kind of information do you receive from the pharmaceutical 
company/CRO?  
To conduct new clinical trials, do you hire new people or try to employ students 
or researchers that have been working with you? 
 
3. Implementing the trial 
What agreements were made with other institutions to access patients? 
How is the process to follow up the patients?  
Can you tell me, how is the routine to implement the protocol? What do you 
evaluate? Who produces the data? 
How easy/complex is it to implement the protocol? 
How do you protect the new information generated?  
Do you consider that conducting clinical trials have impacted other areas of 
research? In what way? 
Beside the protocol transferred by the PC, what other regulations should you 
consider when conducting research? 
 
4. Data transfer/storage 
 When a person that has been working on a project leaves, how do you store the 
knowledge that the person has? 
 Do you have a strategy to generate a back-up of data and results in the lab?  
How do you transmit the information to the pharmaceutical company? Do you 
have software to share data? 
How often do you have communication with the PC?  





How is a vaccine’s safety, efficacy and efficiency determined?  
Are you allowed to process your own data?  
How do you corroborate the consistency of your data?    
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Responsibility Country City Case of Study 
[DM-USP, NUSTAN, Apr-13-2015] Leonardo Silva Abril 13 2015 Data Manager Brazil Sao Paulo NUSTAN 
[Monitor-CRO, KINGE-Col Nov-27-2014] Silvia Martinez Nov 27 2014 CRO Colombia Medellín KINGE 
[Monitor-CRO, SAVA-Col Dic-10-2014] Pablo Montes Dic 10 2014 CRO Colombia Armenia SAVA 
[Monitor-CRO, SAVA-Mex, Jul-08-2015]  Julio 8 2015 CRO Mexico Tizimi- Yucatan SAVA 
[NUSTAN Chair, Apr-13-2017] Dr. Pablo Esmeralda Abril 13 2015 Sponsor Brazil Sao Paulo SAVA 
[OM SMO-2, SAVA-Col, Dic-03-2014] Manuela Figueroa Dic 03 2014 Project manager Colombia Bogotá SAVA 




[PI 2-Site2, SMO-3, SAVA-Mex, Jul-01-2015] GP Sofia Villareal Julio 1 2015 Sub- Researcher Mexico Temixco SAVA 
[PI- R-IDVI, KINGE, Oct-15-2014] Dr. Ignacio Valdivia Oct 15 2014 Principal Investigator Colombia Medellín KINGE 
[PI Site3, SAVA-Mex, Jul-08-2015] Dr. Gabriel Valderrama Julio 8 2015 Principal Investigator Mexico Tizimi- Yucatan SAVA 
[PI-Site 4, SMO-3, SAVA-Mex, Jul-09-2015] Dr Maria Cristina Macias Julio 9 2015 Principal Investigator Mexico Valladolid SAVA 
[PI-Site-1, SMO-1, SAVA-Col, Dic-10-2014] Dr. Augusto Perla Dic 10 2014 Principal Investigator Colombia Armenia SAVA 
[PI-SMO-1, SAVA-Col, Dic-02-2014] Dr. Roberto Cristales Dec 02 2014 SMO Colombia Bogotá SAVA 
[PI-SMO-2, SAVA-Col, May-17-2015] Dr. Horacio Espinela Mar 17 2015 SMO Colombia Bogotá SAVA 




[PI-USP, NUSTA, Apr-01-2015] Dr. João Espinela April 1 2015 Principal Investigator Brazil Sao Paulo NUSTAN 
[PM R-IDVI, KINGE, Nov-05-2014] Leonora Opalo Nov 05 2014 Project manager Colombia Medellín KINGE 
[PM2 R-IDVI, KINGE, Nov-05-2014]  Oct 22 2014 Project manager Colombia Medellín KINGE 





[PM-Site-4, SMO-3, SAVA-Mex, Jul-09-2015] Paloma Abán Julio 9 2015 Project manager Mexico Valladolid SAVA 
[PM-USP, NUSTA, Apr-01-2015] Laura Ferreyra April 1 2015 Project manager Brazil Sao Paulo NUSTAN 
[PQ R-IDVI, KINGE, Nov-06-2014] Natalia Topacio Nov 06 2014 
Pharmaceutical 
chemistry 
Colombia Medellín KINGE 
[QA, R-IDVI, KINGE, Nov-11-2014] Emilia Coral Nov 11 2014 Quality Manager Colombia Medellín KINGE 
[Rep-Health secretary Antioquia, Feb-10-
2015] 




[SAVA Sponsor Brz, Apr-10-2015] Wallace Coutinho Abril 10 2015 Sponsor Brazil Sao Paulo SAVA 




[SAVA-Sponsor Col, Mar-24-2015] Ana Diamante Mar 24 2015 Sponsor Colombia Bogotá SAVA 
[Sponsor- KINGE, Oct-25-2014] Dr. Jaime Plata Oct 25 2014 Sponsor Colombia Medellín KINGE 
[Sub-Res, R-IDVI, KINGE, Nov-05-2014] GP David Vega Nov 05 2014 Sub- Researcher Colombia Medellín KINGE 
[Sub-Res, Site-3, SMO-3, SAVA-Mex, Jul-08-
2015] 
Dr Camilo Miranda Julio 8 2015 Sub- Researcher Mexico Tizimi- Yucatan SAVA 
[Sub-Res-Site 4, SMO-3, SAVA-Mex, Jul-09-
2015] 
William Arango Julio 9 2015 Sub- Researcher Mexico Valladolid SAVA 
[Sub-Res-Site2, SMO-3, SAVA-Mex, May-15-
2015] 
Felipe Rojas Julio 1 2015 Sub- Researcher Mexico Taltizaplan SAVA 
[Sub-Res-USP, NUSTA, Apr-14-2015] Dr. Rodrigo Coutinho Abril 14 2015 Sub- Researcher Brazil Sao Paulo NUSTAN 
[SW-Site 4, SMO-3, SAVA-Mex, Jul-09-2015] Alberto Congote Julio 9 2016 Social Worker Mexico Valladolid SAVA 
[SW-Site4, SMO-3, SAVA-Mex, Jul-09-2015] Maria Luisa Tobar Julio 9 2015 Social Worker Mexico Valladolid SAVA 
Nurse-Site4, SMO-3, SAVA-Mex, Jul-09-
2015] 
 Julio 9 2015 Nurse Mexico Valladolid SAVA 
  Nov 05 2014 
Ethic committee 
secretary 
Colombia Medellín KINGE 
  Julio 9 2015 Health Promoter Mexico Valladolid SAVA 
  Julio 9 2015 Health Promoter Mexico Valladolid SAVA 
  Nov 18 2014 
Informatic 
coordinator 





  Mar 19 2015 INVIMA Colombia Bogotá 
Colombian 
Regulation 
  Julio 9 2015 Laboratory Technician Mexico Valladolid SAVA 
  Julio 9 2015 Nurse Mexico Valladolid SAVA 
  Julio 9 2015 Nurse Mexico Valladolid SAVA 
  Dic 03 2014 Principal Investigator  Bogotá SAVA 
  Dic 04 2014 Principal Investigator  Bogotá SAVA 
  Abril 15 2015 Seminar in Brazil Brazil Brasilia 
Brasilian 
Regulation 
  May 21-22 
2015 





  Julio 9 2015 Social Worker Mexico Valladolid SAVA 
  Abril 20 2015 Sub- Researcher Brazil Recife SAVA 







Appendix 3.  
Introductory letter to request interviews  
Medellín, Colombia 6th March 2015 
Dear  
My name is Sara Valencia Cadavid and I’m a PhD candidate at the programme of 
Science and Technology Studies at the University of Edinburgh. Right now, I’m 
conducting an academic research to identify how knowledge is employed and flows in 
multi-centric clinical trials to evaluate vaccines in Colombia, Brazil and Mexico. 
The Instituto XXX has been conducting a multi-centric clinical trial to evaluate a XXXX 
vaccine candidate in Brazil. And for this reason, I would like to have an academic 
interview with you, to know more about your experience sponsoring a clinical trial, how 
is your relationship with the research sites, what challenges have you faced on the 
project design and how you have overcome challenges. All information that you will 
provide is confidential and it will be used just with academic purposes. 
I will travel to Brazil and I really appreciate if I can interview you at the day and time 
that best suits you between March 26th and April 4th. The length of the interview is 
between 30 minutes and one hour. 







Informed consent in English 
All people quoted in this thesis signed this confidential form either in Spanish or in 
Portuguese. 
The data obtained during the interview conducted by the researcher Sara Valencia will 
be used only for the research project to which she aspires to the title of Doctor of 
Science and Technology Studies at the University of Edinburgh in Scotland. 
All information provided will be recorded and it is confidential unless you explicitly 
authorize the publication of your name or your organisation’s name. The 
confidentiality agreement means that none of your personal or organizational data will 
appear or be used in reports, thesis and other publications, including, but not limited 
to, journal articles and book chapters. 
Regarding the information provided, I declare that: 
1. My participation is completely voluntary and it is my decision. 
2. I have read and understood the information about the project that I have been 
given, and I have been able to discuss it with the researcher. 
3. I will not receive financial compensation for participating in the project. 
4. I have understood that the interview will be recorded unless I have an 
objection. 
5. I understand that specific parts of the conversation may be used for the report 
and/or future publications but my name will be kept confidential. 
6. I have had the opportunity to discuss this study and ask questions. 
I, _____________________________________ agree to be interviewed by Sara Marcela 
Valencia Cadavid for academic purposes in her PhD research. 
I authorize the use of my name in the material published based on the information I 
provided. 
Yes  O     No O 
Signature ____________________________ Date ______________________ 
